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ABSTRACT 
Peptide	   transporter	   2	   (PEPT2)	   is	   a	   member	   of	   proton-­‐coupled	   oligopeptide	  transporter	   (POT)	   family	   that	   recognizes	   and	   transports	   di-­‐/tri-­‐peptides	   and	  peptide-­‐like	   drugs	   across	   cell	   membranes,	   thus	   playing	   an	   important	   role	   in	  substrate	   pharmacokinetics.	   In	   brain,	   PEPT2	   works	   to	   efflux	   substrates	   from	  cerebrospinal	   fluid	   (CSF)	   into	   choroid	   plexus,	   thus	   limiting	   the	   substrate	  distribution	  in	  CSF.	  However,	  PEPT2	  does	  not	  reduce	  the	  distribution	  of	  substrate	  in	  brain	  parenchyma,	  which	  is	  believed	  to	  be	  a	  more	  relevant	  site	  for	  the	  neurological	  effects	   of	   most	   compounds.	   Moreover,	   this	   finding	   is	   not	   consistent	   with	   the	  observance	   that	   PEPT2	   decreases	   the	   neurological	   effects	   of	   its	   substrates	   (e.g.,	  kyotorphin	   and	   5-­‐aminolevulinic	   acid).	   Considering	   that	   the	   brain	   parenchyma	  consists	   of	   extracellular	   fluid	   (ECF)	   and	   intracellular	   fluid	   (ICF),	  we	   hypothesized	  that	  PEPT2	  has	  an	  impact	  in	  reducing	  substrate	  distribution	  in	  brain	  ECF,	  which	  is	  the	   site	   of	   neurological	   effects	   of	   most	   compounds.	   In	   the	   present	   study,	  intracerebral	   microdialysis	   (the	   only	   method	   to	   directly	   monitor	   drug	  concentrations	  in	  brain	  ECF)	  was	  applied	  to	  rats,	  wildtype	  and	  Pept2	  knockout	  mice	  in	   order	   to	   study	   the	   impact	   of	   PEPT2	   on	   the	   brain	   distribution	   of	   cefadroxil,	   a	  substrate	   of	   PEPT2	   with	   high	   affinity.	   Our	   findings	   demonstrated	   that	   cefadroxil	  concentration	  in	  brain	  ECF	  of	  Pept2	  knockout	  mice	  was	  2.3	  fold	  higher	  as	  compared	  to	  wildtype	  mice,	   indicating	   that	  PEPT2	  as	  an	  efflux	   transporter	  at	   choroid	  plexus	  does	   not	   only	   reduce	   cefadroxil	   concentrations	   in	   CSF	   but	   also	   in	   brain	   ECF.	  Moreover,	  the	  microdialysis	  study	  of	  cefadroxil	  in	  rats	  (±	  probenecid)	  demonstrated	  that	  other	  transporters	  (e.g.,	  OATs,	  MRPs	  and/or	  OATPs)	  were	  also	  involved	  in	  the	  elimination	  of	  cefadroxil	  from	  brain.	  PEPT2	  also	  functions	  as	  an	  uptake	  transporter	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at	  brain	  cells	  (e.g.,	  neurons	  in	  neonate	  and	  adult,	  and	  astrocytes	  in	  neonate),	  which	  resulted	  in	  a	  higher	  cefadroxil	  level	  in	  brain	  ICF	  compared	  to	  brain	  ECF	  (i.e.,	  higher	  unbound	  volume	  distribution	  Vu,brain).	  These	  results	  provided	  significant	   insight	  into	  the	  mechanism	  by	  which	  PEPT2	  affected	  the	  distribution	  of	  its	  substrates	  in	  brain	  (brain	  cells,	  ECF,	  and	  CSF)	  and	  could	  have	  important	  implications	  in	  the	  design	  and	  delivery	  of	  peptide-­‐like	  pharmaceuticals	  for	  brain	  diseases.	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  CHAPTER 1
RESEARCH OBJECTIVES 
The	  brain,	  the	  main	  part	  of	  the	  central	  nervous	  system,	  is	  a	  critical	  organ	  in	  our	  body	   for	   sensory	   reception	  and	   intepretation,	  motor	  control,	   as	  well	   as	   the	  center	  for	   intellect,	   emotions,	   behavior,	   and	   memory	   [1].	   Because	   of	   its	   importance,	  barriers	   between	   the	   brain	   and	   blood	   such	   as	   the	   blood-­‐brain	   barrier	   (BBB)	   and	  blood-­‐cerebrospinal	   fluid	   barrier	   (BCSFB)	   protect	   the	   brain	   by	   strictly	   controlling	  the	  entry	  and	  exit	  of	  endogenous	  and	  exogenous	  compounds.	  One	  of	  the	  protection	  mechanisms	   of	   brain	   barriers	   is	   related	   to	   transport	   proteins	   that	   can	   transfer	  selected	   compounds	   across	   biological	   membranes	   [2].	   A	   variety	   of	   efflux	  transporters	  in	  brain	  have	  been	  found	  and	  they	  are	  able	  to	  remove	  their	  substrates	  from	   the	   CNS.	   My	   doctoral	   study	   primarily	   focuses	   on	   the	   impact	   of	   peptide	  transporter	  2	  (PEPT2)	  on	  the	  brain	  distribution	  of	  cefadroxil.	  PEPT2	  belongs	  to	  the	  SLC15	  family	  of	  proton-­‐coupled	  oligopeptide	  transporters	  (POTs)	   that	   transport	   di-­‐	   and	   tri-­‐peptides	   and	   peptide	   analogs	   across	   cell	  membranes.	   In	   addition	   to	   PEPT2	   (SLC15A2),	   the	   POT	   family	   includes	   PEPT1	  (SLC15A1),	   PHT1	   (SLC15A4)	   and	   PHT2	   (SLC15A3).	   Among	   the	   four	   mammalian	  peptide	  transporters,	  PEPT1	  and	  PEPT2	  have	  been	  widely	  studied	  in	  regard	  to	  their	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distribution,	   function,	  and	  substrate	  specificity	  [3].	   In	  particular,	  studies	  on	  PEPT1	  and	  PEPT2	  have	  provided	  a	  basic	  understanding	  of	  their	  distribution	  and	  function	  in	  the	   small	   intestine,	   kidney,	   and	   brain.	   PEPT1,	   expressed	   in	   all	   regions	   of	   small	  intestine,	  transports	  small	  peptides	  and	  peptidomimetic	  drugs	  from	  the	  luminal	  side	  into	   intestinal	   epithelial	   cells	   and	   is	   responsible	   for	   the	   improved	   intestinal	  absorption	  of	  some	  substrates	  [4].	  In	  the	  kidney,	  PEPT1	  in	  S1	  segments	  and	  PEPT2	  in	  S3	  segments	  of	  proximal	  tubule	  play	  an	  important	  role	  in	  substrate	  reabsorption	  from	  the	  urine	  into	  blood,	  thereby	  reducing	  the	  renal	  clearance	  of	  these	  substances	  [5].	   In	  brain,	  PEPT2	   is	  expressed	  at	   the	  apical	  surface	  of	  epithelial	  cells	   in	  choroid	  plexuses,	  where	   it	   removes	   substrates	   from	  cerebrospinal	   fluid	   (CSF),	   resulting	   in	  the	  reduced	  exposure	  of	  PEPT2	  substrates	  (e.g.	  GlySar	  and	  cefadroxil)	   in	  brain	  [6].	  Besides,	  PEPT2	  is	  also	  expressed	  in	  the	  cell	  membrane	  of	  neurons	  and	  astrocytes	  in	  neonatal	   brain	   parenchyma	   and	   neurons	   of	   adult	   brain	   parenchyma,	   facilitating	  substance	   transport	   from	   the	   extracellular	   fluid	   (ECF)	   into	   cells	   [7].	   It	   has	   been	  demonstrated	   that	   the	   distribution	   of	   GlySar	   in	   the	   parenchyma	   of	  wildtype	  mice	  was	  different	  from	  PEPT2	  knockout	  mice	  as	  evaluated	  using	  autoradiography	  (ARG)	  [8].	  However,	  ARG	  only	  elucidates	  the	  overall	  drug	  distribution	  in	  parenchyma	  and	  is	   unable	   to	  distinguish	  between	   the	   intracellular	   and	   extracellular	  distribution	  of	  substances.	  Moreover,	   the	  kinetic	   changes	  of	   substrate	  concentration	  could	  not	  be	  determined	  simply	  by	  collecting	  brain	  tissues	  at	  a	  single	  time	  point	  post-­‐mortem.	  To	  better	  understand	   the	  role	  of	  PEPT2	   in	  drug	  disposition	   in	  brain,	  and	   its	  effect	  on	  pharmacological	   response,	   methods	   are	   needed	   that	   can	   monitor	   substrate	  concentrations	  in	  relevant	  brain	  compartments	  such	  as	  ECF	  and	  CSF.	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Intracerebral	   microdialysis	   is	   an	   in	   vivo	   technique	   that	   enables	   continuous	  sampling	  of	  substances	  from	  ECF	  in	  a	  specific	  region	  of	  the	  brain.	  Microdialysis	  has	  been	   widely	   used	   for	   monitoring	   endogenous	   molecules	   (e.g.	   neurotransmitters,	  hormones,	  and	  glucose)	  and	  exogenous	  drugs	  in	  brain	  from	  free-­‐moving	  animals	  [9].	  Compared	   to	   other	   sampling	   methods,	   microdialysis	   provides	   not	   only	   the	  concentration	  of	  a	  substance,	  but	  also	  changes	  in	  concentrations	  in	  specific	  regions	  of	  brain.	  Intracerebral	  microdialysis	  is	  a	  promising	  technique	  to	  better	  understand	  the	  impact	  of	  PEPT2	  on	  the	  distribution	  of	  peptide/peptide-­‐like	  drugs	  in	  important	  brain	  regions.	  It	   has	   been	  well	   established	   that	  many	   β-­‐lactam	   antibiotics	   are	   substrates	   of	  both	   PEPT1	   and	   PEPT2	   due	   to	   their	   steric	   resemblance	   to	   the	   backbone	   of	  tripeptides	   [10].	   Cefadroxil	   is	   a	   β-­‐lactam	   antibiotic	   with	   a	   broad	   spectrum	   of	  antibacterial	   activity	   and	   has	   been	   shown	   to	   be	   a	   substrate	   of	   PEPT2	   with	   high	  affinity	   [11].	   In	   addition,	   cefadroxil	   has	   high	  metabolic	   stability	   [12],	   serving	   as	   a	  preferred	  substrate	  for	  studies	  regarding	  the	  pharmacological	  relevance	  of	  PEPT2.	  It	  should	   be	   noted	   that	   cefadroxil	   has	   also	   been	   reported	   as	   a	   substrate	   of	   other	  transporters	   including	   the	   organic	   anion	   transporters	   (OATs)	   [13],	   organic	   anion	  transporting	   polypeptides	   (OATPs)	   [14],	   and	   multidrug	   resistance-­‐associated	  proteins	   (MRPs)	   [15,	  16].	  These	   transporters	  may	  also	  play	  a	   role	   in	   affecting	   the	  distribution	  of	  cefadroxil	  in	  brain.	  	  	  Based	   on	   the	   above	   information,	   we	   hypothesized	   that	   the	   functional	   and/or	  genetic	   knockout	   of	   PEPT2	   would	   substantially	   alter	   the	   regional	   distribution	  kinetics	  of	  cefadroxil	   in	  brain,	  resulting	  in	  elevated	  levels	  of	  drug	  in	  brain	  ECF	  and	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CSF,	  and	  reduced	   levels	   in	  brain	  cell.	  Still,	  other	   transporters	  would	  also	   influence	  cefadroxil	  levels	  in	  brain.	  The	  specific	  aims	  of	  this	  proposal	  are	  shown	  below:	  1) To	  determine	   the	   influence	  of	   the	   functional	   inhibition	  of	  PEPT2	  and	  other	  relevant	  transporters	  on	  the	  distribution	  of	  cefadroxil	  in	  brain	  parenchymal	  ECF,	  CSF,	  and	  blood	  in	  rats.	  2) To	   determine	   the	   influence	   of	   PEPT2	   depletion	   on	   the	   distribution	   of	  cefadroxil	  in	  brain	  parenchymal	  ECF,	  CSF,	  and	  plasma	  in	  wildtype	  and	  Pept2	  knockout	  mice.	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  CHAPTER 2
BACKGROUND AND LITERATURE REVIEW 
2.1 Proton-­‐Coupled	  Oligopeptide	  Transporters	  
The	   proton-­‐coupled	   oligopeptide	   transporters	   (POT),	   also	   referred	   as	   peptide	  transporters	  (PTR),	  are	  solute	  carrier	  proteins	  (SLC)	  responsible	  for	  the	  transport	  of	  di-­‐	   and	   tri-­‐peptides,	   as	   well	   as	   peptide	   analogs,	   across	   biological	   membranes.	   In	  mammals,	   four	   transporters	  have	  been	  discovered	  as	  members	  of	   the	  POT	   family:	  PEPT1	   (SLC15A1),	   PEPT2	   (SLC15A2),	   PHT1	   (SLC15A4),	   and	  PHT2	   (SLC15A3)	   [1].	  PEPT1,	   the	   first	   mammalian	   POT	   identified,	   was	   cloned	   from	   a	   rabbit	   intestinal	  cDNA	   library	   and	   exhibits	   low	   affinity	   and	   high	   capacity	   [2,	   3].	   PEPT2	   was	  subsequently	  cloned	  from	  a	  human	  kidney	  cDNA	  library,	  which	  is	  a	  high-­‐affinity	  and	  low-­‐capacity	  peptide	  transporter	  [4,	  5].	  The	  more	  recent	  members,	  PHT1	  and	  PHT2,	  were	   cloned	   from	   a	   rat	   brain	   cDNA	   library	   [6,	   7].	   These	   peptide/histidine	  transporters	   are	   different	   from	   PEPT1/2	   in	   that	   they	   recognize	   L-­‐histidine	   as	   a	  substrate	   in	   addition	   to	   di-­‐/tripeptides	   and	   peptidomimetics.	   Instead	   of	   being	  expressed	  at	   the	  plasma	  membrane,	  PHT1	  and	  PHT2	  are	   located	   in	   the	  subcelluar	  structure	   including	   endosomes	   and	   lysosomes.	   Recent	   studies	   have	   shown	   that	  PHT1	  and	  PHT2	  expressed	  in	  the	  immune	  cells	  like	  dendritic	  cells	  are	  components	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in	   toll-­‐like	   receptors	   (TLRs)	   signalling	   pathways,	   thus	   playing	   a	   role	   in	   immune	  responses	  [8,	  9].	  	  	  
2.1.1 Distribution	  and	  function	  The	   tissue	  distribution	  of	  PEPT1	  and	  PEPT2	  are	  different	   and,	   thus,	   they	  play	  distinct	  physiological	  roles	  in	  various	  tissues.	  PEPT1	  is	  mainly	  localized	  in	  the	  small	  intestine,	  including	  the	  duodenum,	  jejunum,	  and	  ileum	  [10].	  Expressed	  at	  the	  brush	  border	  membrane	  of	   absorptive	   epithelial	   cells	   of	   the	   small	   intestines,	   PEPT1	   can	  translocate	   di-­‐/tri-­‐peptides	   and	  peptidomimetics	   into	   the	   epithelial	   cells.	   In	   doing	  so,	  the	  small	  peptides	  derived	  from	  the	  digestion	  of	  dietary	  proteins	  are	  absorbed,	  as	  well	  as	  some	  drugs	  and/or	  prodrugs	  with	  steric	  resemblance	  to	  peptides	  [11-­‐14].	  PEPT1	  was	   also	   detected	   in	   the	   S1	   segment	   of	   proximal	   tubule	   in	   rat	   kidney	   and	  might	  contribute	  to	  the	  reabsorption	  of	  peptides/mimetics	  [15].	  Besides,	  PEPT1	  was	  found	   in	   the	   apical	  membrane	  of	   bile	   duct	   epithelial	   cells	   by	   immunofluorescence	  [16].	   Moreover,	   PEPT1	   mRNA	   is	   expressed	   in	   human	   liver	   and	   pancreatic	   tissue	  [17].	  However,	  the	  physiological	  functions	  of	  PEPT1	  in	  these	  latter	  tissues	  remain	  to	  be	  determined.	  In	  addition	  to	  normal	  tissues,	  PEPT1	  was	  found	  in	  several	  tumor	  cell	  lines	   and,	   therefore,	   studied	   as	   a	   tool	   to	   deliver	   anticancer	   drugs	   into	   tumor	   cells	  [18].	  Compared	  to	  PEPT1,	  PEPT2	  exhibits	  wider	  tissue	  distribution.	  In	  kidney,	  PEPT2	  is	  expressed	  in	  the	  S3	  segment	  of	  proximal	  tubule	  and	  has	  been	  confirmed	  to	  play	  a	  major	  role	  in	  the	  reabsorption	  of	  peptides/mimetics	  from	  tubular	  fluid	  [15,	  19].	  On	  the	  other	  hand,	  PEPT1	  is	  believed	  to	  play	  a	  minor	  role	  in	  the	  renal	  reabsorption	  of	  substrates	  based	  on	  previous	   studies	   [19,	  20].	   In	  addition	   to	   the	  kidney,	  PEPT2	   is	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highly	   expressed	   in	   brain,	   specifically	   choroid	   plexus	   epithelium,	   neurons,	   and	  neonatal	  astrocytes	  [21].	  In	  the	  epithelial	  cells	  of	  choroid	  plexus,	  PEPT2	  is	  localized	  at	  the	  apical	  surface	  facing	  the	  cerebrospinal	   fluid	  (CSF)	  and	  is	  responsible	  for	  the	  efflux	   of	   peptides/mimetics	   from	   CSF	   to	   blood	   at	   the	   brain-­‐CSF	   barrier	   (BCSFB).	  Thus,	  it	  is	  thought	  that	  PEPT2	  functions	  in	  regulating	  neuropeptides	  in	  the	  brain	  and	  in	   removing	   neurotoxins	   from	   the	   brain	   [22].	   Moreover,	   PEPT2	   expressed	   in	   the	  plasma	   membrane	   of	   neurons	   and	   neonatal	   astrocytes	   might	   contribute	   to	   the	  cellular	  uptake	  of	  peptides	   in	  brain	  parenchyma	  [23].	  PEPT2	  is	  also	  present	   in	  the	  lung,	   particularly	   in	   alveolar	   type	   II	   pneumocytes,	   bronchial	   and	   tracheal	  epithelium,	  where	  it	  mediates	  the	  uptake	  of	  substances	  into	  the	  epithelial	  cells	  [24].	  In	  the	  enteric	  nervous	  system	  (ENS),	  it	  was	  found	  that	  PEPT2	  was	  expressed	  at	  glial	  cells	  and	  tissue-­‐resident	  macrophages	  using	  an	  immunohistochemical	  method,	  and	  might	   contribute	   to	   the	   clearance	   of	   neuropeptides	   in	   the	  ENS	   [25].	   Furthermore,	  expression	  of	  PEPT2	  was	  found	  in	  the	  eye,	  mammary	  gland	  and	  reproductive	  tract	  [26].	  However,	  little	  is	  known	  about	  their	  functions	  in	  these	  latter	  organs.	  There	   is	   relatively	   less	   information	   known	   about	   the	   tissue	   distribution	   and	  physiological	   function	  of	  PHT1	  and	  PHT2.	  PHT1	  mRNA	  was	  found	  in	  rat	  brain	  and	  eye	  [6]	  and	  the	  protein	  expression	  of	  PHT1	  was	  detected	  extensively	  in	  brain	  tissues	  of	  adult	  mice	  [27].	  PHT2	  mRNA	  is	  expressed	  primarily	  in	  rat	  lymphatic	  system,	  lung,	  spleen,	  and	  thymus,	  with	  weaker	  signals	  being	  detected	  in	  heart,	  brain	  and	  liver	  [7].	  However,	  PHT1	  and	  PHT2	  might	  not	  contribute	  to	  peptide	  transport	  at	  the	  choroid	  plexus	   since	   the	   uptake	   of	   GlySar,	   a	   substrate	   of	   POTs,	   was	   not	   inhibited	   by	   L-­‐
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histidine	  at	  either	  the	  apical	  or	  basolateral	  side	  of	  rat	  choroid	  plexus	  epithelial	  cells	  [28].	  	  
2.1.2 Driving	  forces	  for	  peptide	  transport	  Peptide	   transporters	   are	   called	   proton-­‐coupled	   oligopeptide	   transporters	  because	  they	  co-­‐transport	  peptides	  and	  protons	  into	  epithelial	  cells	  as	  symporters.	  Transport	  of	  peptides	  against	  the	  concentration	  gradient	  is	  a	  function	  of	  POTs,	  while	  proton	  transport	  along	  an	  inwardly	  directed	  H+	  gradient	  is	  the	  driving	  force	  for	  the	  uptake	  of	  peptides	  [29,	  30].	  It	  has	  been	  confirmed	  that	  there	  is	  an	  acid	  microclimate	  at	  the	   luminal	  surface	  of	  epithelial	  cells	   in	  the	   intestine	  and	  kidney.	  The	  pH	  of	  this	  acid	   microclimate	   in	   the	   intestine	   is	   about	   6.1-­‐6.8,	   while	   the	   intracellular	   pH	   of	  epithelial	   cells	   is	   usually	   7.3	   [31,	   32].	   According	   to	   the	   model	   of	  peptide/peptidomimetic	   transport	   in	   intestinal	   and	   renal	   epithelial	   cells	   (Figure	  2-­‐1),	  the	  H+	  gradient	  is	  generated	  and	  maintained	  by	  a	  Na+-­‐H+	  antiporter	  (NHE3)	  at	  the	  apical	  side,	  which	  continuously	  pumps	  H+	  out	  of	  the	  cells	  and	  transports	  Na+	  into	  cells	  [29].	  The	  driving	  force	  for	  NHE3	  is	  the	  inwardly	  directed	  Na+	  gradient,	  which	  is	  established	   and	   maintained	   by	   Na+-­‐K+	   ATPase	   at	   the	   basolateral	   membrane.	   The	  chain	  of	  driving	  forces	  suggests	  that	  peptide	  transport	  is	  the	  result	  of	  a	  coordinated	  effort	  by	  several	  integral	  membrane	  proteins,	  and	  this	  coordination	  system	  assures	  the	  homeostasis	  of	   involved	   ions	   (H+,	  Na+,	  and	  K+),	  as	  well	  as	   the	  stable	   inwardly-­‐directed	  H+	  gradient	  as	  the	  driving	  force	  for	  peptide/mimetic	  uptake	  [11,	  29].	  	  As	  a	  result,	  peptide	  transport	  could	  be	  affected	  by	  changes	  in	  the	  expression	  level	  and/or	  functional	  activity	  of	  any	   involved	  transporter,	  which	  should	  be	  considered	  during	  data	  interpretation	  with	  respect	  to	  POT	  function.	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After	  the	  uptake	  of	  di-­‐/tripeptides	  into	  cells,	  most	  peptides	  are	  hydrolyzed	  into	  amino	  acids	  by	   intracellular	  peptidases	   and	   then	   removed	   from	   the	   cell	   by	   amino	  acid	   transporters	   at	   the	   basolateral	   membrane.	   Some	   drugs	   or	   prodrugs	   also	  undergo	  degradation	  and	  are	  pumped	  out	  by	  other	   transporters	  at	   the	  basolateral	  side.	  Some	  peptide/peptidomimetics	  do	  not	  experience	  intracellular	  hydrolysis	  and	  are	  pumped	  out	  of	  the	  cell	  intact	  by	  other	  transporters	  at	  the	  basolateral	  membrane.	  For	   instance,	   MRP3	   and	   MRP4	   were	   found	   responsible	   for	   the	   transport	   of	  cefadroxil,	  a	  substrate	  of	  peptide	  transporters,	  at	   the	  basolateral	  membrane	  of	   the	  intestinal	  epithelial	  cells	  [33].	  	  Figure	   2-­‐2	   shows	   the	   proposed	  model	   of	   peptide/mimetic	   transport	   in	   brain	  choroid	   plexus,	   which	   is	   similar	   to	   the	   model	   in	   intestine	   and	   kidney.	   However,	  there	   is	   little	   information	   on	   whether	   or	   not	   the	   acid	   microclimate	   exists	   at	   the	  apical	   surface	   of	   choroidal	   epithelial	   cells.	   Moreover,	   little	   is	   known	   about	   the	  detailed	  driving	  force	  for	  PEPT2	  in	  choroid	  plexus	  [22].	  It	  has	  been	  confirmed	  that	  Na+-­‐K+	  ATPase	  is	  localized	  to	  the	  apical	  membrane,	  and	  the	  Na+-­‐H+	  exchanger	  to	  the	  basolateral	  membrane,	  both	  having	  a	  different	  localization	  from	  the	  intestinal/renal	  models	   [22,	   34,	   35].	  However,	   it	   has	   also	  been	   suggested	   that	   other	   types	  of	  NHE	  may	   be	   expressed	   at	   the	   apical	   membrane,	   thereby	  making	   protons	   available	   for	  H+/peptide	  (or	  mimetic)	  symport	  by	  PEPT2	  [22,	  36].	  
2.1.3 Transporter	  structural	  features	  All	   POTs	   are	   integral	   membrane	   proteins,	   usually	   with	   a	   high	   degree	   of	  glycosylation	   [37].	  Human	  PEPT1	   consists	   of	   708	   amino	   acids,	   and	  human	  PEPT2	  comprises	  729	  amino	  acids	  with	  around	  50%	  amino	  acid	  identity	  to	  PEPT1	  [1].	  As	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suggested	  by	  hydropathic	  analysis,	  both	  PEPT1	  and	  PEPT2	  have	  12	  transmembrane	  domains	  (TMD)	  with	  the	  N-­‐terminal	  and	  C-­‐terminal	  facing	  the	  cytoplasmic	  side,	  and	  a	  large	  extracellular	  loop	  between	  TMD	  9	  and	  TMD	  10	  [26].	  This	  protein	  topology	  is	  consistent	  with	  the	  findings	  from	  epitope	  insertion	  studies	  [38].	  However,	  a	  detailed	  three-­‐dimensional	   structure	   of	   mammalian	   peptide	   transporters	   and	   their	  translocation	  mechanisms	  have	  not	  been	  identified.	  Various	  approaches	  have	  been	  performed	   to	   investigate	   the	   relationship	   between	   protein	   regions	   and	   their	  corresponding	   function.	   On	   the	   basis	   of	   function	   analysis	   of	   the	   established	  chimeras	   of	   PEPT1	   and	   PEPT2,	   it	   was	   shown	   that	   TMD	   1-­‐4	   and	   TMD	   7-­‐9	   are	  important	   regions	   for	   determining	   substrate	   affinity	   and	   substrate	   binding,	  indicating	   they	  might	   form	   the	   binding	   pocket	   of	   substrates	   [39].	   In	   contrast,	   the	  large	   extracellular	   loop	   between	   TMDs	   9	   and	   10	   has	   the	   lowest	   identity	   between	  PEPT1	   and	   PEPT2,	   suggesting	   that	   this	   region	  may	   not	   play	   an	   important	   role	   in	  transport	  function	  since	  it	  is	  not	  present	  in	  the	  proton-­‐dependent	  bacterial	  peptide	  transporter	  YdgR	  [40].	  	  Based	  on	  site-­‐directed	  mutagenesis	  studies	  of	  PEPT1,	  it	  has	  been	  demonstrated	  that	  His57	  is	  important	  in	  the	  binding	  and	  translocation	  of	  H+,	  and	  the	  nearby	  Tyr56	  and	  Tyr64	  may	  help	  to	  stabilize	  the	  charge	  [41,	  42].	  His121	  seems	  to	  be	  involved	  in	  substrate	   recognition	   by	   neutralizing	   the	   charge	   of	   acidic	   peptides	   through	  protonation	   [42].	   For	  PEPT2,	  His87	   appears	   to	  be	   essential	   for	   transport	   function	  because	  the	  mutant	  at	  this	  site	  did	  not	  exhibit	  any	  detectable	  transport	  activity	  for	  PEPT2	  [11,	  43].	  Besides,	  the	  variation	  of	  Arg57His	  was	  found	  to	  cause	  the	  complete	  loss	  of	   the	   transport	   activity	   [44].	  PEPT2	  has	  been	   found	   to	  possess	   two	  variants,	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hPept*1	  and	  hPept*2,	   in	  all	  of	  the	  ethnic	  groups	  tested.	  These	  two	  variants	  showed	  similar	  Vmax	   values	   for	   a	  model	   dipeptide,	  while	  hPept*1	   exhibited	   a	   3-­‐fold	  higher	  affinity	  than	  hPept*2,	  as	  well	  as	  differences	  in	  pH	  sensitivity	  [45].	  The	  crystal	  structure	  of	  a	  prokaryotic	  peptide	  transporter,	  PepTSo,	  was	  recently	  identified,	  providing	  new	  insight	  into	  the	  mechanism	  of	  peptide	  transporter	  [46].	  In	  the	  structure,	   two	  hydrophilic	   cavities,	   a	   central	   cavity	  and	  a	   smaller	  extracellular	  cavity,	   are	   present	   and	   likely	   to	   be	   the	   binding	   sites	   of	   peptide	   and	   proton,	  respectively.	  Based	  on	  the	  crystal	  structure	  of	  PepTSo,	  a	  possible	  model	  of	  transport	  mechanism	   was	   proposed,	   in	   which	   peptide	   transport	   was	   accomplished	   via	   the	  transitions	   among	   three	   states:	   outward-­‐facing	   state,	   occluded	   state,	   and	   inward-­‐facing	  state	  [46].	  However,	   further	  effort	   is	  still	  needed	  to	  identify	  the	  structure	  of	  mammalian	  peptide	  transporters	  and	  to	  better	  understand	  its	  transport	  mechanism.	  	  
2.1.4 Substrate	  specificity	  Proton-­‐coupled	   oligopeptide	   transporters	   have	   a	   broad	   substrate	   spectrum,	  covering	   di-­‐/tripeptides	   and	   a	   variety	   of	   peptide	   analogs.	   With	   some	   exceptions,	  peptide	  transporters	  are	  able	  to	  recognize	  and	  transport	  400	  dipeptides	  and	  8000	  tripeptides	   from	  20	  standard	  amino	  acids.	  Besides,	  numerous	  β-­‐lactam	  antibiotics,	  select	  angiotensin-­‐converting	  enzyme	  inhibitors,	  and	  other	  drugs	  and	  prodrugs	  with	  steric	  resemblance	  to	  peptides	  are	  also	  the	  substrates	  of	  PEPT1	  and	  PEPT2	  [11,	  29].	  Most	   studies	   about	   substrate	   specificities	   are	   based	   on	   the	   relationship	   between	  substance	   structures	   and	   corresponding	   inhibition	   or	   transport	   activities.	   The	  minimal	   structural	   requirement	   for	   substrate	   recognition	   by	   PEPT1	   has	   been	  reported	   as	   two	   oppositely	   charged	   groups	   (NH2	   and	   COOH	   for	   dipeptides)	   being	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separated	   by	   an	   intramolecular	   distance	   of	   500-­‐630	   nm	   [47].	   Other	   general	  structural	   features	   of	   substrates	   have	   also	   been	   found,	   and	   are	   summarized	   as	  follows	  [1,	  11,	  26,	  29]:	  a) An	  NH2	  group	  at	  α	  position	  is	  essential	  for	  substrate	  recognition;	  b) A	  carboxylic	  group	  is	  not	  required	  at	  the	  C-­‐terminal,	  but	  there	  has	  to	  be	  an	  electrogenic	  group,	  like	  aryl	  group	  or	  phosphoric	  group;	  c) A	   peptide	   bond	   is	   not	   essential	   and	   can	   be	   replaced	   by	   ketomethylene	   or	  thioxo;	  d) Hydrophobic	  side	  chains	  are	  preferred	  for	  high	  affinity;	  e) For	  tripeptides,	  neutral	  amino	  acids	  are	  preferred	  as	  the	  third	  residue;	  f) With	  regard	  to	  stereospecificity,	  L-­‐amino	  acids	  are	  preferred;	  g) When	  a	  peptide	  bond	  is	  present,	  it	  should	  be	  in	  trans-­‐conformation.	  
2.1.5 Regulation	  of	  peptide	  transporters	  The	   expression	   levels	   and/or	   function	   activities	   of	   peptide	   transporters	   are	  regulated	  by	  various	  factors,	  such	  as	  development,	  physiological	  status,	  pathological	  conditions,	  hormones,	   and	  drugs	   [26].	   It	   has	  been	   reported	   that	   the	  expression	  of	  PEPT1	  and	  PEPT2	  is	  variable	  as	  a	  function	  of	  development	  and	  age.	  After	  birth,	  the	  expression	   level	   of	   PEPT1	   was	   found	   to	   increase	   markedly	   over	   3-­‐5	   days	   to	   a	  maximal	   level	   in	   the	   small	   intestine,	   then	   rapidly	   decline	   afterward,	   and	   finally	  became	  steady	  and	  close	  to	  the	  adult	   level	  after	  28	  days.	  In	  kidney,	  the	  expression	  level	  of	  PEPT2	   increased	  steadily	  during	  the	   first	   two	  weeks	  after	  birth	   [48].	  With	  respect	  to	  brain,	  the	  expression	  of	  PEPT2	  in	  cerebral	  cortex	  showed	  a	  maximal	  level	  in	   the	   fetus	   and	   then	   declined	   steadily	   over	   the	   next	   75	   days	   after	   birth	   [21].	   In	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addition,	   in	   neonatal	   rats	   PEPT2	   was	   expressed	   in	   both	   astrocytes	   and	   neurons,	  while	  in	  adult	  rats	  only	  neurons	  expressed	  PEPT2.	  In	   the	   small	   intestine,	   food	   intake	   has	   an	   effect	   on	   the	   expression	   levels	   of	  PEPT1.	  With	  a	  high-­‐protein	  diet,	   an	   increase	  was	  observed	   in	  PEPT1	  mRNA	  along	  with	   an	   increase	   in	   the	   intestinal	   transport	   of	   a	  model	   dipeptide	   in	   rats	   [49,	   50].	  However,	  an	  increase	  was	  also	  observed	  in	  PEPT1	  expression	  in	  the	  small	  intestine	  of	   fasted	   rats	   [51].	   Moreover,	   it	   was	   found	   that	   a	   diurnal	   rhythm	  was	   related	   to	  PEPT1	  expression	  in	  rat	  small	  intestine,	  which	  was	  later	  speculated	  to	  be	  the	  result	  of	  diurnal	  food	  intake	  [52].	  	  The	   expression	   of	   peptide	   transporters	   is	   affected	   by	   some	   pathological	  conditions.	  PEPT1	  in	  the	  small	  intestine	  is	  upregulated	  during	  inflammation,	  which	  also	   elicits	   an	   aberrant	   colonic	   expression	   of	   PEPT1	   where	   there	   is	   normally	   no	  PEPT1	   expression	   in	   healthy	   adult	   rats.	   In	   addition,	   an	   upregulation	   of	   colonic	  PEPT1	  expression	  was	  observed	   in	  patients	  with	   inflammatory	  bowel	  disease,	   like	  ulcerative	   colitis	   and	  Crohn’s	  disease	   [53].	   In	   choroid	  plexus,	   it	  was	   reported	   that	  PEPT2	  mRNA	   increased	   as	   a	   response	   to	   peripheral	   inflammation	   [54].	   Although	  this	   finding	   remains	   to	   be	   confirmed,	   it	   suggests	   that	   inflammation	  may	   influence	  the	  expression	  of	  peptide	  transporter	  in	  other	  tissues,	  such	  as	  brain.	  The	  expression	  of	  peptide	   transporters	  was	  also	  modulated	  by	   levels	  of	   some	  hormones	  including	  thyroid	  hormone,	  leptin,	  insulin,	  and	  EGF,	  as	  well	  as	  some	  drugs	  such	   as	  pentazocine,	   5-­‐fluorouracil,	   Ca2+-­‐channel	   blockers	   and	   cyclosporine	  A	   [19,	  26].	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2.2 Substance	  Flux	  in	  Brain	  
The	   brain	   is	   the	   most	   complex	   organ	   in	   human,	   even	   in	   all	   vertebrates,	  responsible	   for	   perception,	   information	   processing,	   motor	   control,	   as	   well	   as	   the	  center	  for	  the	  intellect,	  emotions,	  behavior,	  and	  memory	  [55].	  In	  order	  to	  maintain	  a	  stable	   chemical	   environment	   for	   normal	   function	   of	   the	   central	   nervous	   system	  (CNS)	   consisting	   of	   brain	   and	   spinal	   cord,	   there	   are	   a	   series	   of	   elaborate	  mechanisms	  to	  control	  the	  entry,	  disposition,	  and	  exit	  of	  substances	  in	  the	  brain	  and	  spinal	   cord.	   These	   mechanisms	   involve	   tight	   junctions	   at	   the	   brain	   barriers,	  enzymes	  and	  transporters,	  and	  the	  circulation	  of	  CSF.	  
2.2.1 CSF	  and	  choroid	  plexus	  	  Cerebrospinal	   fluid	   (CSF)	   is	   a	   clear,	   colorless	   fluid,	   continuously	   circulating	  through	  the	  four	  ventricles	  in	  brain	  and	  the	  subarachnoid	  space	  around	  brain,	  with	  the	  driving	  force	  being	  the	  difference	  in	  hydrostatic	  pressure	  between	  the	  CSF	  and	  venous	  blood	  [56].	  Most	  of	  the	  CSF	  (more	  than	  75%)	  is	  formed	  in	  choroid	  plexuses	  (CPs)	   located	  at	   the	   roof	  of	   the	  ventricles,	   and	  a	   small	  portion	  of	  CSF	   comes	   from	  extracellular	  fluid	  (ECF)	  of	  brain	  parenchyma	  across	  the	  ependymal	  lining	  into	  the	  ventricles	   [57].	   As	   shown	   in	   Figure	   2-­‐3,	   CSF	   formed	   in	   the	   two	   lateral	   ventricles	  flows	   through	   the	   interventricular	   foramina	   into	   the	   third	   ventricle,	   where	   more	  CSF	  is	  produced	  by	  the	  CP.	  The	  fluid	  then	  passes	  through	  the	  cerebral	  aqueduct	  from	  the	  third	  ventricle	  into	  the	  fourth	  ventricle,	  where	  again	  more	  CSF	  is	  added.	  There	  are	  three	  foramina	  at	  the	  wall	  of	  the	  fourth	  ventricle	  through	  which	  the	  CSF	  enters	  the	  subarachnoid	  space,	  an	  area	  formed	  by	  the	  pia	  mater	  and	  arachnoid	  mater	  (the	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dura,	   arachnoid,	   and	   pia	   maters	   are	   three	   membranes	   consisting	   of	   meninges	  enveloping	   the	   CNS).	   Finally	   the	   CSF	   exits	   from	   the	   subarachnoid	   space	   into	   the	  venous	   blood	   through	   small	   unidirectional	   valves	   called	   arachnoid	   granulations,	  which	   are	   made	   of	   a	   cluster	   of	   arachnoid	   villi	   protruding	   into	   the	   dural	   sinus.	  Besides	  entering	   the	  arachnoid	  granulations	   into	  blood,	  part	  of	   the	  CSF	  exits	   from	  CNS	   via	   lymphatic	   drainage	   pathways	   into	   extracranial	   lymphatic	   vessels	   [55,	   58,	  59].	  The	   volume	   of	   human	   CSF	   is	   around	   150	  mL	   and	   only	   25	  mL	   of	   the	   fluid	   is	  contained	  within	  the	  ventricles	  [57].	  The	  rate	  of	  CSF	  production	  is	  about	  21	  mL/hr	  with	  a	  turnover	  rate	  of	  3-­‐4	  times	  per	  day	  [58].	  CSF	  has	  multiple	  functions	  in	  the	  CNS	  such	  as	  [55,	  57,	  59]:	  	  3) Mechanical	   protection:	   the	   brain	   “floats”	   in	   CSF	   and,	   thus,	   CSF	   in	   the	  subarachnoid	   space	   plays	   a	   supportive	   role	   mechanically	   as	   a	   cushion	  between	  the	  skull	  and	  brain.	  4) Chemical	  protection:	  the	  CSF	  acts	  like	  a	  buffer	  for	  brain	  and	  spinal	  cord	  with	  a	  highly	  stable	  chemical	  environment.	  For	  example,	  the	  ionic	  composition	  of	  the	   CSF	   is	  maintained	   constant	   because	   the	   extracellular	   concentration	   of	  some	  ions	  (e.g.	  Ca2+	  and	  Na+)	  are	  important	  for	  the	  production	  and	  spread	  of	  action	  potentials	  and,	  thus,	  crucial	  for	  neuronal	  signaling.	  5) Chemical	   communication:	   the	  CSF	  mediates	  efficient	  exchange	  of	  nutrients	  and	  waste	  products	  between	  the	  blood	  and	  nervous	  tissue.	  In	  addition,	  the	  CSF	   is	   likely	   to	   act	   as	   a	   channel	   for	   the	   spread	   of	   neuroactive	   hormones	  within	  the	  CNS.	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2.2.2 Barriers	  in	  brain	  Due	   to	   the	   importance	   of	   the	   brain,	   there	   are	   several	   barriers	   developed	   in	  brain	   to	   protect	   it	   from	   toxic	   and	   exogenous	   substances	   (Figure	   2-­‐3).	   The	   blood-­‐brain	  barrier	  (BBB)	  has	  been	  focused	  on	  for	  decades	  as	  a	  barrier	   for	  CNS-­‐targeted	  drug	   delivery.	   The	   BBB	   is	   situated	   at	   the	   interface	   of	   blood	   and	   brain	   tissues,	  consisting	   of	   endothelial	   cells	   of	   capillaries	   and	   an	   underlying	   thick	   basement	  membrane	   [60].	   The	   major	   morphological	   basis	   for	   the	   BBB	   is	   tight	   junctions	  between	   adjacent	   endothelial	   cells	   of	   cerebral	   capillaries,	   which	   lack	   fenestration	  and	   pinocytotic	   vesicles.	   The	   network	   of	   complex	   tight	   junctions	   blocks	   the	  paracellular	  pathway	  of	  substances.	  Therefore,	  molecules	  have	  to	  cross	  the	  barrier	  either	   by	   passive	   diffusion,	   transporters,	   or	   transcytosis	   through	   endothelial	   cells	  [61].	   In	   addition	   to	   endothelial	   cells,	   the	   basement	   membrane	   enveloping	   the	  capillaries	   is	   part	   of	   the	   BBB.	   The	   basement	   membrane	   is	   a	   layer	   containing	  pericytes	   and	   end-­‐feet	   of	   astrocytes,	   which	   play	   a	   supportive	   role	   for	   endothelial	  cells	   and	   maintain	   permeability	   characteristics	   of	   the	   BBB	   [55,	   60].	   It	   should	   be	  noted	  that	  some	  brain	  regions	  lack	  a	  BBB	  and	  these	  regions	  are	  collectively	  termed	  circumventricular	  organs	  (CVOs),	  whose	  function	  usually	  requires	  free	  access	  to	  the	  bloodstream	  such	  as	  monitoring	   the	  chemical	  environment	   in	  blood	  and	  releasing	  hormones	  into	  the	  blood	  [57,	  59].	  However,	  specialized	  ependymal	  cells	  (tanycytes)	  with	  tight	  junctions	  form	  a	  barrier	  between	  circumventricular	  organs	  and	  the	  rest	  of	  the	  brain	  [57].	  Another	  barrier	   in	  brain	   is	   the	  blood-­‐CSF	  barrier	   (BCSFB),	   formed	  by	   choroid	  plexus	   epithelial	   cells.	   The	   choroid	   plexus	   is	   a	   structure	   comprising	   a	   layer	   of	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epithelial	  cells	  surrounding	  a	  network	  of	  capillaries	  [22].	  Unlike	  cerebral	  capillaries	  of	   the	   BBB,	   endothelial	   cells	   of	   capillaries	   at	   choroid	   plexuses	   do	   not	   have	   tight	  junctions	   and,	   thus,	   substances	   can	   pass	   readily	   through	   fenestrations	   and	  intercellular	  spaces.	  Capillaries	  and	  CP	  epithelium	  are	  separated	  by	  a	   thin	   layer	  of	  connective	   tissue	   that	   consists	   of	   collagen	   bundles	   and	   a	   few	   fibroblast-­‐like	   cells	  (referred	   to	   as	   pia	   cells	   in	   some	   literature)	   [62-­‐64].	   CP	   epithelium	   is	   a	   layer	   of	  cuboidal	  epithelial	  cells	  that	  are	  similar	  to	  ependymal	  cells	  except	  they	  have	  linking	  tight	  junctions,	  which	  are	  the	  structural	  basis	  of	  the	  BCSFB.	  Numerous	  microvilli	  are	  present	   at	   the	   apical	   side	   of	   CP	   epithelial	   cells	   facing	   the	   CSF	   of	   the	   ventricles.	  Furthermore,	  the	  CP	  folds	  itself	  into	  numerous	  fronds	  and	  villi,	  which	  together	  with	  microvilli	   extensively	   increase	   the	   surface	   area	   of	   CP,	   thereby,	   facilitating	   the	  efficient	  secretion	  of	  CSF	  into	  ventricles	  [57].	  In	  addition	  to	  the	  BCSFB	  at	  CP	  in	  the	  ventricles,	  the	  outermost	  part	  of	  arachnoid	  mater	   forms	   a	   barrier	   at	   the	   interface	   with	   dura.	   These	   well-­‐packed	   cells	   in	   the	  arachnoid	   barrier	   have	   numerous	   tight	   junctions,	   which	   restrict	   chemical	  communication	   between	   the	   CSF	  within	   subarachnoid	   space	   and	   the	   ECF	   of	   dura	  mater,	  where	  there	  is	  no	  barrier	  between	  blood	  and	  dural	  ECF	  [65,	  66].	  	  Besides	  the	  physical	  barrier	  resulting	  from	  tight	  junctions,	  the	  BBB	  and	  BCSFB	  express	   a	   number	   of	   efflux	   transporters	   for	   the	   removal	   of	   waste	   products	   and	  potential	  toxins	  from	  the	  brain	  [67,	  68].	  Moreover,	  many	  enzymes	  are	  present	  in	  the	  BBB	  and	  BCSFB,	   forming	  a	  metabolic	  barrier	   that	   can	   limit	   substance	  movements,	  and	   remove	   endogenous	   compounds	   and	   xenobiotics	   [69].	  All	   of	   these	  barriers	   in	  brain	   serve	   to	   increase	   the	   selectivity	   of	   substances	   entering	   the	   CNS	   and	   the	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continuous	  removal	  of	  potential	   toxins,	   thereby,	  maintaining	  a	  stable	  environment	  for	  correct	  functioning	  of	  the	  nervous	  system.	  
2.2.3 Flux	  pathways	  in	  brain	  The	   brain	   is	   the	   most	   delicate	   and	   complex	   organ	   in	   the	   body.	   Its	   chemical	  communication	  with	   the	  rest	  of	  body	  (primarily	  blood)	   is	  under	  strict	  control	  and	  regulation	  due	  to	   the	  existence	  of	  multiple	  barrier	  mechanisms.	  With	  an	  extensive	  surface	  area	  and	  the	  presence	  of	  numerous	  transporters,	  the	  BBB	  (and	  BCSFB)	  are	  major	  sites	  of	  chemical	  exchange	  between	  the	  brain	  (and	  CSF)	  and	  blood.	  
Flux	  pathways	  between	  blood	  and	  brain	  parenchyma	  The	   BBB	   is	   the	   site	   of	   direct	   chemical	   exchange	   between	   blood	   and	   brain	  parenchyma	  with	  the	  exception	  of	  circumventricular	  organs.	  Paracellular	  passage	  of	  water-­‐soluble	  compounds	  is	  severely	  restricted	  by	  the	  presence	  of	  tight	  junctions	  at	  the	  BBB.	  Instead,	  most	  hydrophilic	  compounds	  are	  selectively	  transported	  into	  the	  brain	   by	   transporters	   that	   are	   present	   in	   endothelial	   cells	   [61].	   For	   example,	  nutrients	  cross	  the	  BBB	  via	  transporters,	  such	  as	  GLUT1	  (glucose	  transporter	  1)	  and	  LAT1	   (L-­‐type	   amino	   acid	   transporter),	   both	   of	   which	   are	   facilitative	   transporters	  mediating	   substance	   transport	   along	   concentration	   gradient	   at	   the	   abluminal	   and	  luminal	   surfaces	   of	   endothelial	   cells	   [70,	   71].	   On	   the	   other	   hand,	   it	   is	   easier	   for	  lipophilic	  compounds	  to	  cross	  capillary	  endothelial	  cells	  by	  passive	  diffusion,	  which	  depends	  highly	  on	  the	  molecular	  size	  and	  hydrophobicity	  of	  substances.	  In	  general,	  molecules	   with	   higher	   octanol/water	   partition	   coefficients	   tend	   to	   penetrate	   into	  brain	   tissues	   more	   readily	   [61].	   However,	   a	   significant	   number	   of	   lipophilic	  compounds	  have	  lower	  brain	  permeabilities	  than	  predicted	  from	  their	  lipophilicity,	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which	   is	   the	  result	  of	  efflux	  transporters	  expressed	  at	  the	  BBB	  (Figure	  2-­‐4).	  These	  efflux	   transporters	   play	   an	   important	   role	   in	   reducing	   the	   exposure	   of	   potential	  toxins	   in	  brain,	  but	   also	   in	   substantially	   limiting	   the	  penetration	  of	  drugs	   into	   the	  CNS	   [72].	  Drug	   transporters	   at	   the	  BBB	  belong	   to	   two	   superfamilies:	  ATP-­‐binding	  cassette	   (ABC)	   transporters	   including	   P-­‐glycoprotein	   (Pgp),	   multidrug	   resistance	  proteins	   (MRP),	   and	   breast	   cancer	   resistance	   protein	   (BCRP);	   and	   solute	   carrier	  (SLC)	   transporters	   including	   organic	   anion-­‐transporting	   polypeptides	   (OATP)	   and	  organic	   anion	   transporters	   (OAT)	   [73].	   Unlike	   small	   molecules	   using	   passive	  diffusion	  or	  transporters,	  macromolecules	  like	  insulin	  and	  albumin	  move	  across	  the	  BBB	  mainly	  by	  receptor-­‐mediated	  or	  adsorptive	  endocytosis	  [74].	  	  
Flux	  pathways	  between	  blood	  and	  CSF	  CSF	  in	  the	  subarachnoid	  space	  (SAS)	  has	  two	  forms	  of	  interfaces	  with	  the	  extra-­‐CNS	   environment:	   arachnoid	   granulations	   and	   the	   arachnoid	   barrier	   cell	   layer.	  Arachnoid	   granulation	   is	   a	   structure	   at	   the	   interface	   between	   CSF	   and	   blood,	   the	  main	  site	  for	  the	  drainage	  of	  the	  CSF	  into	  the	  systematic	  circulation	  [57].	  Therefore,	  it	   is	   the	   place	   where	   numerous	   compounds	   in	   CSF	   including	  waste	   products	   exit	  from	   the	   CNS.	   However,	   it	   is	   not	   likely	   for	   substances	   in	   blood	   to	   enter	   the	   CNS	  through	   arachnoid	   granulations	   because	   of	   the	   bulk	   motion	   from	   CSF	   into	   blood	  (350	  μL/min)	  and	  its	  characteristics	  of	  unidirectional	  valves	  [58,	  75].	  As	  mentioned	  previously,	  there	  is	  a	  barrier	  made	  of	  well-­‐packed	  arachnoid	  cells	  and	  their	  linking	  tight	   junctions	  between	   the	  CSF	  and	  dural	  ECF.	  There	  might	  be	  a	   small	  amount	  of	  compound	   exchange	   across	   the	   arachnoid	   barrier	   between	   CSF	   and	   blood	  circulation	   in	   dura	   mater.	   An	   immunohistochemical	   analysis	   revealed	   that	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arachnoid	  barrier	  cells	  also	  express	  some	  transporters	  including	  Pgp	  and	  BCRP	  that	  may	  function	  as	  efflux	  transporters	  eliminating	  compounds	  from	  CSF	  [76].	  However,	  there	  have	  been	  limited	  studies	  focusing	  on	  the	  chemical	  exchange	  across	  arachnoid	  barrier	  cells.	  On	   the	   other	   hand,	  movement	   of	   substances	   at	   the	   BCSFB	   (i.e.	   at	   the	   choroid	  plexuses	   in	  ventricles)	  have	  been	  widely	  studied	  because	  the	  choroid	  plexuses	  are	  not	  only	  the	  tissue	  in	  which	  the	  BCSFB	  is	  located	  but	  also	  the	  tissue	  that	  contributes	  most	   to	   the	   secretion	  of	   the	  CSF.	  Therefore,	   choroid	  plexuses	   are	   the	  main	   site	   of	  compound	  exchange	  between	  the	  CSF	  and	  blood.	  Compared	   to	   the	  BBB	  with	  an	   in	  
vitro	   electrical	   resistance	   of	   8000	   Ωcm2,	   the	   BCSFB	   exhibits	   a	   lower	   level	   of	  tightness	   (i.e.	   “leakier”)	   with	   an	   electrical	   resistance	   of	   150-­‐175	   Ωcm2,	   which	   is	  probably	   the	   result	   of	   adapting	   the	   choroid	   plexuses	   to	   function	   in	   CSF	   secretion	  [22].	   Similar	   to	   the	   BBB,	   choroid	   plexus	   epithelial	   cells	   express	   a	   number	   of	  transporters	   to	   mediate	   and	   control	   substance	   flux	   across	   the	   BCSFB.	   Some	  transporters	  at	  the	  BBB	  are	  also	  expressed	  at	  the	  BCSFB,	  such	  as	  Pgp,	  MRP1,	  OAT3,	  and	  OATP1,	  some	  of	  which,	  however,	  may	  have	  different	  function.	  For	  example,	  Pgp	  expressed	   at	   the	   luminal	   side	   of	   the	   BBB	   endothelial	   cells	   mediates	   the	   efflux	   of	  substrates	  into	  blood,	  while	  Pgp	  at	  the	  apical	  side	  of	  CP	  epithelium	  is	  responsible	  for	  the	  influx	  of	  substrates	  into	  CSF	  [72,	  73].	  
Flux	  pathways	  between	  CSF	  and	  brain	  parenchyma	  In	  contrast	  to	  the	  barriers	  between	  CNS	  and	  blood,	  no	  tight	  junctions	  exist	  at	  the	  interface	  between	  CSF	  and	  brain	  parenchyma	  and,	  thus,	  molecules	  can	  diffuse	  more	  readily	   across	   this	   interface.	   In	   ventricles,	   the	   CSF-­‐brain	   parenchyma	   interface	   is	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formed	  by	   ependymal	   cells,	  which	   connect	   each	  other	   by	   gap	   junctions	   instead	  of	  tight	   junctions	   [22].	   In	   the	   subarachnoid	   space,	   the	   pia	  mater	   and	   glia	   limitan	   (a	  layer	  made	  of	  astrocyte	  end-­‐feet)	  comprise	  the	  interface	  between	  the	  CSF	  and	  brain	  parenchyma,	   which	   is	   also	   permeable	   leading	   to	   the	   effective	   chemical	   exchange	  [66].	   In	   addition	   to	  molecule	   diffusion	   across	   this	   interface,	   there	   is	   bulk	   flow	   of	  interstitial	   fluid	   (ISF)	   in	   brain	   parenchyma	   across	   the	   ependymal	   lining	   into	  ventricles,	   forming	   a	   small	   portion	   of	   CSF,	   which	   is	   considered	   to	   be	   originally	  generated	   from	  the	  brain	  capillaries	   [57].	  A	  recent	  study	  using	   in	  vivo	   two-­‐photon	  imaging	   of	   fluorescent	   tracers	   discovered	   that	   paravascular	   spaces	   serve	   as	  channels	   for	   the	   bulk	   flows	   between	   CSF	   and	   brain	   ECF	   [77].	   Specifically,	  subarachnoid	  CSF	  enters	  brain	  parenchyma	  through	  the	  channels	   formed	  between	  artery	   vessel	   and	   astrocytic	   endfeet;	   and	   brain	   ECF	   flows	   into	   CSF	   compartment	  along	   paravenous	   spaces.	   The	   paravascular	   pathways	   provide	   higher	   exchange	  efficiency	   between	   CSF	   and	   brain	   ECF	   compared	   to	   diffusion/flow	   in	   the	  extracellular	  spaces.	  When	  substance	  concentrations	  in	  parenchymal	  ISF	  are	  higher	  than	  that	  in	  CSF,	  molecules	  may	  move	   from	   the	  parenchyma	   into	  CSF,	  where	   the	  molecules	   further	  move	  with	   the	  CSF	   flow	   through	   the	   ventricles	   and	   subarachnoid	   space,	   and	   then	  finally	  leave	  the	  CNS	  into	  the	  systematic	  circulation	  through	  arachnoid	  villi.	  This	  is	  the	   so-­‐called	   sink	   effect	   (or	   sink	   action),	   which	   describes	   the	   CSF	   drainage	   as	   a	  “sink”[58,	  61,	  78].	  The	  sink	  effect	  plus	  the	  presence	  of	  efflux	  transporters	  at	  the	  CP	  contributes	   to	   the	   reduction	   of	   waste	   products	   and	   xenobiotics	   in	   CNS,	   thereby	  demonstrating	   the	   chemical	   protection	   function	   of	   CSF.	   On	   the	   other	   hand,	   when	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substance	   concentrations	   are	   higher	   in	   CSF	   than	   ISF,	   the	   molecules	   are	   likely	   to	  penetrate	  into	  brain	  parenchyma,	  for	  example	  in	  cases	  of	  injection	  into	  ventricles	  or	  cisterna	  magna	  or	  [23].	  
2.2.4 Role	  of	  PEPT2	  in	  brain	  	  As	  previously	  mentioned,	  PEPT2	  is	  located	  at	  epithelial	  cells	  of	  choroid	  plexus,	  neurons,	  and	  neonatal	  astrocytes	  in	  brain,	  where	  this	  transporter	  protein	  was	  found	  to	  have	  a	  significant	  impact	  on	  the	  disposition	  of	  peptides	  and	  peptidomimetics	  [22].	  At	   choroid	  plexuses,	  PEPT2	  situated	  at	   the	  brush	  border	  membrane	  can	   transport	  substrates	   from	   CSF	   into	   epithelial	   cells,	   thus	   limiting	   the	   CNS	   exposure	   of	  peptides/peptidomimetics,	  which	  has	  been	  confirmed	  using	  CP	  cell	  monolayers	  and	  isolated	  CP	  whole	  tissue	  for	  a	  series	  of	  PEPT2	  substrates	  [28,	  36,	  79-­‐82].	  Consistent	  with	  this	  finding,	  in	  vivo	  studies	  on	  GlySar,	  cefadroxil	  and	  the	  endogenous	  substance	  5-­‐ALA	   demonstrated	   higher	   CSF	   substrate	   concentrations	   and	   lower	   CP	  accumulations	  in	  Pept2	  null	  mice	  compared	  to	  wild-­‐type	  mice	  following	  intravenous	  or	   intracerebroventricular	   injection	   [20,	   83-­‐85].	   In	   brain	   parenchyma,	   neonatal	  astrocytes	   from	  wild-­‐type	  mice	  exhibited	  higher	  uptake	  of	  neuropeptides	   (such	  as	  carnosine,	  L-­‐kyotorphin,	  and	  5-­‐ALA)	  than	  that	  from	  Pept2	  null	  mice,	  and	  the	  uptake	  was	  inhibited	  by	  PEPT2	  substrates	  [86-­‐88].	  These	  findings	  suggest	  that	  PEPT2	  plays	  a	  significant	  role	  in	  the	  removal	  of	  neuropeptides,	  peptide	  fragments,	  and	  peptide-­‐like	  drugs	   from	  CSF	  and	  ECF	  of	  parenchyma.	  By	   influencing	  substance	  disposition,	  PEPT2	  could	  have	  an	  impact	  on	  the	  pharmacological	  or	  toxic	  effect	  of	  substrates	  as	  well.	   For	   example,	   a	   greater	   neurotoxicity	   of	   5-­‐ALA	  was	   found	   in	  Pept2	   null	  mice	  than	   in	   wild-­‐type	   mice	   [84].	   Compared	   to	   wild-­‐type	   mice,	   Pept2	   null	   mice	   also	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showed	   higher	   antinociceptive	   response	   following	   the	   administration	   of	   L-­‐kyotorphin	  [85].	  With	  respect	  to	  the	  influence	  of	  PEPT2	  on	  regional	  distribution	  of	  substrates	  in	  the	  brain,	  quantitative	  autoradiography	  of	  [14C]GlySar	  after	  intracerebroventricular	  injection	  showed	  distinct	  regional	  distribution	  of	  GlySar	  in	  brain	  between	  wild-­‐type	  and	  Pept2	  null	  mice.	  Specifically,	  Pept2	  null	  mice	  showed	  a	   lower	  uptake	  of	  GlySar	  by	   the	   choroid	  plexuses	  and	  by	   the	  ependymal-­‐subependymal	   layer,	   but	   a	   greater	  half-­‐distance	   of	   penetration	   into	   the	   parenchyma	   [23].	   However,	   no	   further	  information	   is	   available	   about	   the	   influence	  of	  PEPT2	  on	   the	   regional	  distribution	  kinetics	  of	  its	  substrates,	  especially	  the	  ECF	  of	  brain	  parenchyma.	  
2.3 Microdialysis	  
Microdialysis,	   an	   in	   vivo	   technique	   that	   enables	   the	   continuous	   sampling	   and	  collection	   of	   unbound	   substances	   from	   ECF,	   was	   originally	   developed	   by	  neuroscientists	   for	   measuring	   neurotransmitters	   in	   the	   brain.	   The	   concept	   of	  microdialysis	   started	   in	   the	   1960s	   with	   the	   invention	   of	   “probes”	   (push-­‐pull	  cannulas,	   dialysis	   bags,	   and	   dialytrodes)	   inserted	   into	   brain	   tissue	   [89].	   In	   1974,	  Ungerstedt	   and	   colleagues	   [90]	   developed	   an	   improved	   microdialysis	   probe	   to	  efficiently	  measure	   neurotransmitters	   in	   rat	   brain,	  which	   formed	   the	   basis	   of	   the	  present	   microdialysis	   technique	   using	   needle	   probes.	   With	   the	   facilitation	   of	   the	  development	   of	   sensitive	   analytical	   methods,	   microdialysis	   has	   been	   widely	   used	  not	  only	  in	  the	  neurosciences,	  but	  also	  in	  other	  areas	  such	  as	  pharmacokinetics	  and	  toxicology.	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2.3.1 Principle	  of	  microdialysis	  The	   main	   components	   of	   microdialysis	   include	   a	   microdialysis	   probe,	   a	  perfusion	  pump,	   inlet	   and	  outlet	   tubing,	   and	  collecting	  vials	   (or	   connections	   to	  an	  analytical	  instrument	  system	  for	  on-­‐line	  monitoring).	  The	  microdialysis	  probe	  is	  the	  most	   important	   component,	   which	   is	   implanted	   into	   the	   tissue	   (e.g.	   brain	  parenchyma)	  or	  body	   fluid	   (e.g.	  CSF	  and	  blood)	  before	   the	  dialysis	  process.	  There	  are	   a	   variety	   of	   probe	   types	   with	   different	   geometries,	   the	   selection	   of	   which	  depends	   on	   the	   selected	   tissue	   [91,	   92].	   For	   intracerebral	   microdialysis,	   the	  concentric	  probe	  is	  most	  often	  used	  as	  shown	  in	  Figure	  2-­‐5.	  The	  tip	  of	  a	  concentric	  probe	   is	   made	   of	   semipermeable	   membrane	   and	   an	   inner	   cannula,	   where	   the	  membrane	  permits	   free	  movement	  of	  unbound	   solutes	  with	   small	  molecular	   sizes	  and	   restricts	   macromolecules	   such	   as	   proteins.	   A	   variety	   of	   membranes	   with	  different	  pore	  sizes	  and	  materials	  are	  available,	  which	  should	  be	  chosen	  according	  to	   the	  physicochemical	  properties	  of	   compounds	  of	   interest	   to	  assure	   the	  efficient	  diffusion	   of	   the	   compounds	   across	   the	  membrane	   [93,	   94].	   During	   the	   process	   of	  microdialysis,	  the	  probe	  is	  perfused	  with	  perfusate	  at	  a	  constant	  flow	  rate	  (typically	  ranging	   between	   0.1	   and	   5	   μL/min)	   [95].	   Perfusate	   is	   an	   aqueous	   solution	   with	  closely	   matched	   ionic	   composition	   to	   the	   periprobe	   fluid	   to	   make	   the	   minimal	  disturbance	  to	  the	  tissue	  physiological	  environment	  by	  avoiding	  unwanted	  drainage	  or	  introduction	  of	  water	  and	  solute	  molecules	  [93].	  After	  perfusate	  flows	  out	  of	  the	  inner	  cannula	  and	  arrives	  at	  the	  membrane,	  solute	  exchange	  between	  the	  perfusate	  and	  the	  periprobe	  fluid	  occurs	  across	  the	  membrane	  along	  a	  concentration	  gradient.	  Thus,	  microdialysis	   can	   be	   applied	   for	   tissue	   ECF	   sampling	  when	   the	   perfusate	   is	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devoid	   of	   the	   compound	   of	   interest,	   as	   well	   as	   for	   delivering	   compounds	   into	  selected	   tissues	   (retrodialysis).	   Overall,	   in	   the	   microdialysis	   device	   system	   the	  perfusate	  originates	  from	  the	  infusion	  pump	  and	  flows	  through	  the	  inlet	  tubing	  and	  microdialysis	  probe,	  where	  solutes	  diffuse	  across	  the	  membrane.	  Subsequently,	  the	  solution	   flowing	  out	  of	   the	  probe	   (dialysate)	  enters	   the	  outlet	   tubing	  and	   flows	   to	  the	  collection	  vials	  or	  on-­‐line	  analytical	  detection	  system	  [91].	  
2.3.2 Relative	  recovery	  Since	   fluid	   continuously	   flows	   through	   the	   microdialysis	   probe,	   substance	  exchange	  between	  the	  two	  sides	  of	  the	  membrane	  never	  reaches	  equilibrium	  when	  substance	   concentration	   in	   the	   perfusate	   differs	   from	   that	   in	   the	   periprobe	   fluid.	  Therefore,	   a	   problem	  with	   the	   application	   of	   microdialysis	   for	   tissue	   sampling	   is	  that	   the	  measured	  concentration	  of	  analyte	   in	   the	  dialysate	   is	   less	   than	  that	   in	   the	  ECF	   surrounding	   the	   probe.	   In	   order	   to	   evaluate	   the	   actual	   concentrations	   of	  substance	   in	   tissue	   based	   on	   the	   monitored	   concentrations	   in	   dialysate,	   it	   is	  necessary	   to	   correct	   for	   the	   relative	   recovery	   or	   extraction	   fraction	   of	   the	   probe	  [93].	  In	  the	  case	  where	  perfusate	  is	  devoid	  of	  analyte,	  the	  ratio	  of	  the	  concentration	  in	   dialysate	   to	   that	   in	   tissue	   ECF	   is	   referred	   to	   as	   relative	   recovery	   [95].	   When	  perfusate	  contains	  a	  certain	  amount	  of	  analyte,	  the	  degree	  of	  equilibration	  between	  dialysate	  and	  tissue	  ECF	  is	  referred	  to	  as	  extraction	  fraction	  (EF)	  [94]:	  
	   	  	   (Eq	  1)	  
where	   Cin	   is	   the	   analyte	   concentration	   in	   perfusate,	   Cout	   is	   the	   analyte	  concentration	  in	  dialysate,	  and	  Ce	  is	  the	  analyte	  concentration	  in	  external	  medium,	  
EF = Cin −CoutCin −Ce
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i.e.	   the	   ECF	   of	   surrounding	   tissue.	   Relative	   recovery	   (RR)	   is	   the	   special	   case	   of	  extraction	  fraction	  when	  Cin=0,	  and	  RR=Cout/Ce.	  Relative	  recovery	  or	  extraction	  fraction	  is	  influenced	  by	  several	  factors	  such	  as	  the	   perfusion	   flow	   rate,	   membrane	   material	   and	   surface	   area,	   physicochemical	  properties	  of	  analyte,	  and	  the	  properties	  of	  selected	  tissue	  [91,	  93].	   In	  general,	   the	  lower	  the	  perfusion	  flow	  rate,	  the	  higher	  the	  relative	  recovery	  [96].	  When	  the	  flow	  rate	   is	   less	   than	  0.1	  μL/min,	   substance	  exchange	  across	   the	  membrane	   is	   close	   to	  equilibrium	   and,	   therefore,	   the	   relative	   recovery	  may	   be	   close	   to	   100%	   [97,	   98].	  However,	   at	   extremely	   slow	   flow	   rates,	   a	   more	   sensitive	   analytical	   method	   is	  required	   for	   the	   reduced	   sample	   volume	   and	   analyte	   amount.	   Alternatively,	   the	  sampling	  period	  has	  to	  be	  elongated,	  however,	  reducing	  the	  time	  resolution.	  Thus,	  in	  most	   situations	   the	   flow	  rate	  of	  1	  μL/min	   is	  used	   [91,	  93].	   In	  addition	   to	   the	   flow	  rate,	   factors	   influencing	  molecular	  diffusion	  may	  change	  relative	  recovery	  because	  chemical	   exchange	   between	   the	   perfusate	   and	   ECF	   is	   the	   result	   of	   the	   molecule	  diffusion.	  For	  example,	  higher	  temperatures	  can	  increase	  the	  diffusion	  coefficient	  of	  a	  substance	  and,	  thereby,	  increase	  its	  relative	  recovery.	  Increase	  in	  the	  surface	  areas	  of	   the	   probe	   membrane	   can	   also	   lead	   to	   an	   increased	   recovery	   [96,	   99].	   Other	  factors	  include	  molecular	  size	  and	  lipophilicity	  of	  the	  substances	  of	  interest,	  as	  well	  as	   molecular	   weight	   cut-­‐offs	   and	   the	   material	   of	   membranes	   [100,	   101].	   In	   the	  mathematical	   framework	   developed	   by	   Bungay	   [102]	   for	   microdialysis	   at	   steady	  state,	  a	  mass	  transport	  resistance	  (R)	  is	  used	  to	  express	  analyte	  diffusion	  including	  the	  resistances	   in	  dialysate	  (Rd),	  probe	  membrane	  (Rm)	  and	  external	  medium	  (Re),	  among	  which	  Re	   is	   the	   largest	   resistance	  generally	  observed	   for	   small	  hydrophilic	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substances.	   Factors	   contributing	   to	   the	   large	   tissue	   resistance	   are:	   (1)	   increased	  hindrance	   caused	   by	   the	   presence	   of	   cells	   with	   low-­‐permeable	   membranes;	   (2)	  increased	  diffusional	  pathway	  or	  tortuosity;	  and	  (3)	  analyte	  binding	  to	  cell	  surface	  proteins.	  	  Since	   the	   largest	   resistance	   exists	   in	   the	   studied	   tissue,	   relative	   recovery	  measured	   from	   in	   vitro	   microdialysis	   methods	   does	   not	   correctly	   reflect	   in	   vivo	  recovery,	  which	   is	  necessary	   to	  obtain	  accurate	  concentrations	   in	   the	  ECF.	  Several	  calibration	  methods	  have	  been	  developed	  to	  estimate	  in	  vivo	  relative	  recovery.	  
No-­‐net-­‐flux	  method	  The	  no-­‐net-­‐flux	  calibration	  method	  [103]	  involves	  the	  consecutive	  perfusion	  of	  microdialysis	  probe	  with	  perfusates	   containing	  analyte	  of	  different	   concentrations	  under	   steady-­‐state	   conditions	   in	   tissue.	   The	   difference	   in	   analyte	   concentrations	  between	  perfusate	  and	  dialysate	  is	  then	  plotted	  against	  the	  perfusate	  concentration.	  The	  negative	  slope	  of	  the	  resulting	  regression	  line	  represents	  the	  extraction	  fraction	  of	  the	  probe.	  The	  x-­‐intercept	  of	  the	  regression	  line	  represents	  the	  situation	  in	  which	  the	  concentrations	   in	  the	  perfusate	  and	  external	  medium	  are	  equal,	   i.e.	   there	   is	  no	  net	  flux	  occurring	  across	  the	  probe	  membrane.	  	  Steady-­‐state	   conditions	   are	   required	   for	   the	   no-­‐net-­‐flux	   method.	   A	   modified	  method	   has	   been	   also	   developed	   to	  measure	   the	   in	  vivo	   extraction	   fraction	   under	  transient	  conditions,	  termed	  the	  dynamic	  no-­‐net	  flux	  method	  [104,	  105].	  Instead	  of	  perfusions	  with	   different	   analyte	   concentrations	   in	   the	   animal,	   the	   perfusate	   of	   a	  single	   concentration	   is	   used	   for	   a	   group	   containing	   at	   least	   three	   animals.	   The	  analyte	   concentrations	   in	   the	   perfusate	   are	   different	   among	   the	   groups	   and	   the	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extraction	   fraction	   is	  obtained	  by	  making	  a	   regression	   line	  using	   the	  data	   from	  all	  animals	   at	   a	   specific	   time	   point.	   Thus,	   this	   method	   can	   be	   used	   to	   observe	   the	  change	  in	  in	  vivo	  extraction	  fractions	  as	  a	  function	  of	  time.	  
Retrodialysis	  The	  no-­‐net-­‐flux	  and	  dynamic	  no-­‐net-­‐flux	  methods	  are	   time	  consuming	  and/or	  require	   a	   large	   number	   of	   animals.	   Instead,	   calibration	   by	   retrodialysis	   with	   the	  drug	  of	   interest	  or	  a	  calibrator	   is	  easier,	   thus	   the	  most	  commonly	  used	  method	   to	  measure	  extraction	  fraction.	  Retrodialysis	  of	  the	  studied	  drug	  is	  performed	  on	  drug-­‐naïve	   animals	   (i.e.	   Ce=0)	   using	   the	  perfusate	   containing	   a	   known	   concentration	   of	  drug	  [106].	  Extraction	  fraction	  is	  then	  calculated	  as	  EF=(Cin-­‐Cout)/Cin.	  This	  method	  is	  actually	  a	  one-­‐point	  simplification	  of	   the	  no-­‐net-­‐flux	  method	  and	  assumes	  that	   the	  extraction	  fraction	  is	  constant	  during	  the	  experiment.	  The	  relative	  recovery	  can	  also	  be	  assessed	  using	  retrodialysis	  method	  with	  a	  calibrator,	  a	  compound	  with	  similar	  diffusion,	   transport	   and	   metabolism	   characteristics	   to	   the	   studied	   analyte	   and,	  therefore,	   with	   extraction	   fraction	   of	   calibrator	   equal	   to	   the	   drug.	   [107].	   Drug	  experiments	   and	   calibrator	   retrodialysis	   are	   conducted	   simultaneously	   and,	   thus,	  the	  continuous	  assessment	  of	   in	  vivo	   recovery	   is	  possible	  during	   the	  experimental	  time	  period.	  
Flow	  rate	  method	  As	  mentioned	  previously,	  relative	  recovery	  is	  related	  to	  the	  perfusion	  flow	  rate.	  In	   the	   case	   where	   flow	   rate	   is	   zero,	   equilibrium	   is	   then	   reached	   and	   dialysate	  concentrations	   (Cout)	   are	   equal	   to	   the	   concentration	   of	   the	   analyte	   in	   external	  medium	  (Ce).	  This	  relationship	  can	  be	  described	  as:	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   (Eq	  2)	  
where	  K0	  is	  the	  mass	  transfer	  coefficient,	  A	  is	  the	  membrane	  surface	  area,	  and	  F	  is	   the	   flow	   rate.	   In	   the	   flow	   rate	   method,	   different	   flow	   rates	   are	   applied	   and,	  subsequently,	  the	  varying	  Cout	  values	  are	  measured,	  from	  which	  Ce	  and	  the	  product	  of	  K0A	   can	  be	  obtained	   from	  a	   regression	   analysis	   based	  on	  Equation	  2.	   Then	   the	  recovery	   can	   be	   calculated	   for	   different	   flow	   rates	   [108].	   In	   order	   to	   increase	   the	  accuracy	   of	   the	   regression	   analysis,	   very	   low	   flow	   rates	   should	   be	   used,	   which	  require	  longer	  collection	  times	  and	  thereby	  lower	  temporal	  resolutions.	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accurate	   drug	   concentrations	   in	   tissues	   because,	   in	   most	   cases,	   100%	   recovery	  cannot	   be	   reached.	   Because	   of	   the	   diluting	   effect	   of	   low	   recovery	   and	   short	  collection	  intervals	  (e.g.	  10	  min),	  a	  sensitive	  analytical	  method	  is	  required	  to	  detect	  low	  drug	  concentrations	   in	   limited	  dialysate	   sample	  volumes.	  The	  development	  of	  improved	  analytical	  methods	  such	  as	  HPLC	  and	  mass	  spectrometry,	  to	  some	  extent,	  contribute	   to	   the	   wider	   application	   of	   microdialysis	   in	   the	   past	   20	   years.	  Microdialysis	  focuses	  on	  the	  changes	  of	  substance	  concentration	  in	  a	  specific	  tissue.	  However,	  it	  is	  not	  an	  ideal	  tool	  for	  studying	  multiple	  tissues	  even	  though	  two-­‐probe	  microdialysis	  methods	  have	  been	  developed.	  Another	   limitation	   is	  associated	  with	  microdialysis	   of	   some	   compounds,	   especially	   lipophilic	   substances,	   whose	  adsorption	  to	  tubing	  may	  be	  a	  problem	  for	  the	  accurate	  estimation	  of	  concentration	  in	  the	  ECF.	  In	  some	  cases,	  the	  above	  problem	  may	  be	  solved	  by	  adding	  albumin	  into	  perfusate	  to	  block	  the	  non-­‐specific	  binding	  sites	  on	  microdialysis	  devices.[110]	  	  Another	   important	   consideration	   is	   the	   tissue	   trauma	  caused	  by	   implantation	  of	   the	  microdialysis	   probe.	   For	   intracerebral	  microdialysis,	   acute	   tissue	   reactions	  have	   been	   found,	   such	   as	   decreased	   blood	   flow	   and	   increased	   glucose	  phosphorylation.	  However,	  these	  reactions	  are	  normalized	  after	  a	  recovery	  time	  of	  around	  one	  day	  [111].	  The	  long-­‐term	  reaction	  like	  gliosis	  usually	  starts	  two	  or	  three	  days	  after	  surgery	  [112,	  113].	  As	  a	  result,	   it	   is	  recommended	  that	  microdialysis	  be	  conducted	  between	  one	  and	  two	  days	  after	  surgery.	  With	  respect	  to	  BBB	  integrity	  at	  the	  site	  of	  probe	  implantation,	  there	  is	  some	  controversy.	  It	  was	  demonstrated	  that	  the	  BBB	  still	  keeps	  its	  chemical	  selectivity	  based	  on	  a	  comparison	  of	  BBB	  transport	  for	   compounds	   with	   low	   BBB	   and	   relatively	   high	   permeabilities	   [114,	   115].	   In	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contrast,	   some	   studies	   have	   detected	   low	   BBB-­‐permeable	   substances	   like	   Evans	  Blue	  around	  the	  probe	  and	  in	  surrounding	  brain	  tissue,	  suggesting	  a	  compromised	  BBB	   integrity	   [116].	   BBB	   integrity	   may	   be	   related	   to	   the	   quality	   of	   surgical	  technique	   and	   other	   experimental	   conditions,	   which	   should	   be	   optimized	   to	  minimize	  the	  perturbation	  to	  tissue	  physiology.	  	  	  	  
2.3.4 Applications	  Microdialysis	  was	  originally	  applied	  in	  brain	  tissue	  for	  neurochemistry	  studies,	  specifically	   for	   the	   study	   of	   dopamine	   release	   in	   rat	   brain	   [90].	   Other	  neurotransmitters,	   such	   as	   the	   nitric	   oxide	   precursor	   L-­‐arginine	   and	   GABA	   [117,	  118],	  were	  studied	  after	  brain	  trauma	  or	  during	  cerebral	  ischemia	  to	  obtain	  a	  better	  understanding	   in	   changes	   of	   neurotransmitter	   levels	   during	   pathophysiological	  conditions.	  Some	  other	  endogenous	  substances,	  such	  as	  glucose,	  lactate,	  choline,	  and	  creatinine,	  were	  also	  studied	  by	  microdialysis,	  which	  provides	  a	  unique	  opportunity	  to	   improve	  our	  understanding	  of	   the	  physiology	  and	  pathophysiology	  of	   the	  brain	  [119,	  120].	  In	  addition	  to	  endogenous	  substances	  in	  neuroscience,	  microdialysis	  has	  been	   widely	   utilized	   to	   study	   the	   distribution	   and	   transport	   of	   drugs	   in	   brain.	  Function	  of	  the	  BBB,	  including	  efflux	  transporters	  at	  the	  BBB,	  has	  been	  an	  important	  field	  of	  microdialysis	  application.	  It	  has	  been	  shown	  that	  BBB	  transporters	  play	  an	  important	   role	   in	   the	   clearance	   of	   morphine	   (analgesic)	   and	   gabapentin	  (anticonvulsant)	  using	  intracerebral	  microdialysis	  [109,	  121,	  122].	  In	  addition	  to	  the	  brain,	  other	  tissues	  or	  biological	  fluids	  have	  been	  studied	  by	  microdialysis	  including	  subcutaneous	   adipose	   tissue,	   skin,	   skeletal	   muscle,	   eye,	   heart,	   lung,	   liver,	   kidney,	  bone,	   breast,	   tumor,	   blood,	   and	   bile	   [119].	   Microdialysis	   is	   able	   to	   monitor	   drug	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concentrations	  at	  the	  site	  of	  action,	  which	  is	  more	  relevant	  to	  the	  pharmacological	  effect	   than	   plasma	   concentrations,	   thus	   serving	   as	   a	   better	   criteria	   for	   PK/PD	  correlation	   as	   well	   as	   being	   a	   useful	   tool	   for	   drug	   candidate	   selection	   and	   dose	  optimization	  [95,	  123].	  	  The	   technique	   of	   microdialysis	   has	   also	   been	   applied	   in	   clinical	   practice	   and	  research	   to	   study	   the	   biochemistry	   and	   drug	   concentrations	   in	   tissues	   [124].	  Microdialysis	   is	   a	   valuable	   tool	   during	   intensive	   care	   for	   the	   early	   indication	   of	  tissue	  ischemia	  by	  providing	  the	  lactate/pyruvate	  ratio,	  a	  marker	  of	  ischemia	  [125].	  A	   Cerebral	   Tissue	   Monitoring	   System	   (CMA,	   Sweden)	   to	   monitor	   biochemical	  markers	   of	   ischemia	   in	   the	   brain	   has	   been	   approved	   by	   the	   FDA	   for	   clinical	  applications.	   Moreover,	   microdialysis	   is	   used	   for	   glucose	   monitoring	   of	   diabetic	  patients	   without	   repeated	   invasive	   measurements	   [126].	   The	   FDA	   has	   approved	  several	   continuous	   glucose	   monitoring	   devices	   that	   apply	   the	   principle	   of	  microdialysis	   to	  measure	  glucose	   through	   the	   skin	   [127].	  Clinical	  pharmacology	   is	  another	   field	   of	   microdialysis	   application,	   which	   provides	   unbound	   drug	  concentrations	   at	   the	   site	   of	   action	   [124].	   Clinical	   studies	   on	   patients	  with	   breast	  cancer	  and	  melanoma	  using	  microdialysis	  suggested	  no	  association	  between	  tumor	  exposure	  to	  anticancer	  drugs	  and	  serum	  drug	  concentrations	  [128,	  129].	  The	  poor	  penetration	   of	   anticancer	   agents	   into	   solid	   tumor	   may	   limit	   the	   effectiveness	   of	  chemotherapy.	   Microdialysis	   may	   be	   a	   good	   method	   to	   predict	   the	  chemotherapeutic	   effect	   for	   patients	   and,	   thus,	   selecting	   the	   appropriate	   drugs	   to	  obtain	   favorable	   penetrations	   and	   outcomes.	   Microdialysis	   was	   also	   used	   to	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evaluate	   drug	   concentrations	   in	   target	   tissues	   for	   topical	   drugs,	   for	   example	   the	  bioequivalence	  study	  of	  dermal	  drug	  formulations	  [130].	  	  
2.4 Cefadroxil	  
Cephalosporins	   are	   a	   class	   of	   β-­‐lactam	   antibiotics	   with	   the	   same	   bactericidal	  mechanism	   as	   penicillin,	   i.e.	   binding	   penicillin-­‐binding	   protein	   (PBP)	   and,	   thus,	  inhibiting	   the	   formation	   of	   the	   peptidoglycan	   layer	   of	   bacterial	   cell	   walls.	   Unlike	  penicillin,	  cephalosporins	  are	  less	  susceptible	  to	  β-­‐lactamase	  enzymes	  produced	  by	  many	   gram-­‐negative	   bacteria	   [131,	   132].	   Therefore,	   cephalosporins	   have	   a	  relatively	   broader	   spectrum	   of	   antibacterial	   activity	   including	   both	   gram-­‐positive	  and	   gram-­‐negative	   bacteria.	   Cefadroxil	   is	   a	   first-­‐generation	   cephalosporin,	   which	  was	  created	  by	  adding	  a	  para-­‐hydroxyl	  group	  on	  the	  aromatic	  ring	  of	  cephalexin,	  an	  older	  cephalosporin	  drug	  (Figure	  2-­‐6)	  [131].	  Compared	  to	  cephalexin,	  cefadroxil	  has	  a	  longer	  serum	  half-­‐life	  (~1.5	  hours)	  resulting	  in	  more	  lasting	  drug	  concentrations	  in	  the	  blood	  and	  tissues.	  It	  is	  also	  administered	  less	  frequently	  (once	  or	  twice	  a	  day),	  thereby	   improving	   patient	   compliance	   [133-­‐135].	   Moreover,	   food	   in	   the	  gastrointestinal	   tract	   has	   little	   effect	   on	   the	   absorption	   of	   cefadroxil	   [136].	  	  Cefadroxil	   is	   clinically	   used	   to	   treat	   infections	   of	   the	   urinary	   tract,	   skin	   and	   skin	  structures,	  pharyngitis,	  and	  tonsillitis	  [137].	  Cefadroxil	  has	  an	  oral	  bioavailability	  of	  ≥90%	  and	  protein	  binding	  of	  approximately	  20%	  [136,	  138].	  Renal	  excretion	  is	  the	  primary	   way	   for	   the	   elimination	   of	   cefadroxil,	   with	   88-­‐93%	   of	   the	   orally	  administered	  dose	  being	  recovered	  in	  the	  urine	  within	  24	  hours	  [131].	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As	  mentioned	  previously,	   cefadroxil	   is	   a	   substrate	  of	   the	  peptide	   transporters	  PEPT1	   and	   PEPT2.	   In	   the	   intestines,	   PEPT1	   expressed	   at	   the	   apical	  membrane	   of	  enterocytes	   mediates	   the	   uptake	   of	   cefadroxil	   from	   the	   intestinal	   lumen,	  contributing	   to	   the	   high	   bioavailability	   of	   cefadroxil	   [139].	  Pept1	   ablation	   in	  mice	  	  lead	  to	  23-­‐fold	  reduction	  in	  peak	  plasma	  concentration	  (Cmax)	  and	  14-­‐fold	  reuction	  in	  the	  area	  under	  the	  plasma	  concentration-­‐time	  curve	  (AUC)	  [12].	  With	  respect	  to	  renal	  excretion,	  it	  has	  been	  reported	  that	  PEPT2	  at	  the	  proximal	  tubule	  is	  primarily	  responsible	   for	  the	  reabsorption	  of	  cefadroxil	   from	  tubular	   fluid.	  Since	  the	  PEPT2-­‐mediated	   reabsorption	   of	   cefadroxil	   is	   saturable,	   an	   increased	   clearance	   was	  observed	  with	  higher	  doses	  in	  rats	  [140].	  In	  addition,	  PEPT2	  knockout	  mice	  showed	  significantly	   higher	   clearance	   than	  wild-­‐type	  mice,	   especially	   in	   the	   case	   of	   lower	  doses,	  because	  of	   the	   lack	  of	  PEPT2	  reabsorption	   [83].	   In	  brain,	  PEPT2	   in	  choroid	  plexus	  limits	  the	  exposure	  of	  cefadroxil	  because	  of	  its	  efflux	  from	  CSF	  at	  the	  BCSFB	  [80,	   82].	  As	   a	   result,	   the	  CSF-­‐to-­‐blood	   cefadroxil	   concentration	   ratios	   in	  wild-­‐type	  mice	   were	   markedly	   lower	   than	   that	   of	   Pept2	   knockout	   mice	   [83].	   It	   was	   also	  reported	  that	  cefadroxil	  inhibited	  the	  uptake	  of	  GlySar,	  5-­‐ALA,	  and	  kyotorphin	  by	  rat	  and/or	  mouse	  neonatal	   astrocytes,	   demonstrating	   a	   reduced	   functional	   activity	   of	  PEPT2	  during	  competition	  for	  transport	  [86-­‐88].	  In	   addition	   to	   the	   peptide	   transporters,	   cefadroxil	   is	   transported	   by	   other	  proteins.	   An	   uptake	   study	   in	   Xenopus	   oocytes	   expressing	   Oatp2	   indicated	   that	  cefadroxil	   is	   a	   substrate	   of	   Oatp2,	   which	   is	   likely	   to	   contribute	   to	   the	   biliary	  excretion	  of	  some	  β-­‐lactam	  antibiotics	  in	  hepatocytes	  [141].	  Besides,	  cefadroxil	  was	  found	   to	   inhibit	   the	   uptake	   of	   prostaglandin	   F2α,	   a	   substrate	   of	   organic	   anion	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transporters	   (OATs),	   in	   a	   competitive	  manner	  using	  S2	   cells	   expressing	  human	  or	  rat	  OAT1,	  OAT2,	   and	  OAT3,	   respectively.	  OAT	   is	   located	   at	   the	   basolateral	   side	   of	  proximal	  tubule	  in	  the	  kidney	  with	  a	  function	  of	  active	  secretion	  [142].	  It	  has	  been	  found	  that	  coadministration	  of	  probenecid,	  an	  OAT	  substrate,	  increased	  the	  half-­‐life	  and	  reduced	  the	  elimination	  rate	  constant	  of	  cefadroxil,	  suggesting	  that	  cefadroxil	  is	  a	  substrate	  of	  OAT	  that	  mediates	  the	  active	  secretion	  of	  cefadroxil	  into	  urine	  [143].	  OAT3	   is	   also	   expressed	   at	   the	   BBB	   and	  BCSFB,	  mediating	   the	   efflux	   of	   substrates	  from	  CNS	  [73].	  The	  study	  using	  choroid	  plexus	  isolated	  from	  Pept2+/+	  and	  Pept2-­‐/-­‐	  mice	  suggested	   that	  10-­‐15%	  of	   cefadroxil	  uptake	  by	  choroid	  plexus	  was	  mediated	  by	  OAT,	  80-­‐85%	  by	  PEPT2,	  and	  5%	  by	  nonspecific	  mechanisms	  [80].	  Furthermore,	  it	  was	   found	  cefadroxil	   is	  also	  a	  substrate	  of	  MRP3	  and	  MRP4,	  which	  participate	   the	  intestinal	   absorption	   of	   cefadroxil	   by	   pumping	   the	   drug	   out	   of	   enterocytes	   at	   the	  basolateral	  membrane	  [33].	  Cefadroxil	   has	   several	   advantages	   in	   the	   study	   of	   peptide	   transport	   in	   brain	  including:	  (1)	  high	  stability	  in	  the	  body;	  (2)	  high	  affinity	  for	  the	  peptide	  transporter	  PEPT2;	  (3)	  abundant	   information	  on	  cefadroxil	  disposition	   in	  body	  and	  brain;	  and	  (4)	   showing	   the	   pharmacological	   relevance	   of	   peptide	   transporters.	   Therefore,	  cefadroxil	   serves	   as	   a	   good	   model	   compound	   to	   study	   the	   role	   of	   PEPT2	   on	  peptide/mimetic	  disposition	  and	  dynamics	  in	  the	  brain.	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  Figure	  2-­‐1	   Model	   of	   peptide	   transport	   in	   epithelial	   cells	   of	   the	   intestine	   and	  kidney	  [29].	  	   	  
phenotypic character ist ics [15]. The first  six TMDs
contain the regions that  determine pH dependence
and form the major  par t  of the substra te-binding
pocket  [16], whereas TMDs 7–9 have a  role in
defining substra te affinity [17]. These findings
indicate that  the N-terminal TMDs form a pore-like
structure and that  TMDs 7–9 (Fig. 1) form the
substrate-binding pocket . A stretch of amino acids
(residues 1–59) in  the substra te-binding domain
interferes with the side-chains of dipept ides and an
area between TMDs 2 and 3 (residues 60–91)
contr ibutes significant ly to the pH dependency of
t ransport  [18]. Mutagenesis studies have ident ified
several residues that  are either  important  or
essent ia l for  funct ion. His57 (in  TMD 2) appears to be
involved in  proton binding, with two nearby tyrosine
residues (Y56 and Y64) stabilizing the charge [19].
His121 is involved in  substra te recognit ion, by
facilita t ing neutralizat ion of the charge of acidic
peptides through protonation before translocation [19].
Other  residues in  TMDs 1, 3, 5 and 7 modulate
substra te binding. Based on these findings a  model
for  the interact ion between substra te and amino acid
residues in  the binding pocket  has been proposed [20].
Drugs and prodrugs that are substrates of peptide
transporters
Antibiotics
Because of their  effect iveness and generally low
toxicity, the β-lactam family of ant ibiot ics (penicillins
and cephalosporins) includes many of the most
commonly used ant ibacter ia ls. The basic st ructure of
these ant ibacter ia l agents resembles the backbone 
of a  t r ipept ide with the C-terminal pept ide bond
incorporated into the r igid β-lactam r ing. When the
C–N bond of the β-lactam r ing is rota ted by 180°, the
D-stereochemistry of the cephalosporins matches 
the L-stereochemistry of tripeptides, which explains the
good affinity for  binding and t ransport  by the pept ide
carr iers. Because cefadroxil, the aminocephalosporin,
is a  substra te of intest inal and renal pept ide
transporters and because of its enzymatic stability, 
it  has been used in  expression cloning to isolate the
cDNA clones that  encode PEPT1 and PEPT2 [7,21].
This prototypical aminocephalosporin has a  Km of 
1.1 mM for PEPT1 and 50 µM for PEPT2 [7,21]. Figure 3
shows several β-lactams that  are t ransported by
mammalian pept ide t ransporters [22,23] and many
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Table 1. Distribution of the proton-dependent peptide transporters in tissues, cells and subcellular compartments
Transporter Tissue Localizationa Refs
PEPT1b (SLC15A1) Small intestine Brush border membrane of enterocytes [53]
Kidney Brush border membrane of epithelial cells of the proximal tubule S1 segment [54]
Bile duct Apical membrane of cholangiocytes [55]
Pancreas Lysosomes of acinar cells [56]
PEPT2 (SLC15A2) Kidney Brush border membrane of epithelial cells of the proximal tubule (S2 [54]
  and S3 segment)
CNS Epithelial cells of the choroid plexus, ependymal cells and astrocytes [57,42]
PNS Membrane and cytoplasm of glial cells [58]
Lung Apical membrane of bronchial and tracheal epithelial cells, membrane [59]
  and cytoplasm pneumocytes type II
Mammary gland Epithelial cells of the glands and ducts [60]
Spleen, colon, pancreas − [41]
aLocalization based on reverse transcriptase–polymerase chain reaction (RT-PCR), northern-blot analysis, immunohistochemistry and demonstration of function.
bAbbreviation: PEPT, peptide transporter.








































Fig. 2 . Model of peptide transport in epithelial cells from intestine and kidney. Dipeptides and
tripeptides, β-lactams, angiotensin-converting enzyme (ACE) inhibitors and several prodrugs are
taken up into the cells against a conce tration grad ent by eptide transport r 1 (PEPT1) and PEPT2,
the activities of which are coupled to the movement of protons down an electrochemical proton
gradient. The velocity of transport is determined by membrane voltage. In the main, the proton
gradient is generated and maintained by NHE-3, the apical Na+–H+ antiporter, w ith intracellular Na+
removed by Na+–K+ ATPase in the basolateral membrane. Whereas dipeptides and tripeptides
undergo rapid intracellular hydrolysis and free amino acids leave cells via basolateral transporters,
hydrolysis-resistant substrates, which include most peptidomimetics, are released into the 
circulation by a basolateral peptide transporter that is yet to be identified and/or by other drug-
transporting systems.
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  Figure	  2-­‐2	   Model	  of	  peptide/mimetic	  transport	  in	  the	  choroid	  plexus	  [22].	  	  	   	  cellular pH gradient drives PEPT1- and PEPT2-mediated uptakes of peptides. This pH gradient is
even more dramatic when comparing intracellular pH
with the unstirred water layer lining the surface of
brush border membranes [11]. In contrast, there is no
information available on the magnitude of proton
gradients across the plasma membrane of any cell
types in the nervous system [152]. Normally, the pH
of bulk CSF is similar to that in plasma, but about 0.3
units lower in choroid plexus cells [182]. Whether or
not an acid microclimate (an area of low pH adjacent
to the apical membrane) exists at choroidal brush
border membranes, such as that observed in the
intestine and kidney, is uncertain.
The formation of CSF is largely accomplished by
the polarized expression of a Na+/H+ exchanger at the
basolateral (blood-facing) membrane and a Na+/K+
ATPase at the apical (CSF-facing) membrane. A
coordinated activity allows sodium ions to be taken
up from the blood and then extruded from choroid
plexus cells into the ventricles, along with an
obligatory movement of water for osmotic balance
[51,54]. While the apical localization of Na+/K+
ATPase has been confirmed by immunocytochemis-
try, functional data place the Na+/H+ antiporter at the
basolateral membrane [183,184]. However, at least six
isoforms of the Na+/H+ exchanger (NHE) exist, with
NHE2 and NHE3 being specifically targeted to apical
membranes, NHE4 to basolateral membranes, and
NHE1 to both basolateral and apical membranes of
epithelial cells. The inhibition of 5-ALA uptake in rat
choroid plexus by dimethyl amiloride [139] suggests
that an NHE may also be present at the apical
membrane of this tissue. If this proposition is true,
then protons could be available locally for a pH-
stimulated uptake by PEPT2 (Fig. 4). Alternatively, in
the absence of a pH microclimate, accumulation could
be driven by the electrochemical gradient of mem-
brane potential that exists in choroid plexus epithe-
lium. Thus, the PEPT2-mediated uptake of peptides
and peptide analogs may be energized by pH and/or
membrane potential differences that develop at the
microclimate of choroidal apical villi.
5. Concluding remarks
Over the past few years, significant progress has
been made in characterizing the transport mechanisms
of oligopeptides, polypeptides, neuropeptides, and
peptidomimetic drugs in choroid plexus. In particular,
the cloning, membrane localization and functional
activity of POT family members (e.g., PEPT2) have
provided a basis for exploring transporter-based drug
delivery and targeting strategies to the brain, and for
appreciating new barriers at the blood–CSF interface.
Still, there are critical gaps in our understanding of




Fig. 4. Model of peptide/mimetic transport in the choroid plexus.
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  Figure	  2-­‐3	   Sites	  of	  barriers	  in	  the	  brain.	  The	  black	  arrows	  show	  the	  circulation	  of	  the	  CSF	  [144].	  	   	  may cross the endothelial cells of the brain capil-laries, cross the epithelial cells of the choroid
plexus, or it may return to the circulation by bulk
flow of cerebrospinal fluid (CSF) and reabsorption
at the arachnoid villi.
Although compounds may simply diffuse out of
the brain across the endothelial and epithelial cells
of the BBB, it has been known since the early 1960s
that compounds may also be actively transported out
of the brain into the blood. The first demonstration
was by Pappenheimer et al.,[2] who showed that
iodopyracet and phenolsulfonphthalein were trans-
ported from CSF to blood and that the transport of
iodopyracet was inhibited by phenolsulfonphthalein
and p-aminohippurate. Subsequently, the saturable
disappearance from the brain of organic cations,[3]
iodide,[4-6] potassium[7,8] and penicillin[9] was demon-
strated and it is now known that the active efflux
of nutrients, metabolites, peptides, hormones and
neurotransmitters serves to maintain brain homeo-
stasis.[10] Of particular relevance to this discussion
is the demonstration that efflux mechanisms play a
role in limiting the penetration of drugs into the
CNS; it has been shown that anti-HIV drugs, anti-
spastic agents, immunosuppresants, analgesics, anti-















Choroid plexus epithelial cells










Fig. 1. Sites of the blood-brain barrier (BBB). The BBB comprises tight junctions between: (a) the endothelial cells of brain capillaries;
(b) epithelial cells of the choroid plexus; and (c) epithelial cells of the arachnoid membrane (reproduced from Kandel et al.,[1] with
pe mission). ECF = extracellular fluid; CSF = cerebrospin l fluid.
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  Figure	  2-­‐4	   Localization	   of	   selected	   transporters	   at	   the	   blood-­‐brain	   barrier	   (A)	  and	  blood-­‐CSF	  barrier	  (B).	  Arrows	  indicate	  the	  direction	  of	  substrate	  transport	  [145].	  	   	  
The most extensively characterized transporter protein at the BBB
is P-gp. This glycoprotein along with selected MRP isoforms and BCRP
are expressed at the luminal membrane of the brain capillary and
serve as efflux pumps to extrude xenobiotics from the brain tissue
back into the circulation. Thus, they can significantly restrict and pre-
vent entry of substrates into the brain parenchyma [9,10,15–18]. On
the other hand, influx transporters such as members of the organic
anion transporting polypeptide family (OATPs) and organic anion
transporters (OATs) can facilitate both: substrate delivery into the
brain as well as efflux [11,13,15,19,20] (Fig. 1).
In addition to transporters, the BBB also displays a metabolic bar-
rier which together with influx and efflux transporter proteins can
regulate the overall pharmacokinetic and pharmacodynamic profile
of xenobiotics in the brain. Furthermore, complex drug interactions
may occur with these transport and enzyme systems which may ulti-
mately result in therapeutic failure and/or toxicity.
2.2. Blood–cerebrospinal fluid barrier
The BCSFB composed of choroid plexus epithelial cells although
much smaller in surface area also plays a role in the permeability of
nutrients and xenobiotics. The choroid plexus is a highly vascularized
branched structure with numerous villi that project into all four cere-
bral ventricles [21]. Although, the capillaries of the choroid plexus are
fenestrated and provide little resistance to the movement of water
and solutes, a barrier is formed by a monolayer of polarized epithelial
cells surrounding the fenestrated capillaries that are joined together
by tight junctional proteins [22,23]. These junctions form a functional
barrier that restricts the movement of molecules and ions. The main
function of the choroid plexus epithelial cells is to secrete and main-
tain the homeostatic composition of the CSF. The CSF fills the ventri-
cles of the brain, the spinal canal and subarachnoid space. In humans,
the total volume of CSF is approximately 140 ml which is replaced
four to five times daily [24]. The CSF also provides a drainage system
for the brain known as the sink effect into which products of metab-
olism and molecules are diluted and subsequently removed [25,26].
The sink effect is greater for large molecular weight and hydrophilic
compounds. At the level of choroid plexus epithelial cells, similar to
the BBB, polarized expression of numerous receptors, ion channels
and transporters has been reported (Fig. 2) [21,27–29].
2.3. Drug permeability across brain barriers
As indicated above, BBB tightly regulates the influx/efflux of nutri-
ents, endogenous compounds such as hormones as well as xenobiotics
including several pharmacological agents. Numerous factors such as
membrane transporters and metabolic enzymes can modulate the
barrier permeability and either permit or restrict transcellular traffic
of several substrates. It has been reported that up to 11% of all proteins
present at the BBB are transporters [30]. Transport mechanisms across
the BBB include: passive diffusion, carrier mediated transport and
endocytosis/transcytosis pathways [3].
Passive diffusion is a concentration gradient dependent process that
allows molecules to move across cellular membranes down their elec-
trochemical gradient without the requirement of metabolic energy. In
addition to concentration differences, other factors can affect the diffu-
sion of a drug across the BBB such as lipophilicity [31] and molecular
weight [32,33]. Only lipid soluble small molecules with a molecular
weight b400 Daltons (Da) can cross the BBB [34]. However, the major-
ity of small molecule drugs have a higher molecular weight or present
water solubility which prevents their simple diffusion across the barrier
[34]. In addition, even though some small molecules such as HIV-
protease inhibitors exhibit a high degree of lipophilicity, their CSF and
brain concentrations are often undetectable [35]. This effect is believed
to be attributed to the functional expression of several ABC membrane-
associated drug transporters which can actively export these agents out
of the brain [35]. Furthermore, HIV-associated neuro-inflammation and
oxidative stress can significantly affect BBB permeability and CNS drug
disposition [17,36,37].
Carrier mediated transport processes involve putative proteins that
facilitate the movement of poorly permeable solutes across cellular
membranes. These processes can further be divided into two categories:
i) facilitated diffusionwhich involves carrier-mediated passage of solutes
across cellular membranes down their concentration gradient (e.g. glu-
cose transporters and equilibrative nucleoside transporters) [38] and ii)
active transport which also involves a carrier-mediated process but
uses ATP hydrolysis as an energy source to move molecules against
their electrochemical gradient (for example ABC transporters).
Endocytosis/transcytosis allow the internalization, sorting and traf-
ficking of many plasma macromolecules. Endocytosis is a process
where molecules from the circulation are internalized in vesicles and
are directed to endosomes or lysosomeswithin the cell. Transcytosis re-
fers to the transcellularmovement of molecules. These processes can be
either adsorptive or receptor mediated [39]. Adsorptive endocytosis/
transcytosis facilitates the transport of large peptides such as IgG,
histone, albumin, native ferritin, horse radish peroxidase and dextran.
Adsorptive processes largely depend upon electrostatic interactions
that allow the positively charged moiety of the substrate to bind to
the negatively charged cell membrane. Receptor-mediated processes
are activated by ligand-binding to luminal cell-surface receptors
which lead to internalization of the receptors at the luminal side fol-
lowed by either endocytosis to endosomes/lysosomes or transcytosis
across the membrane to be externalized at the abluminal surface [39].
























































































Fig. 1. Localization of selected ABC and SLC transporters as well as several macromolecule receptors in brain microvessel endothelial cells. Arrows indicate the direction of substrate
transport. (Ins-R=Insulin receptor; Alb-R=Albumin receptor; CP-R=Ceruloplasmin receptor; Tf-R=Transferrin receptor).
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low-density lipoprotein, ceruloplasmin and others utilize receptor me-
diated endocytosis/transcytosis [40] (Fig. 1).
3. Experimentalmethodsused for the studyof drug/nanoformulation
delivery to CNS
3.1. In vitro and ex vivo models
Various in vitro and ex vivo models established for the investiga-
tion of drug transport across the BBB [41,42] can also be employed
to study nanoparticle systems [43]. For details please see Ribeiro et
al.'s review and references therein [44]. Fig. 3 summarizes the differ-
ent types of in vitro BBB models that can be applied for nanocarrier
evaluation. In general, three types of in vitro BBB models have been
established: i) isolated brain capillaries (ex vivo model), ii) in vitro
cell-based models, and iii) cell-free models, e.g. membranes. While
isolated brain capillaries resemble most to the in vivo situation, cell-
based BBB models are most extensively used because they offer a va-
riety of selections and combinations, are easy to obtain and maintain,
and are useful for mechanistic studies and screening of drugs and
nanocarrier systems. Conventional cell-based BBB models, including
monolayer cells in multiwell plates (1-dimensional permeation) and
single/dual/multiple cell lines in transwells (2-dimensional perme-
ation), are called static models because no stirring or flow is applied
during testing. With increasing knowledge and evidence about inter-
actions between cerebral microvessel endothelial cells and cells
surrounding the blood vessels such as astrocytes, pericytes, glial
cells and neurons, co-culture of these cells with microvessel endothe-
lial cells is used in many studies [42,43].
Having recognized the effect on endothelial barrier function of
shear stress caused by blood flow, several groups have developed dy-
namic in vitro models [42,43]. In these systems, endothelial cells and
mixed glia or astrocytes are co-cultured on hollow fibers with a medi-
um flowing through the fibers. Overall, dynamic models mimic in vivo
BBB better than the static models.
Monolayer cell models with high expression of ABC efflux trans-
porters, e.g. P-gp/MDR1 and BCRP, have been used for evaluation of
nanoparticle uptake mechanisms across BBB via cell uptake [45]. Bo-
vine and human endothelial microvessel cells have been used to ex-
amine non-specific cell uptake or apolipoprotein receptor-mediated
internalization of nanoparticles [43]. Despite ample evidence demon-
strating increased cell uptake using these in vitromodels, transcytosis
of nanoparticles is generally not observed.
To monitor cell uptake of nanoparticles, confocal fluorescence mi-
croscopy is useful if the nanoparticles are labeled with a fluorescence
dye or quantum dots [46–48]. When nanoparticles contain heavy
metals, e.g. gold, phase contrast optical microscopy and transmission
electron microscopy can be used [49,50].
3.2. Biodistribution studies
The knowledge of nanoparticulate therapeutics biofate is essential
for maximizing therapeutic effect while minimizing unwanted ad-
verse effects. Biodistribution of nanocarriers could alter the pharma-
cokinetic and toxicity profiles of the pharmacological agents if they
remain trapped in the carriers sufficiently long, e.g. half an hour or
longer. Usually the reticuloendothelial system (RES) will remove for-
eign particles in the blood circulation in a few minutes if they are rec-
ognized by the RES. Therefore, for delivering therapeutics to specific
organs, e.g. CNS, rather than the RES, the surface of the nanocarriers
is modified with a hydrophilic polymer such as poly(ethylene glycol)
(PEG) [51].
Biodistribution and organ targeting of nanoparticles in vivo can be
monitored using the same techniques for medical imaging/diagnostic
including radioscintigraphy, magnetic resonance imaging (MRI), posi-
tron emission tomography (PET), single-photon emission computed to-
mography (SPECT), computed X-ray tomography (CT), and optical
imaging techniques (e.g. multiphoton microscopy) [52–54 and refer-
ences therein] . Nanocarriers or the therapeutics can be labeled with
radio isotopes, e.g. 13C, 123In, 111In, 18F, and 64Cu and imaged by radio-
scintigraphy. For more precise imaging, SPECT and PET can be used
alone or in combination with CT scans to give co-registration of the
two images (PET/CT). MRI can be applied to monitor the distribution
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Fig. 3. In vitro cell culturemodels for drug andnanoparticle transport studies across the BBB.





































































Fig. 2. Localization of selected ABC and SLC transporters in choroid plexus epithelial cells. Arrows indicate the direction of substrate transport.
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  Figure	  2-­‐5	   Schematic	   illustration	  of	  a	  microdialysis	  probe.	  The	  open	  circles	  and	  arrows	   represent	   the	   compound	   of	   interest	   (analyte)	   and	   its	   net	  diffusion.	  The	  closed	  circles	  and	  arrows	  represent	   the	  calibrator	  and	  its	  net	  diffusion	  [95].	  	   	  
endogenous and exogenous molecules. Yet most biochemical
and pharmacological events take place in the tissues. Also,
most drugs with few notable exceptions exert their effects not
within the bloodstream, but in defined target tissues into
which drugs have to distribute from the central compartment.
Assessing tissue drug chemistry has, thus, for long been
viewed as a more rational way to provide clinically meaningful
data rather than gaining information from blood samples. More
specifically, it is often the extracellular (interstitial) tissue space
that is most closely related to the site of action (biophase) of the
drug. Currently microdialysis (mD) is the only tool available
that explicitly provides data on the extracellular space.
Although mD as a preclinical and clinical tool has been
available for two decades, there is still uncertainty about the
use of mD in drug research and development, both from a
methodological and a regulatory point of view. In an attempt
to reduce this uncertainty and to provide an overview of the
principles and applications of mD in preclinical and clinical
settings, an AAPS-FDA workshop took place in November
2005 in Nashville, TN, USA. Stakeholders from academia,
industry and regulatory agencies presented their views on mD
as a tool in drug research and development.
Historical Development
The concept of mD goes back to the early 1960s, when
push pull cannulas, dialysis sacs, and dialytrodes were
inserted into animal tissues to directly study tissue biochem-
istry, notably transmitter release in the rodent brain. In 1974
Ungerstedt and Pycock (1) reported on the use of Bhollow
fibers,^ which were steadily improved and eventually resulted
in the needle probe (Fig. 1). The probe is inserted as such or
via a guide cannula into the tissue. While the majority of mD
applications are preclinical studies on neurotransmitter
release, mD was rapidly used also for pharmacokinetic studies
in rodents, and further adopted for the clinical setting,
initially with experiments on subcutaneous adipose tissue
glucose levels in the mid-1980s. Soon thereafter mD was also
employed to monitor endogenous metabolite and transmitter
levels in the human brain. The first studies on human drug
pharmacokinetics were published in the early 1990s. Today
US Food and Drug Administration (FDA)Vand European
Union Conformite Europeene (CE)Vapproved mD-catheters
are available for use in humans and mD can be performed in
virtually every given human tissue, including myocardium,
brain, lung and also human tumors. As of today there are more
than 10,000 publications available on mD, including about
1,600 publications on its human applications. Besides other
documents, and in light of the FDA_s Critical Path initiative,
the CDER (Center for Drug Evaluation and Research)
Report to the Nation 2003 indicates a need for tools that
enable the measurement of tissue concentrations by stating
that the CDER continues to extend its Blong-standing interest
in the application of doseYresponse principles by viewing
drugs and their actions directly at the level of the drug target,
rather than indirectly via plasma concentrations.^
BASIC PRINCIPLES
Technique
A number of reviews are available on methodological
aspects of the mD technique (2Y7). The technique involves
the implantation of a small probe into a specific region of a
tissue or fluid-filled space (8). Variety of probe designs have
been used, including linear, U-shaped, or concentric geome-
tries. Semi-permeable membrane materials used in probe
construction range from low-to high-molecular weight cut
off. During mD, a physiologically compatible perfusion fluid
(perfusate) is delivered through the probe at a low and
constant flow rate (typically ranging between 0.1 and 5.0 ml/
min). Exchange of solutes occurs in both directions across the
semi-permeable membrane of the probe (Fig. 1) depending
on the orientation of the solute concentration gradients.
Thus, the probe can be used in the delivery as well as in the
sampling mode. For a perfusion fluid that is devoid of the
compound of interest, the microdialysate concentration is
usually a fraction of the tissue extracellular diffusible
(unbound) level. This fraction is referred to as the relative
recovery. In investigations that examine changes in the levels
of endogenous compounds from their baseline values, it may
not be necessary to determine the relative recovery, if it is
reasonable to assume that recovery remains relatively
constant throughout the experiment. These studies typically
evaluate percent changes from a baseline level when an
intervention (e.g., the administration of a drug) is introduced.
However, in pharmacokinetic investigations without baseline
values for exogenous substances, knowledge of the relative
recovery becomes crucial for the determination of true
extracellular tissue concentrations (9). Furthermore, recovery
becomes time-dependent when the tissue extracellular con-
centrations vary during the course of the experiment (10).
Many experimental conditions affect probe recovery, in-
cluding mD flow rate (perfusion), temperature, probe mem-
brane composition and surface area, nature of the dialyzed
tissue (which precludes the use of calibration in vitro as a sur-
Fig. 1. A microdialysis probe of concentric design is shown. The
magnified membrane region illustrates net diffusion of a compound
(analyte) of interest (open circles) into the probe, and the net
diffusion of the calibrator (closed circles) which has been added to
the perfusate, from the probe to the extracellular space.
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  Figure	  2-­‐6	   Molecular	  structure	  of	  cefadroxil	  with	  pKa	  values	  in	  parentheses.	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  CHAPTER 3
EFFECT OF INHIBITION OF PEPT2 AND OTHER 
RELEVANT TRANSPORTERS ON THE DISTRIBUTION 
OF CEFADROXIL IN RAT BRAIN  
3.1 Abstract	  	  
Background:	   Cefadroxil,	   a	   cephalosporin	   antibiotic,	   is	   a	   substrate	   of	   peptide	  transporter	   2	   (PEPT2)	   and	   other	  membrane	   transporters	   including	   organic	   anion	  transporters	  (OATs),	  multidrug	  resistance-­‐associated	  proteins	  (MRPs),	  and	  organic	  anion	   transporting	  polypeptides	  (OATPs).	  These	   transporters	  are	  expressed	  at	   the	  blood–brain	  barrier	  (BBB),	  blood-­‐cerebrospinal	  fluid	  barrier	  (BCSFB),	  and/or	  brain	  cells.	  The	  effect	  of	  these	  transporters	  on	  cefadroxil	  distribution	  in	  brain	  is	  unknown,	  especially	  in	  the	  extracellular	  and	  intracellular	  fluids	  within	  brain.	  	  
Methods:	   Intracerebral	   microdialysis	   was	   used	   to	   measure	   unbound	  concentrations	   of	   cefadroxil	   in	   rat	   blood,	   striatum	   extracellular	   fluid	   (ECF)	   and	  lateral	   ventricle	   cerebrospinal	   fluid	   (CSF).	   The	   effect	   of	   PEPT2	   inhibition	   by	  intracerebroventricular	  (icv)	  infusion	  of	  Ala-­‐Ala,	  a	  substrate	  of	  PEPT2,	  on	  cefadroxil	  levels	   in	   brain	   was	   evaluated.	   The	   distribution	   of	   cefadroxil	   in	   brain	   was	   also	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compared	   in	   the	  absence	  and	  presence	  of	  probenecid,	   an	   inhibitor	  of	  OATs,	  MRPs	  and	  OATPs,	  where	  both	  drugs	  were	  administered	   intravenously.	   In	  addition,	  using	  an	   in	   vitro	   brain	   slice	  method,	   the	   distribution	   of	   cefadroxil	   in	   brain	   intracellular	  fluid	   (ICF)	   was	   studied	   in	   the	   absence	   and	   presence	   of	   transport	   inhibitors	  (probenecid	  for	  OATs,	  MRPs	  and	  OATPs;	  Ala-­‐Ala	  and	  glycylsarcosine	  for	  PEPT2).	  	  
Results:	   Icv	   infusion	   of	   Ala-­‐Ala	   did	   not	   change	   cefadroxil	   levels	   in	   brain	   ECF,	  CSF	  or	  blood.	  	  The	  ratio	  of	  unbound	  cefadroxil	  AUC	  in	  brain	  ECF	  to	  blood	  (Kp,uu,ECF)	  was	   ~2.5-­‐fold	   greater	   during	   probenecid	   treatment.	   In	   contrast,	   the	   ratio	   of	  cefadroxil	   AUC	   in	   CSF	   to	   blood	   (Kp,uu,CSF)	   did	   not	   change	   significantly	   during	  probenecid	  infusion.	  In	  the	  brain	  slice	  study,	  Ala-­‐Ala	  and	  glycylsarcosine	  decreased	  the	   unbound	   volume	   of	   distribution	   of	   cefadroxil	   in	   brain	   (Vu,brain),	   indicating	   a	  reduction	   in	   cefadroxil	   accumulation	   in	   brain	   cells.	   In	   contrast,	   probenecid	  increased	  cefadroxil	  accumulation	  in	  brain	  cells,	  as	  indicated	  by	  a	  greater	  value	  for	  Vu,brain.	  	  
Conclusions:	   Transporters	   (OATs,	   MRPs,	   and	   perhaps	   OATPs)	   that	   can	   be	  inhibited	   by	   probenecid	   play	   an	   important	   role	   in	   mediating	   the	   brain-­‐to-­‐blood	  efflux	   of	   cefadroxil	   at	   the	   BBB.	  However,	   the	   icv	   infusion	   of	   Ala-­‐Ala	   did	   not	   show	  significant	  effect	  on	   the	  cefadroxil	  distribution	   in	  brain	  ECF	  or	  CSF,	  which	  may	  be	  due	   to	   the	   degradation	   of	   Ala-­‐Ala	   in	   biological	   matrix	   and	   therefore	   having	  ineffective	  inhibition	  on	  PEPT2.	  The	  uptake	  of	  cefadroxil	  in	  brain	  cells	  involves	  both	  the	   influx	   transporter	   PEPT2	   and	   efflux	   transporters	   (probenecid-­‐inhibitable).	  These	   findings	   demonstrate	   that	   drug-­‐drug	   interactions	   via	   relevant	   transporters	  may	  affect	  the	  distribution	  of	  cephalosporins	  in	  both	  brain	  ECF	  and	  ICF.	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3.2 Introduction	  
Cephalosporins,	  a	  class	  of	  beta-­‐lactam	  antibiotics,	  have	  been	  widely	  used	  for	  the	  prophylaxis	   and	   treatment	   of	   a	   variety	   of	   infections	   [1].	   In	   addition	   to	   their	  antibacterial	  activity,	  the	  therapeutic	  effects	  of	  different	  cephalosporins	  depend	  on	  their	   pharmacokinetics	   and	   tissue	   distribution,	   which	   are	   affected	   by	   multiple	  membrane	  transporters.	  Due	  to	  the	  resemblance	  of	  the	  molecular	  structure	  of	  some	  cephalosporins	  to	  the	  backbone	  of	  tripeptide,	  those	  cephalosporins	  are	  substrates	  of	  proton-­‐coupled	   oligopeptide	   transporters	   (POT)	   such	   as	   peptide	   transporter	   1	  (PEPT1)	  and	  peptide	  transporter	  2	  (PEPT2).	  	  With	   high	   affinity	   to	   both	   PEPT1	   and	   PEPT2,	   cefadroxil	   (a	   first-­‐generation	  cephalosporin)	   has	   been	   used	   as	   a	   model	   drug	   to	   study	   the	   impact	   of	   peptide	  transporters	  on	  the	  absorption,	  distribution,	  and	  elimination	  of	  their	  substrates.	  In	  small	  intestine,	  PEPT1,	  a	  member	  of	  POTs,	  mediates	  peptide/mimetic	  uptake	  at	  the	  apical	  side	  of	  enterocytes,	   leading	  to	  a	  high	  oral	  bioavailability	   [2,	  3].	  Thus,	  PEPT1	  knockout	   led	   to	   a	   23-­‐fold	   reduction	   in	   peak	   plasma	   concentrations	   and	   a	   14-­‐fold	  decrease	   in	   systemic	   exposure	   of	   cefadroxil	   in	   mice	   [3].	   The	   kidney	   is	   the	   main	  elimination	  organ	   for	   cefadroxil	  with	  >90%	  of	   the	   orally	   administered	  dose	  being	  recovered	  in	  the	  urine	  within	  24	  hours	  on	  human	  subjects	  [4,	  5].	  The	  studies	  show	  that	   peptide	   transporters	   are	   involved	   in	   cefadroxil	   reabsorption	   at	   the	   proximal	  tubule	   of	   the	   kidney	   and	  PEPT2	  plays	   a	  major	   role	   in	   this	   process	   accounting	   for	  95%	  of	  reasorbed	  substances	  compared	  to	  PEPT1	  [6].	  Studies	  on	  the	  distribution	  of	  cefadroxil	  in	  brain	  have	  focused	  on	  the	  function	  of	  PEPT2	  at	  the	  blood-­‐cerebrospinal	  fluid	  barrier	   (BCSFB)	  and	  brain	   cells.	  PEPT2	   in	   choroid	  plexus	   removes	  cefadroxil	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from	  cerebrospinal	   fluid	  (CSF).	  As	  a	  result,	   the	  CSF-­‐to-­‐blood	  concentration	  ratio	  of	  cefadroxil	  in	  wild-­‐type	  mice	  was	  markedly	  lower	  than	  that	  in	  Pept2	  knockout	  mice	  [6,	   7].	   In	   addition,	   cefadroxil	   inhibited	   the	   uptake	   of	   PEPT2	   substrates	   in	   rodent	  neonatal	   astrocytes,	   demonstrating	   an	  uptake	   function	  of	   PEPT2	   in	  brain	   cells	   [8-­‐10].	  	  In	   addition	   to	   the	   POT,	   it	   has	   been	   reported	   that	   cefadroxil	   is	   a	   substrate	   of	  other	  transporters	  including	  organic	  anion	  transporters	  (OATs)	  [11],	  organic	  anion	  transporting	   polypeptides	   (OATPs)[12],	   and	   multidrug	   resistance-­‐associated	  proteins	   (MRPs)	   [13,	   14].	   Moreover,	   the	   clearance	   of	   cefadroxil	   is	   significantly	  reduced	  by	  co-­‐administration	  of	  probenecid	  [6,	  15].	  Probenecid	  is	  widely	  known	  as	  an	  inhibitor	  of	  OATs,	  which	  mediates	  renal	  secretion	  at	  the	  basolateral	  membrane	  of	  proximal	   tubule	   epithelia.	   However,	   probenecid	   can	   also	   inhibit	   the	   MRPs	   and	  OATPs	  that	  also	  may	  contribute	   to	  cefadroxil	  secretion	   in	   the	  kidney	  [16,	  17].	  The	  influence	   of	   probenecid	   on	   the	   renal	   elimination	   of	   cefadroxil	   may	   be	   the	  combinational	  effect	  via	  multiple	  transporters.	  As	   a	   class	   of	   antibiotics	   with	   relatively	   wide	   antibiotic	   spectrum,	   several	  cephalosporins	  such	  as	  cefatriaxone	  and	  cefotaxime	  are	  used	  for	  the	  treatement	  of	  central	  nervous	  system	  (CNS)	  infection	  such	  as	  meningitis	  [18].	  However,	  cefadroxil	  usually	  is	  not	  prescribed	  for	  brain	  infection	  due	  to	  its	  low	  level	  in	  brain.	  Besides	  its	  low	  permeability,	  carrier-­‐mediated	  transport	  may	  contribute	  to	  the	  low	  distribution	  of	  cefadroxil	  in	  brain	  since	  most	  of	  the	  relevant	  transporters	  (i.e.	  PEPT2,	  OAT,	  OATP,	  and	  MRP)	  mediate	   the	   elimination	   of	   substrates	   as	   efflux	   transporters	   from	  brain	  extracellular	   fluid	   (ECF)	   at	   blood-­‐brain	   barrier	   (BBB)	   and/or	   from	   CSF	   at	   BCSFB	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[19-­‐23].	  Although	  the	  function	  of	  PEPT2	  on	  cefadroxil	  level	  in	  CSF	  has	  been	  studied	  [6],	   there	   are	   no	   studies	   on	   the	   influence	   of	   transporters	   on	   the	   distribution	   of	  cefadroxil	  in	  brain	  extracellular	  fluid	  (ECF),	  an	  important	  site	  for	  theraputic	  effect.	  A	  deeper	   understanding	   of	   the	   effect	   of	   transporters	   on	   CNS	   cephalosporin	  distribution	  is	  helpful	  for	  the	  more	  efficient	  use	  of	  cephalosporins	  for	  treating	  brain	  infections.	  The	   present	   chapter	   examined	   the	   impact	   of	   PEPT2	   and	   other	   relevant	  transporters	   on	   cefadroxil	   distribution	   in	   brain	   ECF	   and	   CSF	   using	   Ala-­‐Ala	   (a	  substrate	   of	   PEPT2)	   and	   probenecid	   (an	   inhibitor	   of	   OAT,	   MRP	   and	   OATP),	  respectively.	  In	  vivo	  microdialysis	  was	  applied	  to	  measure	  cefadroxil	  concentrations	  in	   rat	   brain	   ECF,	   CSF	   and	   blood.	   In	   addition,	   an	   in	   vitro	   brain	   slice	   method	   was	  performed	  to	  study	  cefadroxil	  distribution	  within	  the	  rat	  brain	  parenchyma.	  	  
3.3 Methods	  	  
3.3.1 Chemicals	  	  Cefadroxil,	   cefadroxil-­‐D4	   (deuterated),	   probenecid,	   Ala-­‐Ala,	   glycylsarcosine	  (GlySar),	  and	  amoxicillin	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA),	  isoflurane	   from	  Baxter	  Medical	   AB	   (Kista,	   Sweden),	   and	   100	   IU/mL	   heparin	   from	  Leo	  Pharma	  AB	  (Malmö,	  Sweden).	  Acetonitrile	  and	  formic	  acid	  were	  obtained	  from	  Merck	  (Darmstadt,	  Germany).	  All	  other	  chemicals	  were	  of	  analytical	  grade	  or	  better.	  Ringer’s	  solution	  was	  used	  to	  perfuse	  the	  microdialysis	  probes	  and	  consisted	  of	  145	  mM	  NaCl,	  0.6	  mM	  KCl,	  1.0	  mM	  MgCl2,	  and	  1.2	  mM	  CaCl2	  in	  2	  mM	  phosphate	  buffer,	  pH	   7.4.	   Artificial	   extracellular	   fluid	   (aECF),	   used	   to	   buffer	   the	   brain	   slices,	   was	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comprised	   of	   10	   mM	   glucose,	   129	   mM	   NaCl,	   3	   mM	   KCl,	   1.2	   mM	  MgSO4,	   0.4	   mM	  K2HPO4,	   1.4	  mM	  CaCl2,	   and	   25	  mM	  HEPES,	   pH	   7.6,	   at	   room	   temperature.	   Normal	  saline	  was	   obtained	   from	  Braun	  Medical	   AB	   (Stockholm,	   Sweden)	   and	   the	  Milli-­‐Q	  system	  (Millipore,	  Bedford,	  Massachusetts)	  was	  used	  to	  purify	  the	  water.	  	  
3.3.2 Animals	  	  Male	   Sprague–Dawley	   rats	   (260–300	   g)	   were	   obtained	   from	   Taconic	   (Lille	  Skensved,	  Denmark).	  Rats	  were	  acclimated	  for	  at	  least	  7	  days	  in	  a	  temperature-­‐	  and	  humidity-­‐controlled	  environment	  with	  12-­‐hour	  light/	  dark	  cycles	  before	  study.	  The	  protocols	   in	   this	  study	  were	  approved	  by	  the	  Animal	  Ethics	  Committee	  of	  Uppsala	  University,	  Sweden	  (C351/11	  and	  C328/10).	  	  
3.3.3 Microdialysis	  study	  of	  cefadroxil	  in	  the	  absence	  and	  presence	  of	  probenecid	  	  Surgery	  was	  performed	  one	  day	  before	  microdialysis	  in	  order	  to	  implant	  vessel	  catheters	  and	  microdialysis	  probes	  as	  described	  previously	  [24]	  with	  modification.	  Briefly,	  under	   isoflurane	  anesthesia	  and	  with	  body	  temperature	  controlled	  at	  38°C	  (CMA/150	   temperature	   controller,	   CMA,	   Stockholm,	   Sweden),	   catheters	   were	  inserted	   into	   the	   left	   femoral	   vein	   for	   cefadroxil	   infusion,	   the	   left	   jugular	   vein	   for	  control	  (Day	  1)	  or	  probenecid	  infusion	  (Day	  2),	  and	  the	  left	  femoral	  artery	  for	  blood	  sampling.	  A	  CMA/20	  probe	  with	  10	  mm	  polyarylethersulphone	  (PAES)	  membrane	  was	   inserted	   into	   the	   right	   jugular	   vein.	   The	   rat	   was	   then	   fixed	   on	   a	   stereotaxic	  frame	  equipped	  with	  an	  anesthesia	  mask.	  Two	  guide	  cannulas	  were	  implanted	  into	  the	  brain	  striatum	  (ST	  coordinates,	  +0.2	  mm	  anteroposterior,	  −4.7	  mm	  lateral,	  −3.8	  mm	  dorsoventral	  with	   an	   angle	   of	   15°	   at	   the	   coronal	   plane	   towards	  midline)	   and	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lateral	   ventricle	   (LV	   coordinates,	   −0.9	  mm	   anteroposterior,	   +1.6	  mm	   lateral,	   −2.9	  mm	  dorsoventral),	  and	  fixed	  to	  the	  skull	  by	  a	  screw	  and	  dental	  cement.	  A	  CMA	  12	  probe	  with	  3	  mm	  PAES	  membrane	  was	  inserted	  into	  the	  striatal	  guide	  cannula	  for	  monitoring	  brain	  ECF	  and	  a	  CMA	  12	  probe	  with	  1	  mm	  PAES	  membrane	  was	  inserted	  into	  the	  ventricular	  guide	  cannula	   for	  CSF	  sampling.	  At	   the	  end	  of	   the	  surgery,	   the	  rat	  was	  placed	  in	  a	  CMA	  120	  system	  for	  freely	  moving	  animals	  in	  which	  it	  had	  free	  access	   to	   food	   and	   water,	   and	   allowed	   to	   recover	   for	   24	   hours	   before	  experimentation.	  	  On	   Day	   1,	   a	   90-­‐min	   stabilization	   period	   was	   performed	   in	   which	   Ringer’s	  solution,	   containing	   cefadroxil-­‐D4,	  was	  perfused	   through	   the	  microdialysis	   probes	  by	  pump	  (CMA	  400,	  Solna,	  Sweden)	  at	  a	  flow	  rate	  of	  0.5	  μL/min.	  During	  this	  period,	  and	  throughout	  the	  entire	  experiment	  (another	  420	  min),	  microdialysis	  samples	  (10	  μL	   each)	  were	   collected	   every	   20	  min	   using	   a	   fraction	   collector	   (CMA	  142,	   Solna,	  Sweden)	  and	  stored	  at	  4°C	  until	  analysis.	  To	  quantify	  unbound	  drug	  concentrations	  in	   brain	   and	   blood,	   cefadroxil-­‐D4	   was	   used	   to	   calibrate	   the	   probes	   using	  retrodialysis	  [25].	  Because	  cefadroxil	  levels	  in	  brain	  and	  blood	  were	  quite	  different,	  1	  μg/mL	  cefadroxil-­‐D4	  was	  used	  to	  perfuse	  the	  blood	  probe	  and	  0.1	  μg/mL	  for	  the	  brain	   probe.	   At	   90	   min,	   cefadroxil	   solution	   (6	   mg/mL	   in	   normal	   saline)	   was	  administered	   intravenously	   (iv)	   as	   a	   bolus	   infusion	   of	   0.3	  mg/kg/min	   for	   20	  min	  followed	  by	  a	  constant-­‐rate	  infusion	  of	  0.15	  mg/kg/min	  for	  160	  min	  (for	  a	  total	  of	  180	  min).	  In	  addition	  to	  the	  microdialysis	  samples,	  arterial	  blood	  samples	  (100	  μL)	  were	  drawn	  predose	   and	   at	   5,	   18,	   90,	   150,	   185,	   190,	   210,	   240,	   300,	   and	  420	  min	  after	  initiating	  the	  cefadroxil	  bolus	  infusion.	  Plasma	  was	  harvested	  from	  blood	  after	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centrifuging	  at	  7200	  g	  for	  5	  min	  and	  then	  frozen	  at	  −20°C	  until	  analysis.	  On	  Day	  2,	  the	   cefadroxil	   experiment	   was	   repeated,	   however,	   15	   mg/mL	   probenecid	   in	   5%	  NaHCO3	  in	  saline	  (as	  opposed	  to	  5%	  NaHCO3	  in	  saline	  only	  on	  Day	  1)	  was	  added	  as	  a	  20	  mg/kg	  bolus	  followed	  by	  20	  mg/kg/hr	  infusion	  for	  420	  min	  (i.e.,	  cefadroxil	  in	  the	  presence	  of	  probenecid).	  	  
3.3.4 Microdialysis	  study	  of	  cefadroxil	  in	  the	  absence	  and	  presence	  of	  Ala-­‐Ala	  	  The	   surgery	   and	   microdialysis	   method	   for	   this	   study	   was	   similar	   to	   that	  described	   before	   for	   probenecid	   except,	   in	   this	   case,	   the	   dipeptide	   Ala-­‐Ala	   was	  administered	   instead	   and	   by	   intracerebroventricular	   (icv)	   infusion.	   In	   order	   to	  perform	  the	  microdialysis	  sampling	  and	  icv	  infusion	  simultaneously,	  a	  microdialysis	  probe	  with	  an	  additional	  infusion	  cannula	  passing	  through	  the	  lumen	  of	  probe	  (IBR	  combination	   probe	  with	   1	  mm	   polyacrylanitrile	  membrane,	   BASi,	  West	   Lafayette,	  IN,	   USA)	   was	   implanted	   into	   the	   lateral	   ventricle	   (coordinates,	   −0.9	   mm	  anteroposterior,	   −1.6	   mm	   lateral,	   −2.9	   mm	   dorsoventral).	   For	   these	   studies	   (i.e.,	  cefadroxil	  in	  the	  absence	  and	  presence	  of	  Ala-­‐Ala),	  the	  experiment	  was	  performed	  in	  one	  day.	  In	  brief,	  following	  the	  90-­‐min	  stabilization	  period,	  cefadroxil	  saline	  solution	  was	   infused	   iv	  at	  0.3	  mg/kg/min	   for	  20	  min	   followed	  by	  0.15	  mg/kg/min	   for	  400	  min	   (for	   a	   total	   of	  420	  min).	  An	   icv	   infusion	  of	  Ringer’s	   solution,	  0.3	  μL/min,	  was	  started	  30	  min	  prior	   to	   cefadroxil	   administration	  and	  maintained	   for	   another	  240	  min	  (control	  phase).	  At	  this	  time,	  an	  icv	  infusion	  of	  0.32	  mg/mL	  Ala-­‐Ala	  in	  Ringer’s	  solution	  was	  started	  and	  then	  maintained	  for	  another	  180	  min.	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3.3.5 In	  vitro	  brain	  slice	  study	  	  The	   brain	   slice	   protocol	   was	   based	   on	   a	   previously	   published	   method	   with	  minor	  modifications	   [26].	  Briefly,	   fresh	  brains	  were	  collected	   in	  which	  six	  300-­‐μm	  coronal	  slices	  were	  prepared	   from	  each	  animal	  using	  a	  microtome	  (Leica	  VT1200,	  Leica	   Microsystems	   AB,	   Sweden).	   Resultant	   slices	   were	   transferred	   to	   an	   80-­‐mm	  diameter	  beaker	  with	  15	  mL	  aECF	  containing	  0.8	  μM	  cefadroxil	  with	  or	  without	  5	  mM	  GlySar,	   5	  mM	  Ala-­‐Ala,	   or	   1	  mM	   probenecid.	   Covered	   by	   a	   lid	   comprised	   of	   a	  Teflon	  fluorinated	  ethylene-­‐propylene	  film	  (DuPont,	  Katco	  Ltd,	  UK),	  the	  beaker	  was	  incubated	   in	  a	   shaker	   (MaxQ4450,	  Thermo	  Fisher	  Scientific,	  Nino	  Lab,	  Sweden)	  at	  45	   rpm,	   37°C,	   for	   2	   hr.	   Throughout	   the	   incubation,	   there	   was	   a	   constant	   flow	   of	  oxygen	  into	  the	  shaking	  chamber	  to	  maintain	  slice	  viability.	  After	  incubation,	  200	  μL	  of	   blank	   rat	   brain	   homogenate	  without	   cefadroxil	   was	   added	   to	   200	   μL	   of	   buffer	  sample	   to	   keep	   the	   matrix	   consistent	   among	   all	   the	   samples	   for	   the	   following	  analysis.	   The	   brain	   slices	   were	   then	   weighed,	   after	   drying	   on	   filter	   paper,	   and	  homogenized	   individually	   in	   aECF	   (9:1	   ratio,	   w/v)	   using	   an	   ultrasonic	   processor	  (VCX-­‐130,	   Sonics,	   Chemical	   Instruments	   AB,	   Sweden).	   All	   samples	  were	   stored	   at	  −20°C	  until	  analysis.	  	  In	   all	   experiments,	   coronal	   slices	   were	   prepared	   from	   the	   same	   anatomical	  plane	  corresponding	  to	  the	  striatal	  region	  (no	  midbrain	  structures)	  in	  order	  to	  avoid	  potential	  discrepancies	  in	  the	  assessment	  of	  the	  unbound	  volume	  of	  distribution	  of	  cefadroxil	  in	  brain	  (Vu,brain).	  In	  our	  studies,	  the	  Vu,brain	  values	  of	  cefadroxil	  were	  similar	   in	   each	   rat	   with	   little	   variability	   (mean	   coefficient	   of	   variation	   ≤5.4%).	  Potential	  regional	  differences	  in	  the	  Vu,brain	  of	  cefadroxil	  were	  not	  studied.	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3.3.6 Chemical	  analysis	  	  The	   analysis	   of	   cefadroxil	   (and	   cefadroxil	   D-­‐4)	   was	   carried	   out	   using	   liquid	  chromatography–tandem	   mass	   spectrometry	   (LC-­‐MS/MS).	   Specifically,	   5	   μL	  microdialysis	   samples	   were	   injected	   into	   the	   LC-­‐MS/MS	   after	   adding	   amoxicillin	  solution	  as	  an	  internal	  standard.	  For	  plasma	  and	  homogenate	  samples,	  the	  proteins	  were	  precipitated	  by	  adding	  acetonitrile	  at	  a	  ratio	  of	  1:3.	  After	  centrifuging	  at	  7200	  g	  for	  3	  min,	  the	  supernatant	  was	  diluted	  with	  0.1%	  formic	  acid	  before	  injecting	  into	  the	  LC-­‐MS/MS.	  Standard	  curves	  and	  quality	  control	  samples	  were	  used	  to	  quantify	  and	   validate	   the	   concentrations	   of	   cefadroxil	   in	   all	   biological	   matrices	   from	   the	  study.	  	  Chromatographic	  separation	  was	  achieved	  on	  a	  HyPurity	  C18	  column	  (50	  ×	  4.6	  mm,	  particle	  size	  3	  μm)	  protected	  by	  a	  HyPurity	  C18	  guard-­‐column	  (10	  ×	  4.0	  mm,	  particle	   size	   3	   μm;	   Thermo	   Hypersil-­‐Keystone,	   PA,	   USA).	   A	   gradient	   elution	  involving	  mobile	  phase	  A	  (0.1%	  formic	  acid)	  and	  mobile	  phase	  B	  (0.1%	  formic	  acid	  in	   1:1	   acetonitrile:water)	   was	   delivered	   by	   two	   Shimadzu	   LC-­‐10ADvp	   pumps	  (Shimadzu,	   Kyoto,	   Japan)	   at	   0.8	   mL/min,	   which	   was	   split	   to	   0.3	   mL/min	   before	  entering	  the	  MS	  detector.	  A	  Quattro	  Ultima	  Pt	  mass	  spectrometer	  (Waters,	  Milford,	  MA,	  USA)	  was	  used	   for	  detection	  on	  positive	  electrospray	   ionization	   (ESI+)	  mode.	  The	  transition	  mode	  was	  m/z	  363.9	  →	  207.9	  for	  cefadroxil,	  m/z	  368.0	  →	  212.0	  for	  cefadroxil-­‐D4,	   and	  m/z	  366.0	  →	   348.9	   for	  amoxicillin.	  All	  data	  were	  acquired	  and	  processed	  using	  Masslynx	  4.1	  (Waters,	  Milford,	  MA,	  USA).	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3.3.7 Data	  analysis	  The	   relative	   recovery	  of	   cefadroxil	   in	   each	  microdialysis	  probe	  was	  estimated	  from	  retrodialysis	  of	  the	  calibrator,	  cefadroxil-­‐D4,	  and	  calculated	  as:	  
	  
(Eq	  1)	  where	  Cin,CEF-­‐D4	  is	  the	  concentration	  of	  cefadroxil-­‐D4	  in	  perfusate	  and	  Cout,CEF-­‐D4	  is	  the	   concentration	   of	   cefadroxil-­‐D4	   in	   dialysate.	   The	   unbound	   concentrations	   of	  cefadroxil	  in	  blood	  (Cu,blood),	  brain	  ECF	  (Cu,ECF),	  and	  CSF	  (Cu,CSF)	  were	  calculated	  from	  their	  respective	  concentrations	  in	  dialysate	  (Cdialysate)	  as:	  
	  
(Eq	  2)	  For	   the	   microdialysis	   study	   of	   cefadroxil	   (with	   and	   without	   probenecid),	   the	  trapezoidal	   method	   was	   used	   to	   calculate	   area	   under	   the	   curve	   for	   unbound	  cefadroxil	  (AUCu)	  in	  blood,	  ECF,	  and	  CSF	  from	  0–420	  min.	  AUCu	  values	  from	  420	  min	  to	   infinity	   were	   determined	   by	   extrapolation	   from	   the	   time	   of	   the	   last	   measured	  
concentration	  Clast	  according	  to	   ,	  in	  which	  λz	  is	  the	  terminal	  rate	  
constant	  obtained	  from	  the	  slope	  of	  the	  last	  7	  observations.	  The	  blood	  concentration	  of	   cefadroxil	   at	   steady-­‐state	   (Cu,ss,blood)	   was	   calculated	   from	   the	   average	   of	  concentrations	   during	   the	   120–180	   min	   time	   period.	   The	   unbound	   partition	  coefficient	   of	   cefadroxil	   in	   brain	   ECF	   (Kp,uu,ECF)	   and	   CSF	   (Kp,uu,CSF)	  was	   obtained	   as	  follows:	  
	  
(Eq	  3)	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(Eq	  4)	  Non-­‐compartmental	  analyses	  were	  performed	  using	  the	  microdialysis	  samples	  from	   blood	   to	   obtain	   the	   pharmacokinetic	   parameters	   of	   unbound	   cefadroxil,	   in	  which	   area	   under	   the	   moment	   curve	   (AUMCu)	   was	   also	   obtained	   by	   trapezoidal	  method.	   The	   mean	   input	   time	   (MIT)	   was	   66	   min	   calculated	   from	  
,	   where	   R0	   and	   Tin	   denote	   the	   infusion	   rate	   and	  
infusion	   time	   of	   the	   two	   consecutive	   cefadroxil	   infusions.	   With	   the	   correction	   of	  MIT,	  the	  mean	  residence	  time	  with	  an	  iv	  bolus	  (MRTiv)	  was	  obtained:	  
	  
(Eq	  5)	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where	  Cu,ss	  was	  calculated	  during	  the	  120–200	  min	  time	  period	  for	  the	  control	  phase	   (i.e.,	   without	   Ala-­‐Ala)	   and	   during	   the	   320–420	   min	   time	   period	   for	   the	  dipeptide	  phase	  (i.e.,	  with	  Ala-­‐Ala).	  In	   analyzing	   brain	   slice	   data,	   the	   unbound	   volume	   of	   distribution	   in	   brain	  (Vu,brain,	  in	  mL/g	  brain)	  was	  calculated	  for	  cefadroxil	  as:	  
	  
(Eq	  10)	  
where	   Abrain	   is	   the	   total	   amount	   of	   cefadroxil	   in	   brain	   slice,	   Cbuffer	   is	   the	  concentration	  of	  cefadroxil	  in	  buffer	  at	  the	  end	  of	  incubation,	  and	  Vi	  is	  the	  volume	  of	  buffer	   film	   surrounding	   the	   brain	   slice	   because	   of	   incomplete	   adsorption	   by	   the	  filter	  paper;	  Vi	  was	  reported	  as	  0.094	  mL/g	  brain	  [27].	  
3.3.8 Statistical	  analysis	  	  Data	   are	   expressed	   as	   mean	   ±	   SEM.	   A	   two-­‐tailed	   paired	   t-­‐test	   was	   used	   to	  compare	  cefadroxil	  parameters	  between	  the	  control	  and	  inhibition	  phases.	  A	  value	  of	  p	  <0.05	  was	  considered	  statistically	  significant.	  For	   the	  brain	  slice	  study,	  a	  one-­‐way	  ANOVA	  with	  Dunnett’s	  test	  was	  performed	  to	  compare	  each	  treatment	  group	  to	  the	   control.	   GraphPad	   Prism	   v5.04	   (GraphPad	   Software	   Inc.,	   San	   Diego,	   CA)	   was	  used	  for	  all	  statistical	  analyses.	  	  
3.4 Results	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for	  the	  1-­‐mm	  probe	  in	  lateral	  ventricle,	  and	  71	  ±	  2%	  for	  the	  10-­‐mm	  probe	  in	  blood.	  As	   shown	   in	   Figure	   3-­‐1A,	   steady-­‐state	   concentrations	   of	   cefadroxil	   in	   blood	  were	  quickly	  achieved	  after	  the	  bolus	  infusion	  of	  0.3	  mg/kg/min	  for	  20	  min	  followed	  by	  the	   constant-­‐rate	   infusion	   of	   0.15	   mg/kg/min	   for	   160	   min.	   Compared	   to	   Day	   1	  (control	  phase),	   probenecid	   infusion	   increased	  Cu,ss,blood	  and	  AUCu	  of	   cefadroxil	   by	  ~60%.	   The	   elevated	   systemic	   exposure	   probably	   resulted	   from	   a	   decrease	   in	  cefadroxil	  clearance	  from	  16.9	  ±	  1.0	  to	  10.7	  ±	  0.7	  mL/	  min/kg	  (Table	  3-­‐1).	  However,	  the	   MRT	   and	   t1/2	   did	   not	   differ	   significantly	   between	   days,	   reflecting	   a	   reduced	  volume	  of	   distribution	   (Vss)	  with	  probenecid,	   indicating	  probenecid	  may	  decrease	  the	  accumulation	  of	   cefadroxil	   in	   certain	   tissues.	  Plasma	  cefadroxil	   concentrations	  were	   comparable	   to	   the	   unbound	   blood	   concentrations	   from	   microdialysis,	  consistent	  with	  previous	  studies	  showing	  that	  the	  unbound	  fraction	  of	  cefadroxil	  in	  plasma	  (fu)	  is	  nearly	  1.0	  [28].	  	  In	  addition	  to	  increasing	  unbound	  cefadroxil	  blood	  concentrations,	  probenecid	  increased	  the	  AUCu	  of	  drug	  in	  brain	  ECF	  4-­‐fold	  (p	  <0.05)	  and	  the	  AUCu	  of	  drug	  in	  CSF	  2-­‐fold	   (p	   >0.05)	   (Figure	   3-­‐1B	   and	   Figure	   3-­‐1C,	   and	   Table	   3-­‐1).	   To	   determine	   if	  cefadroxil	   penetration	   into	   brain	   was	   affected	   by	   probenecid,	   brain	   drug	  concentrations	  were	   corrected	  by	   the	   corresponding	  values	   in	  blood	   (Figure	  3-­‐2).	  During	  probenecid	  infusion	  (Day	  2),	  the	  Cu,ECF	  values	  of	  cefadroxil,	  relative	  to	  blood,	  were	  higher	  than	  control	  (Day	  1)	  at	  all	  time	  points.	  In	  contrast,	  the	  Cu,CSF	  values	  of	  cefadroxil,	  relative	  to	  blood,	  were	  comparable.	  To	  evaluate	  the	  effect	  of	  probenecid	  on	   cefadroxil	   penetration	   into	   brain,	   the	   unbound	   partition	   coefficient	   Kp,uu	  was	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calculated	  for	  both	  brain	  ECF	  and	  CSF	  using	  AUCu	  values	  from	  0–420	  min	  and	  from	  0-­‐infinity	   (Figure	   3-­‐3).	   Kp,uu	  was	   around	   0.02	   in	   both	   brain	   ECF	   and	   CSF	   in	   the	  control	   situation,	   indicating	   limited	   penetration	   of	   cefadroxil	   into	   brain	   and	  extensive	  efflux	  at	  the	  BBB	  (Table	  3-­‐1).	  Kp,uu,ECF	  values	  were	  about	  2.5-­‐fold	  greater	  with	   probenecid	   treatment	   as	   compared	   to	   control.	   In	   contrast,	   there	   were	   no	  significant	  differences	  in	  Kp,uu,CSF	  between	  control	  and	  probenecid	  treatments.	  This	  may	  reflect,	   in	  part,	   greater	  experimental	  variability	   in	   the	  direction	  of	   change	   for	  this	  parameter	  (Figure	  3-­‐3	  C	  and	  D).	  	  
3.4.2 Microdialysis	  study	  of	  cefadroxil	  in	  the	  absence	  and	  presence	  of	  Ala-­‐Ala	  	  Recoveries	  were	   16	   ±	   2%,	   12	   ±	   1%,	   and	  72	   ±	   1%	   for	   probes	   in	   the	   striatum,	  lateral	   ventricle	   and	  blood,	   respectively.	  Ala-­‐Ala	   is	   a	  natural	  dipeptide	   that	   can	  be	  degraded	  in	  the	  body;	  thus,	  Ala-­‐Ala	  was	  infused	  by	  the	  icv	  route	  in	  order	  to	  achieve	  high	  concentrations	  in	  CSF.	  The	  goal	  of	  the	  study	  was	  to	  determine	  if	  Ala-­‐Ala	  affects	  the	  distribution	  of	  cefadroxil	  by	  comparing	   levels	   in	  ECF	  and	  CSF	  between	  vehicle	  control	   phase	   and	   during	  Ala-­‐Ala	   infusions.	   As	   shown	   in	   Figure	   3-­‐4,	   the	   unbound	  concentrations	  of	  cefadroxil	  did	  not	  change	  substantially	  in	  brain	  ECF	  or	  CSF	  during	  Ala-­‐Ala	  infusions.	  Furthermore,	  there	  was	  no	  significant	  difference	  between	  control	  and	   Ala-­‐Ala	   infusions	   in	   Kp,uu,ECF	   (0.033	   ±	   0.004	   to	   0.041	   ±	   0.008,	   p	   =	   0.15)	   or	  Kp,uu,CSF	  (0.038	  ±	  0.017	  to	  0.043	  ±	  0.016,	  p	  =	  0.43).	  	  
3.4.3 In	  vitro	  brain	  slice	  study	  	  Vu,brain	  describes	   the	   relationship	   between	   the	   total	   amount	   of	   drug	   in	   brain	  and	  the	  unbound	  concentration	  of	  drug	  in	  ECF,	  and	  is	  useful	  as	  a	  measure	  of	  intra-­‐
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parenchymal	   distribution	   [29].	   A	   higher	   value	   Vu,brain	   suggests	   that	   more	   drug	  accumulates	  inside	  the	  brain	  cells.	  For	  control	  brain	  slices,	  the	  Vu,brain	  of	  cefadroxil	  was	  3.67	  ±	  0.23	  mL/g	  brain	  (Figure	  3-­‐5).	  Two	  PEPT2	  substrates,	  Ala-­‐Ala	  and	  GlySar,	  reduced	   the	   Vu,brain	   of	   cefadroxil	   to	   0.95	   ±	   0.45	   and	   1.10	   ±	   0.05	   mL/g	   brain,	  respectively,	   indicating	   that	   they	   reduced	   the	   accumulation	   of	   cefadroxil	   inside	  brain	  cells	  (p	  <	  0.001).	  In	  contrast,	  probenecid	  increased	  the	  Vu,brain	  of	  cefadroxil	  to	  6.06	   ±	   0.15	  mL/g	   brain,	   suggesting	   that	   probenecid	   led	   to	  more	   accumulation	   of	  cefadroxil	  inside	  brain	  cells	  (p	  <	  0.001).	  	  
3.5 Discussion	  	  
The	   current	   study	  used	  microdialysis	   and	  brain	   slice	  methods	   to	   examine	   the	  transport	   mechanisms	   affecting	   the	   distribution	   of	   cefadroxil,	   a	   cephalosporin	  antibiotic,	   in	   brain.	   The	   results	   demonstrated	   that:	   1)	   co-­‐administration	   of	  probenecid	   increased	   blood	   cefadroxil	   levels;	   2)	   probenecid	   markedly	   increased	  brain	   ECF	   cefadroxil	   concentrations;	   3)	   the	   probenecid	   effect	   on	   brain	   ECF	   levels	  were	  partially	  due	   to	   increased	  blood	   concentrations	  but	   also	  due	   to	   inhibition	  of	  cefadroxil	  efflux	  at	   the	  BBB	  (OATs,	  OATPs	  and/or	  MRPs);	  4)	   in	  contrast,	   increased	  CSF	   cefadroxil	   concentrations	   with	   probenecid	   were	   only	   due	   to	   elevated	   blood	  concentrations	   of	   antibiotic;	   5)	   intracerebroventricular	   infusion	   of	   the	   PEPT2	  substrate,	  Ala-­‐Ala,	  did	  not	  increase	  brain	  ECF	  or	  CSF	  cefadroxil	  levels;	  and	  6)	  brain	  slice	  experiments	  demonstrated	  that	  PEPT2	  was	  involved	  in	  the	  uptake	  of	  cefadroxil	  into	   brain	   cells	   and	   that	   probenecid	   blocked	   a	  mechanism	   transporting	   cefadroxil	  out	  of	  cells.	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In	   the	   interaction	   study	   between	   cefadroxil	   and	   probenecid,	   intravenous	   co-­‐administration	  of	  probenecid	  reduced	  the	  clearance	  of	  cefadroxil.	  This	   finding	  was	  consistent	  with	  previous	  studies	  [6,	  15]	  showing	  that	  probenecid	  inhibits	  the	  renal	  secretion	  of	  many	  cephalosporins	  by	  OATs	   (and	  perhaps	  MRPs	  and	  OATPs)	  at	   the	  kidney	   proximal	   tubule	   [30].	   Even	   though	   steady-­‐state	   concentrations	   were	  achieved	   quickly	   for	   unbound	   cefadroxil	   in	   blood,	   steady-­‐state	   concentrations	   in	  brain	   ECF	   were	   not	   fully	   reached	   within	   the	   infusion	   period	   of	   3	   hr.	   As	   a	  consequence,	   Cu,ECF	   decreased	   more	   slowly	   than	   Cu,blood	   after	   termination	   of	   the	  cefadroxil	   infusion.	   The	   above	   phenomenon	   may	   be	   due	   to	   low	   permeability	   of	  passive	  diffusion	  of	   cefadroxil	   at	   the	  BBB,	   considering	   its	   high	  hydrophilicity.	   The	  Kp,uu	  of	  brain	  ECF	  is	  determined	  by	  the	  net	  influx	  and	  efflux	  clearances	  at	  the	  BBB,	  as	  Kp,uu	  =	  CLin/CLout	  [29].	   If	  only	  passive	  transport	  occurs	  at	  the	  BBB,	  Kp,uu	  is	  equal	  to	  unity	  due	  to	  the	  equal	  values	  for	  CLin	  and	  CLout.	  However,	  the	  Kp,uu,ECF	  of	  cefadroxil	  was	   about	   0.02,	   indicating	   that	   cefadroxil	   CLout	   is	  much	   higher	   than	   CLin.	   Thus,	   it	  appears	   that	   there	   is	   net	   efflux	   transport	   for	   cefadroxil	   at	   the	   BBB.	   It	   has	   been	  reported	  that	  cefadroxil	   is	  a	  substrate	  of	  OATs	  and	  MRPs	  [11,	  13,	  14].	  Specifically,	  OAT3	  located	  at	  the	  basolateral	  (abluminal)	  side	  of	  the	  BBB	  and	  MRPs	  at	  the	  apical	  (luminal)	   side	  of	   the	  BBB	  mediate	  brain-­‐to-­‐blood	   transport	   as	   efflux	   transporters,	  thus	  possibly	   contributing	   the	   low	  Kp,uu,ECF	  of	   cefadroxil	   [19,	   31,	   32].	   Inhibition	  of	  OAT3	  and/or	  MRPs	  at	  the	  BBB	  is	  the	  probable	  reason	  why	  probenecid	  increased	  the	  Kp,uu,ECF	   of	   cefadroxil	   ~2.5	   fold.	   In	   addition	   to	   OATs	   and	   MRPs,	   cefadroxil	   was	  reported	   to	   be	   a	   substrate	   of	   OATPs	   [12].	   However,	   OATPs	   are	   bidirectional	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transporters	   [22,	  23,	  33]	  and	   their	  net	  effect	  on	  cefadroxil	   transport	  at	   the	  BBB	   is	  unknown.	  A	  schematic	  representation	  of	  the	  membrane	  transporters	  involved	  in	  the	  CNS	  distribution	  of	  cefadroxil	  is	  shown	  in	  Figure	  3-­‐6.	  	  OATs	   and	  MRPs	   [20,	   31]	   are	   also	   responsible	   for	   the	   transport	   of	   substrates	  from	  CSF	  to	  blood	  at	  the	  BCSFB.	  Therefore,	  it	  was	  expected	  that	  inhibition	  of	  OATs	  and	   MRPs	   by	   probenecid	   would	   increase	   the	   Kp,uu,CSF	   of	   cefadroxil.	   However,	   no	  significant	   change	   was	   found	   for	   this	   parameter.	   The	   differential	   effect	   of	  transporter	   inhibition	  by	  probenecid	  on	  the	  distribution	  of	  cefadroxil	   in	  brain	  ECF	  and	  CSF	  may	  be	  related	  to	  the	  physiological	  and	  structural	  differences	  between	  BBB	  and	   BCSFB.	   The	   complement	   of	   efflux	   transporters,	   their	   expression	   levels,	   and	  cellular	   location	   may	   affect	   the	   relative	   importance	   of	   individual	   transporters	   in	  each	   of	   the	   two	   systems.	   In	   addition,	   the	   endothelial	   BBB	   is	   tighter	   than	   the	  epithelial	   BCSFB	   (choroid	   plexus),	   affecting	   paracellular	   diffusion	   [34].	   A	   recent	  study	   on	   the	   effects	   of	   probenecid	   on	   methotrexate	   transport	   found	   a	   different	  modulation	   of	  methotrexate	   distribution	   in	   brain	   ECF	   and	   CSF	   [35].	   There	  was	   a	  dose-­‐dependent	  effect,	  in	  which	  probenecid	  increased	  the	  brain	  ECF-­‐to-­‐plasma	  ratio	  for	   two	   dose	   regimens	   of	   methotrexate	   (40	   mg/kg	   and	   80	   mg/kg),	   whereas	  probenecid	  only	  significantly	   increased	   the	  CSF-­‐to-­‐plasma	  ratio	  at	   the	  higher	  dose	  [35].	  The	  differential	   effects	  of	  probenecid	  on	   cefadroxil	   at	   the	  BBB	  and	  BCSFB	   in	  our	  study	  are	  unlikely	  to	  be	  due	  to	  differences	  in	  inhibitor	  concentration	  at	  the	  two	  sites	  as	  Deguchi	  et	  al.	  [36]	  found	  higher	  probenecid	  concentrations	  in	  CSF	  than	  ECF	  after	  systemic	  dosing.	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In	  a	  previous	  study,	  Pept2	  ablation	  resulted	  in	  a	  marked	  increase	  in	  the	  CSF-­‐to-­‐blood	   concentration	   ratio	   of	   cefadroxil,	   indicating	   the	   importance	   of	   PEPT2	   in	  eliminating	  cefadroxil	  from	  CSF	  at	  the	  BCSFB	  [6].	  However,	  in	  the	  present	  study,	  an	  
icv	   infusion	   of	   the	   PEPT2	   substrate	   Ala-­‐Ala	   did	   not	   significantly	   change	   CSF	  cefadroxil	  concentrations.	  This	  lack	  of	  effect	  may	  reflect	  insufficient	  concentrations	  of	  Ala-­‐Ala	  reaching	  the	  BCSFB.	  Ala-­‐Ala	  was	  chosen	  to	  inhibit	  PEPT2	  because	  it	  has	  a	  relatively	  high	  affinity	  for	  that	  transporter	  (Ki	  =	  6.3	  μM,	  similar	  to	  that	  of	  cefadroxil	  with	  a	  Ki	  =	  3.0	  μM)	  [37].	  However,	  Ala-­‐Ala	  has	  the	  disadvantage	  of	  being	  degraded	  by	  peptidases,	  many	  of	  which	  are	  found	  in	  the	  choroid	  plexus	  and	  brain	  [38].	  	  Vu,brain	  is	   a	  measure	   of	   drug	  distribution	  within	  brain	  parenchyma.	  The	  water	  volume	   in	   brain	   parenchyma	   is	   0.8	  mL/g	   brain	   and	   a	   Vu,brain	  of	   around	   0.8	  mL/g	  brain	   indicates	   a	   drug	   is	   distributed	   evenly	   through	   the	   whole	   brain	   tissue	   [29].	  Since	  cefadroxil	  is	  a	  hydrophlic	  drug	  with	  a	  fraction	  unbound	  in	  plasma	  of	  nearly	  1	  [28],	   its	  non-­‐specific	  binding	   in	  brain	   is	   likely	   to	  be	  negligible.	  This,	   together	  with	  the	  cefadroxil	  Vu,brain	  of	  3.67	  mL/g	  brain	  in	  the	  present	  study	  indicates	  the	  presence	  of	   uptake	   transporter(s)	   at	   the	  membrane	   of	   brain	   cells.	   The	  PEPT2	   substrates,	   5	  mM	  Ala-­‐Ala	  and	  GlySar,	  reduced	  the	  Vu,brain	  of	  cefadroxil,	  indicating	  that	  competitive	  inhibition	   of	   PEPT2	   decreased	   the	   uptake	   of	   cefadroxil	   into	   brain	   cells.	   This	   is	  consistent	   with	   previous	   findings	   that	   PEPT2	   is	   expressed	   on	   neurons	   and	  responsible	  for	  cellular	  uptake	  [39].	  In	  contrast,	  probenecid	  increased	  the	  Vu,brain	  of	  cefadroxil,	   indicating	   there	   may	   also	   be	   efflux	   transporters	   (e.g.,	   OATs,	   MRPs	   or	  OATPs)	   removing	   cefadroxil	   from	   brain	   cells.	   Interestingly,	   a	   previous	   study	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demonstrated	  that	  probenecid	  increased	  the	  intracellular	  levels	  of	  valproic	  acid	  by	  1.5-­‐fold	  in	  rabbit	  brain	  during	  in	  vivo	  microdialysis	  [40].	  	  By	   using	   intracerebral	  microdialysis	   in	   vivo	   and	   brain	   slices	   in	   vitro,	   a	   better	  understanding	   was	   obtained	   about	   the	   effect	   of	   transporters	   on	   cefadroxil	  distribution	  in	  brain	  and,	  specifically,	   in	  brain	  extracellular	  and	  intracellular	  fluids,	  and	   CSF.	   From	   our	   study,	   it	   appears	   that	   transporters	   which	   are	   probenecid	  inhibitable	  (i.e.,	  OATs,	  MRPs	  and/or	  OATPs)	  move	  cefadroxil	  in	  a	  vectorial	  direction	  from	  brain	  ECF	   to	  blood,	   and	   that	  PEPT2	   transports	   cefadroxil	   into	  brain	   cells.	   In	  addition,	  as	  probenecid	  increased	  cefadroxil	  uptake	  into	  brain	  slices,	  there	  is	  an	  as	  yet	  unidentified	  cefadroxil	  transporter	  effluxing	  this	  cephalosporin	  from	  brain	  cells.	  It	  is	  concluded	  that	  multiple	  transporters	  play	  a	  role	  in	  the	  distribution	  of	  cefadroxil	  into	   and	   within	   the	   brain.	   The	   impact	   of	   these	   transporters	   on	   specific	  cephalosporins	   will	   depend	   on	   transporter	   affinities	   and	   drug	   levels	   in	   brain.	  Microdialysis	  is	  a	  useful	  tool	  to	  study	  the	  kinetics	  of	  unbound	  drug	  concentrations	  in	  ECF	  and	  CSF	  [41].	  The	  brain	  slice	  method,	  together	  with	  other	  tools	  like	  equilibrium	  dialysis,	  provides	  an	  approach	  to	  study	  the	  distribution	  of	  drugs	  within	  brain	  after	  passing	  the	  BBB	  and	  BCSFB	  [27,	  42].	  	  A	  deeper	  understanding	  of	  the	  brain	  distribution	  of	  cephalosporins	  may	  aid	  in	  the	  better	  use	  of	  these	  antibacterial	  agents	  for	  the	  prophylaxis	  and	  treatment	  of	  CNS	  infections.	   Bacterial	   meningitis	   is	   an	   inflammatory	   process	   of	   the	   leptomeninges	  caused	   by	   bacterial	   infections.	   Bacterial	   meningitis	   is	   the	   most	   frequent	   CNS	  infection	  with	   a	  mortality	   rate	   approaching	   20%	   [43].	   It	   is	   believed	   that	   bacteria	  enter	  the	  CNS	  across	  BBB	  or	  BCSFB	  via	  transcytosis	  and	  finally	  enter	  the	  CSF.	  Even	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though	   BBB	   permeability	   increases	   during	  meningitis	   [18],	   the	   barriers	   and	   their	  efflux	   transporters	   still	   play	   a	   role	   in	   limiting	   cephalosporin	   entry	   to	   brain.	  Clinically,	   the	   cephalosporins	   used	   for	   meningitis	   are	   limited	   to	   ceftriaxone,	  cefotaxime,	   ceftazidime,	   and	   cefepime,	  which	  have	  high	  penetration	   into	  CSF	   [44].	  Another	   CNS	   infection	   is	   cerebritis,	   a	   focal	   brain	   parenchyma	   infection,	   which	   is	  often	   followed	   by	   brain	   abscesses	   and	   permanent	   damage	   [45].	   Treatment	   for	  cerebritis	  and	  brain	  abscesses	  also	  involves	  antibiotics.	  The	  strategy	  of	  blocking	  the	  related	  efflux	  transporters	  at	  the	  BBB	  and	  BCSFB	  is	  a	  promising	  way	  to	  enhance	  the	  penetration	  of	  relevant	  cephalosporins	  into	  brain	  ECF	  and	  CSF.	  	  Probenecid	   was	   firstly	   widely	   used	   to	   decrease	   renal	   clearance	   of	   penicillin	  during	  World	  War	  II,	  when	  antibiotic	  supplies	  were	  low.	  Probenecid	  decreases	  the	  elimination	   rate	   and	   volume	  of	   distribution	   for	   a	   variety	   of	  medications	   including	  most	   cephalosporins	   [46].	   However,	   with	   easier	   and	   cheaper	   production	   of	  antibiotics,	   probenecid	   is	   now	   seldom	   used	   with	   antibiotics.	   The	   present	   study	  showed	  that	  probenecid	  was	  able	  to	  increase	  the	  distribution	  of	  cefadroxil	  in	  brain	  ECF	   not	   only	   by	   reducing	   the	   renal	   clearance	   (and	   increasing	   systemic	   exposure)	  but	   also	   by	   specifically	   increasing	   the	  penetration	   into	   brain	   (i.e.,	   increased	  Kp,uu)	  and	   further	   into	  brain	  cells.	   It	  should	  be	  appreciated	  that,	  although	  this	  study	  was	  not	   designed	   to	   study	   cefadroxil	   under	   clinical	   dosing	   conditions,	   the	   co-­‐administration	   of	   probenecid	   allowed	   cefadroxil	   to	   reach	   the	   lower	   limit	   of	   its	  minimal	   inhibitory	   concentration	   in	   brain	   ECF	   for	   some	   bacteria	   (i.e.,	   about	   0.4	  μg/mL).	   Thus,	   the	   combined	   therapy	   of	   cefadroxil	   (or	   perhaps	   other	  cephalosporins)	  and	  probenecid	  might	  be	  useful	   for	   some	  cases	  of	  meningitis	   and	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brain	  abscesses.	  Whether	  or	  not	   this	   approach	   is	   feasible	  would	  depend	  upon	   the	  extent	  of	  this	  drug-­‐drug	  interaction	  in	  patients	  during	  different	  dosing	  combinations	  of	  both	  antibiotic	  and	   the	   inhibitor.	  Moreover,	   there	   is	  a	  delicate	  balance	  between	  the	  dose–response	  relationships	  of	  bacterial	  kill	   and	  CNS	   toxicity,	  which	  of	   course	  would	  have	  to	  be	  taken	  into	  account.	  	  In	  summary,	  using	   in	  vivo	  microdialysis	  and	   in	  vitro	  brain	  slice	  methods	  in	  rat,	  the	   present	   study	   demonstrated	   that	   probenecid	   increased	   cefadroxil	   distribution	  into	   brain	   extracellular	   and	   intracellular	   fluids	   by	   blocking	   related	   efflux	  transporters	  at	  the	  BBB	  and	  brain	  cells.	  Our	  findings	  suggest	  that	  the	  combination	  of	  probenecid	  and	  some	  cephalosporins	  may	  provide	  a	  strategy	  to	  increase	  therapeutic	  drug	  levels	  in	  brain	  for	  better	  treatment	  of	  CNS	  infections	  like	  bacterial	  meningitis	  and	  brain	  abscesses.	  On	  the	  other	  hand,	  since	  multiple	  transporters	  are	  involved	  in	  transporting	   cephalosporins	   in	   brain,	   there	   is	   also	   the	   potential	   for	   drug-­‐drug	  interactions	   to	   enhance	   cephalosporin-­‐induced	   neurotoxicity.	   However,	   no	  significant	   changes	   in	   cefadroxil	   levels	   in	   brain	   ECF	   or	   CSF	  were	   found	  with	   i.c.v	  infusion	  of	  Ala-­‐Ala,	  which	  was	  probably	  the	  result	  of	  the	  instability	  property	  of	  Ala-­‐Ala	  in	  body.	  Compared	  to	  competitive	  inhibition	  of	  PEPT2	  using	  Ala-­‐Ala,	  the	  mouse	  model	   with	   the	   ablation	   of	   Pept2	   serves	   as	   a	   better	   tool	   to	   specifically	   study	   the	  function	  of	  PEPT2	  on	  cefadroxil	  disposition	  in	  brain.	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Table	  3-­‐1	   Pharmacokinetic	   parameters	   of	   unbound	   cefadroxil	   in	   rat	   blood	   and	  brain	  on	  Day	  1	  (Control,	  Ctrl)	  and	  Day	  2	  (with	  probenecid,	  Pro)	  
Parameters	   Unit	   Day	  1	  (Ctrl)	   Day	  2	  (Pro)	   Pro/Ctrl	  
Blood	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   1747	  ±	  90	   2801	  ±	  175***	   1.60	  
AUCu	  (0-­‐inf)	   μg*min/mL	   1802	  ±	  97	   2873	  ±	  177***	   1.59	  
Cu,ss,blood	   μg/mL	   8.5	  ±	  0.4	   13.8	  ±	  0.9***	   1.62	  
MRTiv	   min	   71	  ±	  4	   77	  ±	  4	   1.05	  
t1/2	   min	   49	  ±	  2	   53	  ±	  3	   1.09	  
CL	   mL/min/kg	   16.9	  ±	  1	   10.7	  ±	  0.7***	   0.63	  
Vss	   L/kg	   1.19	  ±	  0.12	   0.82	  ±	  0.10***	   0.69	  
Brain	  ECF	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   31	  ±	  5	   122	  ±	  31*	   3.93	  
AUCu	  (0-­‐inf)	   μg*min/mL	   40	  ±	  7	   174	  ±	  35**	   4.37	  
Kp,uu,ECF	  (0–420)	   	   0.018	  ±	  0.003	   0.042	  ±	  0.009*	   2.35	  
Kp,uu,ECF	  (0-­‐inf)	   	   0.022	  ±	  0.003	   0.058	  ±	  0.009*	   2.63	  
Brain	  CSF	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   39	  ±	  12	   73	  ±	  27	   1.88	  
AUCu	  (0-­‐inf)	   μg*min/mL	   57	  ±	  15	   117	  ±	  50	   2.04	  
Kp,uu,CSF	  (0–420)	   	   0.022	  ±	  0.006	   0.024	  ±	  0.008	   1.13	  
Kp,uu,CSF	  (0-­‐inf)	   	   0.031	  ±	  0.007	   0.039	  ±	  0.015	   1.26	  Data	   are	   expressed	   as	   mean	   ±	   SEM	   (n	   =	   6).	   A	   paired	   t-­‐test	   was	   performed	   to	  compare	   cefadroxil	   parameters	   between	   the	   control	   (without	   probenecid)	   and	  treatment	  (with	  probenecid)	  phases	  of	  the	  study.	  *p	  <	  0.05,	  **p	  <	  0.01,	  and	  ***	  p	  <	  0.001.	  Abbreviations:	  AUCu,	  Area	  under	  the	  unbound	  concentration-­‐time	  curve	  from	  time	   zero	   to	   420	   min	   (0–420)	   or	   from	   time	   zero	   to	   infinity	   (0-­‐inf);	   Cu,ss,blood,	  Unbound	   steady-­‐state	  blood	   concentration;	  MRTiv,	  Mean	   residence	   time;	   t1/2,	  Half-­‐life;	   CL,	   Total	   clearance;	  Vss,	   Volume	   of	   distribution	   steady-­‐state;	  Kp,uu,ECF,	   Ratio	   of	  AUCu	   in	   brain	  ECF	   to	  AUCu	   in	   blood;	   and	  Kp,uu,CSF,	   Ratio	   of	  AUCu	   in	  CSF	   to	  AUCu	   in	  blood.	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  Figure	  3-­‐3	   The	  unbound	  partition	  coefficient	  (Kp,uu)	  of	  cefadroxil	  in	  rat	  brain	  ECF	  (A,	  B)	  and	  CSF	  (C,	  D)	  for	  each	  of	  the	  six	  animals.	  	  CEF	   represents	   the	   study	   in	  which	   cefadroxil	   is	   given	   alone	   (Day	   1)	  and	   CEF	   +	   PRO	   is	   when	   cefadroxil	   is	   given	   in	   the	   presence	   of	  probenecid	  (Day	  2).	  See	  Table	  3-­‐1	  for	  statistical	  analyses. 
 
  















































































	  	   81	  


























	  	   82	  













































	  	   83	  
	  Figure	  3-­‐6	   Membrane	  transporters	  (potentially)	  involved	  in	  the	  CNS	  distribution	  of	  cefadroxil.	   Several	  references	  were	  used	  to	  inform	  this	  schematic	  representation	  [21,	   47-­‐49].	   There	   is	   much	   debate	   regarding	   the	   isoforms	   and	  membrane	   localization	   of	   MRPs	   at	   the	   BBB.	   There	   is,	   though,	  considerable	   evidence	   for	   some	   MRPs	   having	   an	   apical	   distribution	  clearing	  substrates	  to	  blood	  as	  depicted.	  There	  is	  also	  functional	  evidence	  for	  the	  probenecid-­‐inhibitable	  efflux	  of	  cefadroxil	  from	  brain	  cells	   ,	   the	   nature	   of	   which	   is	   uncertain	   but	   may	   include	   OAT,	   MRP	  and/or	  OATP	  transporters.	  BL	  represents	  the	  basolateral	  membrane,	  AP	  the	  apical	  membrane,	  and	  EP	  the	  ependyma. 
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  CHAPTER 4
INFLUENCE OF PEPTIDE TRANSPORTER 2 (PEPT2) ON 
THE DISTRIBUTION OF CEFADROXIL IN MOUSE BRAIN: 
A MICRODIALYSIS STUDY   
4.1 Abstract	  
Peptide	   transporter	   2	   (PEPT2)	   is	   a	   high-­‐affinity	   low-­‐capacity	   transporter	  belonging	   to	   the	   proton-­‐coupled	   oligopeptide	   transporter	   family.	   Although	   many	  aspects	  of	  PEPT2	  structure-­‐function	  are	  known,	  including	  its	  localization	  in	  choroid	  plexus	  and	  neurons,	  its	  regional	  activity	  in	  brain,	  especially	  extracellular	  fluid	  (ECF),	  is	  uncertain.	   In	   this	  study,	   the	  pharmacokinetics	  and	  regional	  brain	  distribution	  of	  cefadroxil,	  a	  ß-­‐lactam	  antibiotic	  and	  PEPT2	  substrate,	  were	  investigated	  in	  wildtype	  and	  Pept2	  null	  mice	  using	  in	  vivo	  intracerebral	  microdialysis.	  Cefadroxil	  was	  infused	  intravenously	  over	  4	  hours	  at	  0.15	  mg/min/kg,	  and	  samples	  obtained	  from	  plasma,	  brain	   ECF,	   cerebrospinal	   fluid	   (CSF)	   and	  brain	   tissue.	   A	   permeability-­‐surface	   area	  experiment	  was	   also	   performed	   in	  which	   0.15	  mg/min/kg	   cefadroxil	  was	   infused	  intravenously	  for	  10	  min,	  and	  samples	  obtained	  from	  plasma	  and	  brain	  tissues.	  Our	  results	   showed	   that	  PEPT2	  ablation	   significantly	   increased	   the	  brain	  ECF	  and	  CSF	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levels	  of	  cefadroxil	  (2-­‐	  to	  2.5-­‐fold).	  In	  contrast,	  there	  were	  no	  significant	  differences	  between	  wildtype	  and	  Pept2	  null	  mice	  in	  the	  amount	  of	  cefadroxil	  in	  brain	  cells.	  The	  unbound	  volume	  of	  distribution	  of	  cefadroxil	  in	  brain	  was	  60%	  lower	  in	  Pept2	  null	  mice	  indicating	  an	  uptake	  function	  for	  PEPT2	  in	  brain	  cells.	  Finally,	  PEPT2	  did	  not	  affect	  the	  influx	  clearance	  of	  cefadroxil,	  thereby,	  ruling	  out	  differences	  between	  the	  two	   genotypes	   in	   drug	   entry	   across	   the	   blood-­‐brain	   barriers.	   These	   findings	  demonstrate,	   for	   the	   first	   time,	   the	   impact	   of	   PEPT2	   on	   brain	   ECF	   as	  well	   as	   the	  known	  role	  of	  PEPT2	   in	   removing	  peptide-­‐like	  drugs,	   such	  as	   cefadroxil,	   from	   the	  CSF	  to	  blood.	  	  
4.2 Introduction	  
Proton-­‐coupled	   oligopeptide	   transporters	   (POTs)	   move	   di-­‐/tripeptides	   and	  peptidomimetics	   across	   biologic	  membranes	   down	   an	   electrochemical	   membrane	  gradient,	   thereby	   playing	   an	   important	   role	   in	   the	   absorption,	   distribution	   and	  elimination	  of	  substrates	  in	  the	  body	  [1].	  Among	  the	  four	  mammalian	  POTs,	  peptide	  transporter	  2	   (PEPT2,	  also	  known	  as	  SLC15A2)	   is	  a	  high-­‐affinity	  and	   low-­‐capacity	  transporter.	   It	   is	  widely	  expressed	   in	  brain,	  kidney,	   lung,	  eye	  and	  mammary	  gland	  [2,	  3].	  The	  functional	  activity	  of	  PEPT2	  has	  been	  studied	  using	  a	  variety	  of	  substrates	  including	   the	   synthetic	   dipeptide	   glycylsarcosine	   (GlySar)	   [4-­‐6],	   endogenous	  peptidomimetics	   (e.g.,	   5-­‐aminolevulinic	   acid)	   [7,	   8],	   neuropeptides	   (e.g.,	   carnosine	  and	   kyotorphin)	   [9-­‐11],	   as	  well	   as	   peptide-­‐like	   drugs	   (e.g.,	   cefadroxil)	   [12,	   13].	   In	  kidney,	   PEPT2	   is	   expressed	   at	   the	   apical	  membrane	   of	   proximal	   tubule	   epithelial	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cells	  where	  it	  plays	  an	  important	  role	  in	  the	  reabsorption	  of	  substrates	  from	  urine,	  thereby	  limiting	  renal	  clearance	  [14].	  	  PEPT2	   is	   also	   expressed	   at	   the	   apical	   membrane	   of	   choroid	   plexus	   epithelial	  cells	  (CSF-­‐facing),	  the	  site	  of	  the	  blood-­‐cerebrospinal	  fluid	  barrier	  (BCSFB),	  where	  it	  facilitates	  substrate	  efflux	  from	  CSF	  to	  blood,	  thus	  reducing	  substrate	  distribution	  in	  CSF	   [15].	   According	   to	   an	   immunolocalization	   study	   in	   rat	   brain,	   PEPT2	   is	  distributed	   in	   brain	   parenchyma,	   particularly	   at	   the	   plasma	   membrane	   of	   neural	  cells	   (neonates	   and	   adults)	   and	   astrocytes	   (neonates	   only)	   [16].	   As	   an	   uptake	  transporter	   in	  brain	  cells,	  PEPT2	  plays	  a	  role	   in	   the	  homeostasis	  of	  neuropeptides	  and	   the	   distribution	   of	   peptide-­‐like	   therapeutics	   within	   brain	   parenchyma.	  Furthermore,	   our	   previous	   studies	   in	   wildtype	   and	   Pept2	   null	   mice	   indicate	   that	  PEPT2	  has	  a	  profound	  influence	  on	  the	  neurological	  effects	  of	   its	  substrates	   in	  the	  central	  nervous	  system	  (CNS).	  For	   instance,	  PEPT2	  reduces	  the	  neurotoxicity	  of	  5-­‐aminolevulinic	  acid	  [7]	  and	  the	  anti-­‐nociceptive	  effect	  of	  kyotorphin	  [10].	  However,	  in	  these	  two	  studies,	  the	  effect	  of	  PEPT2	  in	  ECF	  is	  inferred	  since	  our	  study	  design	  did	  not	  allow	  direct	  measurement	  of	  this	  biological	  fluid.	  	  	  In	  addition	  to	  small	  peptides,	  PEPT2	  is	  able	  to	  transport	  peptide-­‐like	  drugs	  that	  have	  similar	  structures	  to	  the	  backbones	  of	  di-­‐	  or	  tripeptides	  (e.g.,	  cephalosporins,	  angiotensin-­‐converting	  enzyme	  inhibitors)	  as	  well	  as	  antiviral	  nucleoside	  prodrugs	  [17].	  Among	  such	  drugs,	  cefadroxil	  is	  a	  first-­‐generation	  cephalosporin	  with	  a	  broad	  spectrum	   antibacterial	   activity,	   high	   PEPT2	   affinity,	   and	   favorable	   biological	  stability	   [18,	  19].	  Thus,	   cefadroxil	   serves	   as	   a	   good	  model	   compound	   to	   study	   the	  role	   and	   relevance	   of	   PEPT2	   in	   the	   disposition	   of	   peptide-­‐like	   drugs.	   Comparing	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wildtype	  and	  Pept2	  null	  mice,	  Shen	  et	  al.	  [12]	  found	  that	  PEPT2	  was	  almost	  entirely	  responsible	   for	   the	   renal	   reabsorption	   of	   cefadroxil.	   Moreover,	   the	   CSF/blood	  concentration	  ratio	  was	  higher	   (6-­‐	   to	  7-­‐fold)	   in	   the	  Pept2	  null	  mice,	   indicating	   the	  CSF-­‐to-­‐blood	  efflux	  function	  of	  PEPT2	  at	  the	  BCSFB.	  	  Intracerebral	  microdialysis	  is	  the	  only	  method	  in	  vivo	  that	  allows	  for	  the	  direct	  measurement	   of	   drug	   concentrations	   in	   ECF	   [20,	   21].	   Microdialysis	   also	   has	   the	  advantage	   of	   enabling	   repeated	   sampling	   without	   fluid	   loss	   on	   freely	   moving	  animals.	   In	  our	  previous	  microdialysis	   study	   in	   rats	   [22],	   an	  attempt	  was	  made	   to	  investigate	  the	  role	  of	  PEPT2	  on	  cefadroxil	  disposition	  in	  ECF	  and	  CSF	  by	  functional	  ablation	   of	   PEPT2	   via	   competitive	   inhibition	   of	   cefadroxil	   transport	   using	  intraventricular	   infusion	   of	   the	   dipeptide	   Ala-­‐Ala.	   Unfortunately,	   the	   results	  were	  negative,	   probably	   because	   of	   the	   biological	   instability	   of	   Ala-­‐Ala	   in	   vivo	   [23].	  Compared	  to	  inhibition	  studies,	  Pept2	  null	  mice	  may	  be	  a	  better	  tool	  to	  specifically	  study	  the	  effects	  of	  PEPT2	  on	  cefadroxil	  brain	  distribution.	  	  	  We	  hypothesize	  that	  PEPT2	  ablation	  will	  impact	  the	  disposition	  of	  cefadroxil	  in	  the	   brain	   extracellular	   fluid	   (ECF),	   the	   site	   of	   action	   of	  many	   neuroactive	   agents.	  With	  this	  in	  mind,	  the	  primary	  objective	  of	  this	  study	  was	  to	  determine,	  using	  in	  vivo	  intracerebral	  microdialysis,	  the	  pharmacokinetics	  and	  regional	  brain	  distribution	  of	  cefadroxil	   in	   wildtype	   and	  Pept2	   null	   mice	   following	   a	   4-­‐hr	   intravenous	   infusion.	  The	  secondary	  objective	  was	   to	  calculate	   the	  permeability-­‐surface	  area	  product	  of	  cefadroxil	   in	  mice,	   as	   a	   measure	   of	   the	   impact	   of	   PEPT2	   on	   drug	   transport	   from	  plasma	  to	  brain	  (i.e.,	  influx	  clearance),	  following	  a	  10-­‐min	  intravenous	  infusion.	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4.3 Material	  and	  methods	  
4.3.1 Chemicals	  Cefadroxil	   and	   cefadroxil-­‐D4	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	  MO).	  [3H]Cefadroxil	  (0.57	  Ci/mmol;	  97.6%	  purity)	  was	  obtained	  from	  Moravek	  Inc	  (Brea,	   CA)	   and	   [14C]dextran	   70,000	   (1.4	   mCi/g)	   was	   obtained	   from	   American	  Radiolabeled	   Chemicals	   (ARC,	   St.	   Louis,	   MD).	   Methanol	   and	   acetonitrile	   were	  purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	   MO).	   All	   other	   chemicals	   and	   solvents	  were	  of	  analytical	  grade	  or	  better.	  Ultrapure	  water	  was	  obtained	  using	   the	  Milli-­‐Q	  Reference	  Water	   Purification	   System	   (Millipore,	   Billerica,	  MA).	   Perfusion	   fluid	   for	  microdialysis	  consisted	  of	  Ringer’s	  solution,	  which	  contained	  145	  mM	  NaCl,	  0.6	  mM	  KCl,	  1.0	  mM	  MgCl2,	  and	  1.2	  mM	  CaCl2	  in	  2	  mM	  phosphate	  buffer,	  pH	  7.4.	  	  
4.3.2 Animals	  
Pept2	   null	   mice	   (Pept2-­‐/-­‐)	   with	   >99%	   C57BL/6	   genetic	   background	   were	  developed	  previously	  in	  our	  laboratory	  [24].	  Male	  wildtype	  (Pept2+/+)	  and	  Pept2	  null	  mice	   (12-­‐16	   weeks)	   were	   bred	   in-­‐house	   and	   maintained	   in	   a	   temperature-­‐	   and	  humidity-­‐controlled	   environment	   with	   12-­‐hour	   light/dark	   cycles	   and	   unlimited	  access	   to	   food	   and	   water	   (Unit	   for	   Laboratory	   Animal	   Medicine,	   University	   of	  Michigan,	   Ann	   Arbor,	   MI).	   All	   procedures	   in	   this	   study	   were	   conducted	   in	  accordance	  with	  the	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  as	  adopted	  and	  promulgated	  by	  the	  U.S.	  National	  Institutes	  of	  Health	  and	  were	  approved	  by	  the	  University	  of	  Michigan	  Committee	  on	  Use	  and	  Care	  of	  Animals.	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4.3.3 Animal	  surgery	  Mice	   were	   placed	   on	   a	   heating	   pad	   to	   maintain	   body	   temperature	   and	  anesthetized	  by	  2%	  isoflurane	  inhalation	  together	  with	  0.5	  L/min	  oxygen.	  Once	  fully	  anesthetized,	  the	  mice	  were	  surgically	  implanted	  with	  blood	  vessel	  catheterized	  and	  a	  microdialysis	  probe.	  A	  3-­‐fr	  polyurethane	  cannula	  (fused	  with	  a	  2-­‐fr	  polyurethane	  tip)	   was	   inserted	   into	   the	   right	   jugular	   vein	   for	   cefadroxil	   infusion	   and	   a	   2-­‐fr	  polyurethane	  cannula	  (fused	  with	  a	  1-­‐fr	  polyurethane	  tip)	  was	  inserted	  into	  the	  left	  carotid	  artery	  for	  blood	  sampling.	  To	  avoid	  clotting,	  a	  locking	  solution	  of	  500	  IU/mL	  heparin	   and	   50%	   glycerol	   was	   used	   to	   fill	   the	   arterial	   catheter.	   The	   two	   vessel	  catheters	  were	  passed	  subcutaneously	  to	  the	  upper	  back	  of	  mice	  and	  then	  fixed	  to	  a	  silicone	  cup	  sutured	  to	  the	  skin.	  	  Following	   catheter	   insertion,	   the	   mouse	   was	   placed	   on	   a	   stereotaxic	   frame	  equipped	  with	  an	  anesthesia	  mask	  (Stoelting,	  Wood	  Dale,	  IL).	  A	  guide	  cannula	  was	  implanted	   into	  the	  right	  brain	  striatum	  (coordinates:	  0.6	  mm	  anteroposterior,	   -­‐1.8	  mm	  lateral	  and	  -­‐2.0	  mm	  dorsoventral)	  and	  then	  fixed	  to	  the	  skull	  with	  two	  anchor	  screws	  and	  dental	  cement.	  A	  pre-­‐emptive	  dose	  of	  buprenorphine	  (0.08	  mg/kg)	  was	  administered	  subcutaneously	  and	  additional	  doses	  were	  given	  every	  eight	  hours	  for	  one	   day	   after	   surgery.	   The	   mouse	   was	   allowed	   to	   recover	   for	   5-­‐6	   days	   prior	   to	  experimentation.	  One	  day	  before	  microdialysis,	  the	  mouse	  was	  moved	  to	  an	  infusion	  cage	   (Harvard	  Apparatus,	  MA,	  US)	  where	   it	   could	  move	   freely,	   and	  have	  access	   to	  food	  and	  water.	  At	  the	  same	  time,	  the	  dummy	  in	  the	  guide	  cannula	  was	  replaced	  by	  a	  CMA7	   microdialysis	   probe	   containing	   a	   2-­‐mm	   cuprophane	   membrane	   and	   6000	  Dalton	  cut-­‐off	  (CMA,	  Stockholm,	  Sweden).	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4.3.4 Microdialysis	  study	  design	  Microdialysis	   was	   initiated	   1.5	   hour	   prior	   to	   drug	   infusion	   (i.e.,	   stabilization	  period)	  and	  maintained	  during	  the	  infusion	  of	  cefadroxil.	  During	  this	  time,	  Ringer’s	  solution	  was	  perfused	  through	  the	  microdialysis	  probe	  at	  0.5	  µL/min	  using	  a	  CMA	  402	  pump	   (Stockholm,	   Sweden).	  Cefadroxil	   (6	  mg/mL	   in	   saline)	  was	   then	   infused	  intravenously	   at	   a	   constant	   rate	   of	   0.15	  mg/min/kg	   for	   4	   hours	   using	   a	   Harvard	  Apparatus	  22	  pump	  (Holliston,	  MA,	  US).	  During	  the	  infusion,	  microdialysis	  samples	  were	  collected	  every	  20	  min	  using	  a	  CMA	  142	  microfraction	  collector	   (Stockholm,	  Sweden)	  and	  kept	  on	  ice	  at	  4°C.	  Blood	  samples	  (≈	  10	  µL	  each)	  were	  harvested	  from	  the	  carotid	  artery	  at	  5,	  10,	  20,	  40,	  60,	  80,	  100,	  120,	  180,	  and	  240	  min	  after	  initiating	  the	   intravenous	   drug	   infusion.	   Plasma	  was	   obtained	   by	   centrifuging	   the	   blood	   at	  10,600	   g	   for	   5	   min.	   Before	   terminating	   the	   cefadroxil	   infusion,	   a	   combination	   of	  ketamine	  (120	  mg/kg)	  and	  xylazine	  (10	  mg/kg)	  was	  administered	  intraperitoneally	  to	   anesthetize	   the	  mouse	   so	   that	  CSF	   could	  be	   collected	  quickly	   from	   the	   cisterna	  magna.	  The	  mouse	  was	   then	  decapitated	   and	   the	  brain	  divided	   into	   left	   and	   right	  cortex	   (including	   hippocampus),	   left	   and	   right	   basal	   ganglia	   (including	   striatum),	  and	  cerebellum.	  Samples	  were	  weighed	  and	  stored	  at	  -­‐80°C	  until	  analysis	  (as	  were	  the	   microdialysis	   and	   plasma	   samples).	   If	   blood	   was	   observed	   in	   CSF	   or	   a	  hemorrhage	  was	  found	  in	  brain	  tissue,	  then	  those	  samples	  were	  discarded.	  	  	  The	   CMA7	   microdialysis	   probes	   were	   calibrated	   by	   determining	   the	   relative	  recovery	   of	   [3H]cefadroxil	   in	   three	   mice	   using	   in	   vivo	   retrodiaylsis.	   Briefly,	   three	  microdialysis	   samples	   were	   collected	   from	   each	   mouse	   following	   the	   1.5-­‐hr	  stabilization	   period,	   after	   which	   their	   radioactivities	   were	   measured	   in	   a	   dual-­‐
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channel	   liquid	   scintillation	   counter	   (Beckman	   Coulter	   LS	   6000SC,	   Fullerton,	   CA,	  USA).	  	  
4.3.5 Permeability-­‐surface	  area	  product	  study	  design	  This	  study	  was	  performed	  in	  order	  to	  determine	  whether	  or	  not	  PEPT2	  affected	  the	  transport	  of	  cefadroxil	  from	  plasma	  to	  brain.	  The	  permeability-­‐surface	  area	  (PS)	  product	   was	   measured	   by	   giving	   a	   10-­‐min	   intravenous	   infusion	   of	   cefadroxil	   to	  wildtype	  and	  Pept2	  null	  mice,	  during	  which	  time	  it	  was	  assumed	  that	  there	  was	  no	  efflux	   of	   cefadroxil	   from	   the	   brain.	   Briefly,	   following	   2%	   isoflurane	   anesthesia,	  catheters	  were	   implanted	   in	   the	   right	   jugular	  vein	  and	   left	   carotid	  artery	   for	  drug	  administration	   and	   blood	   sampling,	   respectively.	   Immediately	   after	   surgery,	   and	  under	   isoflurane	  maintenance,	   cefadroxil	   (0.6	   mg/mL	   in	   saline)	   was	   infused	   at	   a	  dose	  of	  0.15	  mg/min/kg	  for	  10	  min.	  Blood	  samples	  (≈	  10	  µL	  each)	  were	  obtained	  at	  1,	  2.5,	  5,	  7.5	  and	  10	  min	  after	  initiating	  the	  cefadroxil	  infusion,	  and	  then	  centrifuged	  to	  collect	  the	  plasma.	  Upon	  termination	  of	  the	  infusion,	  mice	  were	  decapitated	  and	  select	  brain	  tissues	  of	  five	  regions	  were	  harvested	  and	  weighed,	  as	  described	  as	  in	  the	  microdialysis	  study.	  All	  samples	  were	  stored	  at	  -­‐80°C	  until	  analysis.	  	  
4.3.6 Vascular	  Space	  Measurement	  The	  amount	  of	  cefadroxil	  in	  brain	  was	  corrected	  for	  drug	  in	  the	  cerebrovascular	  space	  by	  measuring	  vascular	  volume	  in	  different	  regions	  of	  the	  brain.	  Under	  sodium	  pentobarbital	  anesthesia	   (50	  mg/kg,	   intraperitoneal),	   catheters	  were	   implanted	   in	  the	  right	  jugular	  vein	  and	  left	  carotid	  artery	  of	  mice.	  The	  animals	  then	  received	  an	  intravenous	   infusion	   of	   0.15	   mg/min/kg	   [3H]cefadroxil	   for	   10	   min,	   with	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[14C]dextran	  70,000	  (0.8	  µCi/mouse),	  a	  vascular	  marker,	  being	  administered	  via	  the	  arterial	  catheter	  2	  min	  prior	  to	  terminating	  the	  drug	  infusion.	  Mice	  were	  decapitated	  at	   the	   end	   of	   infusion	   and	   the	   blood	   instantly	   collected	   from	   the	   neck	   for	   drug	  measurements	   in	   the	  blood	  and	  plasma.	  Brain	  tissues	  were	  collected,	  as	  described	  previously	   in	   the	  microdialysis	   study.	   Samples	  were	  weighed	  and	  solubilized	  with	  0.33	  mL	  of	   1	  M	  hyamine	  hydroxide	   for	   two	  days	   at	   37°C.	  A	  30-­‐µL	   aliquot	   of	   30%	  hydrogen	  peroxide	  was	  then	  added	  to	  bleach	  the	  sample,	  which	  was	  followed	  by	  the	  addition	  of	  6	  mL	  Cytoscint	   liquid	  scintillation	  cocktail	   (MP	  Biomedicals,	  Solon,	  OH,	  US)	   and	   vortex	  mixing.	   Radioactivity	  was	  measured	   in	   each	   sample	   using	   a	   dual-­‐channel	  liquid	  scintillation	  counter	  (Beckman	  Coulter	  LS	  6000SC).	  	  
4.3.7 Liquid	  chromatography-­‐tandem	  mass	  spectrometry	  assay	  Quantification	   of	   cefadroxil	   samples	   from	   the	  microdialysis	   and	   permeability-­‐surface	   area	   studies	   was	   performed	   using	   liquid	   chromatography-­‐tandem	   mass	  spectrometry	   (LC-­‐MS/MS).	   Specifically,	   after	  diluting	  8	  µL	  of	  microdialysis	   sample	  with	  20	  µL	  of	  methanol	  (which	  contained	  deuterated	  cefadroxil,	  cefadroxil-­‐D4,	  as	  an	  internal	  standard	  (IS)),	  a	  5-­‐µL	  aliquot	  was	  injected	  into	  the	  LC-­‐MS/MS.	  CSF	  samples	  (1-­‐2	   µL)	   were	   diluted	   5-­‐	   to	   10-­‐fold	   in	   Ringer’s	   solution,	   and	   then	   treated	   and	  analyzed	   exactly	   the	   same	   way	   as	   described	   for	   the	   microdialysis	   samples.	   For	  plasma,	  5-­‐µL	  samples	  were	  diluted	  40-­‐fold	   in	  methanol	  (containing	   IS)	   in	  order	   to	  precipitate	  the	  proteins.	  After	  shaking	  for	  5	  min	  and	  centrifuging	  at	  17,000	  g	  for	  10	  min,	  a	  5-­‐µL	  aliquot	  of	  the	  resultant	  supernatant	  was	  injected	  into	  the	  LC-­‐MS/MS.	  To	  obtain	  brain	  homogenate,	  water	  was	  added	  to	  each	  brain	  sample	  (1:4	  ratio,	  W/V),	  which	  was	  ground	  using	  a	  plastic	  pestle	  and	  then	  further	  homogenized	  finely	  with	  a	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sonicator	  (QSONICA,	  Newtown,	  CT).	  For	  brain	  samples	  from	  the	  microdialysis	  study,	  protein	  was	  precipitated	  from	  20	  µL	  of	  homogenate	  by	  adding	  methanol	  (containing	  IS)	   at	   a	   ratio	   of	   1:5,	   followed	   by	   5	  min	   of	   shaking	   and	   10	  min	   of	   centrifuging	   at	  17,000	  g.	  A	  5-­‐µL	  of	  the	  resultant	  supernatant	  was	  then	  injected	  into	  the	  LC-­‐MS/MS.	  Brain	   samples	   from	   the	   permeability-­‐surface	   area	   study	   had	   lower	   levels	   of	  cefadroxil	  and,	  as	  a	  result,	  protein	  from	  100	  µL	  of	  homogenate	  was	  precipitated	  by	  500	  µL	  of	  acetonitrile	  (containing	  IS),	  and	  the	  supernatant	  dried	  using	  a	  SpeedVac	  Concentrator	   (Thermo	  Scientific,	  Waltham,	  MA)	   at	   room	   temperature	   for	   2	  hours.	  The	  sample	  was	  reconstituted	  in	  100	  µL	  of	  methanol	  to	  concentrate	  the	  drug	  5-­‐fold,	  and	  a	  5-­‐µL	  aliquot	  was	  then	  injected	  into	  the	  LC-­‐MS/MS.	  For	  each	  biological	  matrix,	  standard	  curves	  were	  generated	  (i.e.,	  0.5-­‐200	  ng/mL	  for	  dialysate	  and	  CSF;	  0.1-­‐15.0	  µg/mL	  for	  plasma;	  25-­‐1000	  ng/g	  brain	  for	  microdialysis	  study;	  5-­‐100	  ng/g	  brain	  for	  PS	   study)	   and	   quality	   control	   samples	   (at	   low,	  medium	   and	   high	   concentrations)	  analyzed	  along	  with	  the	  samples.	  The	  coefficient	  of	  determination	  (r2)	  was	  ≥	  0.999	  for	  all	  standard	  curves.	  	  The	   LC-­‐MS/MS	   system	   consisted	   of	   a	   Prominence	   HPLC	   system	   (Shimadzu	  Corporation,	   Kyoto,	   Japan)	   and	   a	   triple	   quadrupole	  mass	   spectrometer	   (API	   4000	  QTRAP®,	  AB	  SCIEX,	  Concord,	  ON,	  Canada).	  Sample	  analytes	  were	  separated	  using	  an	  Atlantis	  C18	  column	  (2.1	  mm×150	  mm,	  particle	  size	  5	  µm;	  Waters,	  Milford,	  MA)	  and	  gradient	  elution	  delivered	  by	  two	  Shimadzu	  pumps	  for	  10	  min	  at	  0.2	  mL/min.	  The	  linear	   gradient	   consisted	   of	   mobile	   phases	   A	   (0.02%	   formic	   acid)	   and	   B	   (100%	  methanol),	  where	  mobile	  phases	  flowed	  at	  0.5%	  B	  from	  0-­‐0.5	  min,	  at	  5-­‐40%	  B	  from	  0.5-­‐3	  min,	  at	  40-­‐95%	  B	  from	  3-­‐4	  min,	  at	  95%	  B	  from	  4-­‐6	  min,	  at	  95-­‐5%	  B	  from	  6-­‐7	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min,	  and	  at	  5%	  B	  from	  7-­‐10	  min.	  Under	  these	  conditions,	  cefadroxil	  and	  cefadroxil-­‐D4	   had	   retention	   times	   of	   6.7	   min.	   The	   mass	   spectrometer	   was	   set	   in	   positive	  electrospray	  mode	  using	  a	  Turbo	  V™	  ion	  source.	  The	  transitions	  were	  monitored	  in	  a	  Multiple	  Reaction	  Monitoring	  (MRM)	  mode	  with	  m/z	  363.9	  →	  208.1	  for	  cefadroxil	  and	   m/z	   368.0	   →	   212.0	   for	   cefadroxil-­‐D4.	   Analysts	   1.0	   (AB	   SCIEX,	   Concord,	   ON,	  Canada)	  was	  used	  to	  acquire	  and	  process	  all	  LC-­‐MS/MS	  data.	  	  
4.3.8 Data	  Analysis	  Cefadroxil	   clearance	   was	   calculated	   at	   steady-­‐state	   using	   the	   plasma	  concentration	  obtained	  at	  the	  end	  of	  the	  4-­‐hour	  infusion	  (Cp,240)	  in	  which:	  
𝐶𝐿 = 𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛  𝑟𝑎𝑡𝑒𝐶!,!"# (1) Relative	   recovery	   of	   cefadroxil	   from	   the	   CMA7	   microdialysis	   probes	   was	  estimated	  during	  in	  vivo	  retrodialysis	  of	  [3H]cefadroxil	  and	  calculated	  as:	  
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 𝐷𝑃𝑀!" − 𝐷𝑃𝑀!"#𝐷𝑃𝑀!"    (2) where	   DPMin	   is	   the	   radioactivity	   of	   perfusate	   and	   DPMout	   is	   the	   radioactivity	   of	  dialysate,	  measured	  in	  disintegrations	  per	  minute	  (DPM).	  Accordingly,	  the	  unbound	  concentration	  of	  cefadroxil	  in	  brain	  ECF	  (Cu,ECF)	  was	  determined	  during	  the	  20-­‐min	  microdialysis	  collection	  period	  using	  the	  midpoint	  time	  of	  drug	  in	  dialysate	  (Cout)	  in	  which:	  
𝐶!,!"# =    𝐶!"#𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (3) 
	  	   99	  
To	   obtain	   the	   ratio	   of	   Cu,ECF	   to	   Cp,	   plasma	   concentrations	   of	   cefadroxil	   were	  estimated	  at	  the	  midpoint	  time	  (Cp,mid)	  using	  drug	  levels	  at	  two	  adjacent	  time	  points	  (Cp,1	  and	  Cp,2)	  such	  that:	  
𝐶!,!"# = 𝐶!,! − 𝐶!,!ln 𝐶!,!𝐶!,! (4) The	   radiolabeled	   compounds,	   [14C]dextran	   and	   [3H]cefadroxil,	   were	   used	   to	  obtain	   the	   vascular	   volume	   (Vbl	   in	   mL/g	   brain)	   for	   each	   brain	   region	   and	   the	  concentration	   ratio	   of	   cefadroxil	   in	   blood	   to	   that	   in	   plasma	   (Rbl-­‐p).	   The	   vascular	  volume-­‐corrected	  amount	  of	  cefadroxil	  in	  brain	  (Abrain	  in	  ng/g	  brain)	  was	  calculated	  as:	   𝐴!"#$% = 𝐴!"#$%&"' − 𝑅!"!! • 𝐶!,!"# • 𝑉!" (5) where	  Ameasured	  is	  the	  amount	  of	  drug	  actually	  measured	  in	  brain	  samples.	  	  The	  amount	  of	  cefadroxil	  in	  brain	  cells	  (Acell)	  was	  calculated	  by	  subtracting	  the	  drug	  content	  in	  brain	  ECF	  from	  Abrain	  in	  which:	  𝐴!"## = 𝐴!"#$% − 𝐶!,!"#,!!"!!"# • 𝑉!"# (6) where	  VECF	  is	  the	  volume	  of	  extracellular	  space	  in	  brain	  (0.18	  mL/g	  brain)	  [25]	  and	  Cu,ECF,220-­‐240	  is	  the	  unbound	  concentration	  of	  cefadroxil	   in	  brain	  ECF,	  as	  determined	  over	  the	  220-­‐240	  min	  time	  interval.	  	  A	   useful	   measure	   of	   drug	   distribution	   in	   brain	   parenchyma	   is	   the	   unbound	  volume	  of	  distribution	  in	  brain	  (Vu,brain	  in	  mL/g	  brain),	  which	  was	  calculated	  as:	  
𝑉!,!"#$% = 𝐴!"#$%𝐶!,!"#,!!"!!"# (7) 
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The	  PS	  product,	  a	  measure	  of	  drug	   transport	   from	  plasma	   to	  brain	   (i.e.,	   influx	  clearance),	  was	  calculated	  as:	  
𝑃𝑆 = 𝐴!"#$%𝐴𝑈𝐶!!!" (8) where	  Abrain	  is	  the	  amount	  of	  cefadroxil	  in	  each	  brain	  region	  at	  the	  10-­‐min	  infusion	  time	   and	   AUC0-­‐10	   is	   the	   area	   under	   the	   plasma	   concentration-­‐time	   curve	   of	  cefadroxil,	  from	  0-­‐10	  min,	  calculated	  using	  the	  trapezoidal	  method.	  	  
4.3.9 Statistical	  Analysis	  Data	   are	   expressed	   as	  mean	   ±	   standard	   error	   of	   the	  mean	   (SEM).	   A	   two-­‐way	  analysis	  of	  variance	  (ANOVA)	  with	  Bonferroni	  correction	  for	  multiple	  comparisons	  was	  performed	  to	  examine	  the	  influence	  of	  two	  factors	  on	  a	  variable	  (i.e.,	  time	  and	  genotype	   or	   brain	   region	   and	   genotype).	   Student’s	   t-­‐test	   was	   used	   to	   compare	   a	  variable	   between	   wildtype	   and	   PEPT2	   null	   groups	   if	   they	   had	   equal	   variance,	  whereas	  Welch’s	   t-­‐test	  was	  used	   for	  unequal	  variance.	  Paired	   t-­‐tests	  were	  used	   to	  compare	  two	  matched	  variables	  in	  the	  same	  animals	  (e.g.,	  Cu,ECF	  and	  Ccsf).	  A	  value	  of	  p	  ≤	  0.05	  was	  considered	  statistically	  significant.	  All	  statistical	  analyses	  were	  carried	  out	  using	  GraphPad	  Prism	  v7.0	  (GraphPad	  Software	  Inc.,	  San	  Diego,	  CA).	  
4.4 Results	  
Steady-­‐state	  plasma	  concentrations	  of	  cefadroxil	  were	  reached	  within	  one	  hour	  of	  the	  4-­‐hr	  intravenous	  infusion	  of	  drug	  at	  0.15	  mg/min/kg	  (Figure	  4-­‐1).	  As	  shown,	  there	  was	  no	  significant	  difference	  in	  plasma	  concentrations	  of	  cefadroxil	  between	  wildtype	   and	   Pept2	   null	   mice	   at	   any	   of	   the	   times	   sampled	   and	   clearance	   was	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virtually	   the	   same	   (34.8	  ±	  1.2	   vs.	   36.5	  ±	  3.4	  mL/min/kg,	   respectively).	  At	   the	   last	  time	  point,	  the	  plasma	  concentration	  of	  cefadroxil	  was	  4.35±0.14	  µg/mL	  in	  wildtype	  mice	   and	  4.45±0.35	  µg/mL	   in	  Pept2	   null	   animals	   (p=0.795).	   Compared	   to	  plasma,	  the	  unbound	  concentrations	  of	  cefadroxil	  in	  brain	  ECF	  showed	  a	  slower	  approach	  to	  steady-­‐state.	   Throughout	   the	   4-­‐hr	   constant-­‐rate	   infusion	   period,	   Pept2	   null	   mice	  exhibited	  higher	  brain	  ECF	  drug	  levels	  than	  wild-­‐type	  mice	  and	  achieved	  significant	  differences	  during	  the	  last	  2	  hours	  of	  cefadroxil	  infusion.	  	  As	  shown	  in	  Table	  4-­‐1	  and	  Figure	  4-­‐2,	   the	  concentrations	  of	  cefadroxil	   in	  brain	  ECF	  were	  about	  2-­‐	   to	  2.5-­‐fold	  greater	  in	  Pept2	  null	  mice	  than	  in	  wildtype	  animals	  during	  this	  time	  period.	  	  To	  confirm	  the	  effect	  of	  PEPT2	  on	  the	  penetration	  of	  cefadroxil	   into	  brain,	   the	  concentration	   ratio	   of	   unbound	   drug	   in	   brain	   ECF	   to	   total	   plasma	   (Cu,ECF/Cp)	  was	  calculated	   as	   a	   function	   of	   time.	   As	   shown	   in	   Figure	   4-­‐3,	   the	   Cu,ECF/Cp	   values	   of	  cefadroxil	   increased	   slowly	   in	  wildtype	  mice	   until	   1.5	   hour,	  whereas	   the	   Cu,ECF/Cp	  values	   in	  Pept2	  null	  mice	  became	  stable	  at	  around	  2.5	  hour.	  The	  Cu,ECF/Cp	  ratios	  of	  cefadroxil	  were	   significantly	   greater	   in	  Pept2	   null	  mice	   over	   the	   last	   2-­‐3	   hours	   of	  infusion	  and,	  at	  steady-­‐state,	  was	  almost	  2.5-­‐fold	  higher	  than	  wildtype	  mice	  at	   the	  last	   sampling	   point	   (i.e.,	   0.050±0.006	   in	   wildtype	  mice	   vs.	   0.121±0.016	   in	   PEPT2	  null	   animals).	   Relative	   recovery	   of	   cefadroxil	   in	   the	   CMA7	   (2-­‐mm)	   microdialysis	  probe,	   as	   determined	   during	   in	   vivo	   retrodialysis	   of	   radiolabeled	   drug,	   was	  4.7±0.1%.	  	  Cisterna	   magna	   and	   brain	   were	   also	   sampled	   at	   the	   end	   of	   the	   cefadroxil	  infusion	  to	  evaluate	  drug	  distribution	  in	  CSF	  and	  brain	  parenchyma	  at	  steady-­‐state.	  Cefadroxil	  levels	  in	  the	  CSF	  of	  Pept2	  null	  mice	  were	  two	  times	  that	  of	  wildtype	  mice	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(Table	  4-­‐1	  and	  Figure	  4-­‐2).	  PEPT2	  ablation,	  however,	  had	  no	  significant	  effect	  on	  the	  concentrations	   of	   cefadroxil	   in	   brain	   parenchyma	   or	   brain	   cells	   (Abrain	   or	   Acell).	  Because	   brain	   regions	   were	   not	   an	   influential	   factor	   for	   either	   Abrain	   or	   Acell,	  according	  to	  two-­‐way	  ANOVA,	  average	  Abrain	  and	  Acell	  values	  were	  determined	  from	  the	   five	   brain	   regions	   for	   each	   mouse.	   Finally,	   no	   significant	   differences	   were	  observed	  between	  brain	  ECF	  and	  CSF	  for	  each	  genotype.	  	  In	   the	   experiments	   using	   radiolabeled	   cefadroxil	   and	   dextran,	   the	   blood-­‐to-­‐plasma	   partitioning	   (or	   concentration	   ratio)	   of	   cefadroxil	   was	   not	   significantly	  different	   between	   the	   two	   genotypes	   (n=5	   per	   group),	   and	   was	   calculated	   as	  0.65±0.01	   when	   including	   all	   animals.	   The	   vascular	   volume	   was	   comparable	  between	  wildtype	   and	  Pept2	   null	  mice	   for	   each	   brain	   region	   (n=5	   per	   genotype),	  ranging	   from	   8.4-­‐8.7	   µL/g	   brain.	   The	   cerebellum,	   however,	   had	   a	   higher	   vascular	  volume	  (13.3±0.3	  µL/g	  brain)	  than	  the	  other	  regions.	  	  Vu,brain,	  a	  measure	  of	  intra-­‐brain	  distribution,	  describes	  the	  relationship	  between	  the	   total	   amount	   of	   drug	   in	   brain	   parenchyma	   and	   the	   unbound	   concentration	   of	  drug	   in	  brain	  ECF.	   In	  the	  present	  study,	  Vu,brain	  values	  were	  determined	  from	  brain	  tissue	  and	  microdialysis	  samples	  at	  steady-­‐state.	  As	  shown	  in	  Figure	  4-­‐4A,	  wildtype	  mice	   had	   a	   higher	   Vu,brain	   for	   cefadroxil	   than	   Pept2	   null	   mice,	   indicating	   that	  relatively	  more	  drug	  accumulated	   inside	   the	  brain	  cells	  of	  wildtype	  animals.	  Two-­‐way	  ANOVA	  showed	  that	  genotype	  was	  a	  significant	  influential	  factor	  that	  explained	  20.5%	  of	  the	  variation.	  	  In	  contrast,	  brain	  region	  did	  not	  have	  a	  significant	  influence	  on	  Vu,brain	  and	  there	  was	  no	  interaction	  between	  genotype	  and	  brain	  region.	  Because	  the	  Vu,brain	  was	   independent	  of	  brain	  region,	  an	  average	  Vu,brain	  was	  calculated	   from	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the	   five	   regions	   of	   each	   mouse.	   As	   shown	   in	   Figure	   4-­‐4B	   and	   Table	   4-­‐1,	   PEPT2	  ablation	   significantly	   decreased	   the	   average	   value	   of	   Vu,brain	   from	   2.13±0.43	  mL/g	  brain	  in	  wildtype	  mice	  to	  0.83	  ±	  0.17	  mL/g	  brain	  in	  Pept2	  null	  animals.	  	  The	   cefadroxil	   PS	   product	   was	   measured	   in	   both	   genotypes	   to	   examine	   the	  effect	  of	  PEPT2	  on	  cefadroxil	   influx	   from	  plasma	  to	  brain.	  As	  shown	  in	  Figure	  4-­‐5,	  the	   PS	   product	   did	   not	   differ	   significantly	   between	  wildtype	   and	  Pept2	   null	  mice,	  regardless	   of	   brain	   region.	   Still,	   in	   cerebellum,	   the	   PS	   product	   was	   about	   2-­‐fold	  higher	  than	  compared	  to	  the	  other	  regions.	  Based	  on	  two-­‐way	  ANOVA,	  it	  was	  shown	  that	  although	  genotype	  did	  not	  have	  an	  effect	  on	  the	  PS	  product,	  brain	  region	  was	  an	  influential	   factor.	   This	   finding	   was	   essentially	   due	   to	   the	   disparate	   value	   in	  cerebellum	  PS	  product	  as	  compared	  to	  either	  side	  of	  the	  cortex	  or	  basal	  ganglia.	  	  
4.5 Discussion	  
The	  present	  study	  used	  intracerebral	  microdialysis	  as	  a	  tool	  to	  study	  the	  role	  of	  PEPT2	  in	  the	  transport	  and	  distribution	  of	  cefadroxil	  in	  brain	  of	  wildtype	  and	  Pept2	  null	   mice.	   In	   this	   regard,	   the	   major	   findings	   of	   this	   study	   were	   that:	   1)	   PEPT2	  ablation	  had	   a	   significant	   effect	   on	   the	   accumulation	   of	   cefadroxil	   in	   brain,	  where	  ECF	   and	   CSF	   concentrations	   were	   increased	   2-­‐	   to	   2.5-­‐fold	   in	   Pept2	   null	   mice	   as	  compared	   to	   wildtype	   animals;	   2)	   the	   unbound	   volume	   of	   distribution	   in	   brain	  (Vu,brain)	  was	  60%	  significantly	   lower	   in	  Pept2	   null	  mice	   than	   in	  wildtype	   animals,	  indicating	  an	  uptake	  function	  of	  PEPT2	  in	  brain	  cells;	  and	  3)	  PEPT2	  ablation	  did	  not	  affect	   the	   influx	   clearance	   of	   cefadroxil	   from	   plasma	   to	   brain,	   as	   suggested	   by	  comparable	  PS	  product	  values	  between	  the	  genotypes	  in	  all	  five	  brain	  regions.	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The	  rate	  of	  drug	  transport	  across	  barriers	  of	  the	  CNS	  can	  be	  described	  by	  two	  pharmacokinetic	   parameters	   [26,	   27]:	   1)	   the	   rate	   of	   drug	   entering	   the	  brain	   from	  blood	   that	   is	  usually	   characterized	  by	  an	   influx	  clearance	   (CLin)	  and	  2)	   the	   rate	  of	  drug	  being	  removed	  from	  the	  brain	  and	  back	  to	  blood	  that	  is	  usually	  characterized	  by	   an	   efflux	   clearance	   (CLout).	   Although	   CLin	   and	   CLout	   characterize	   the	   rate	   of	  transport	   across	   blood-­‐brain	   barriers,	   the	   unbound	   partition	   coefficient	   (Kp,uu),	  determined	   by	   the	   net	   influx	   and	   efflux	   clearances	   such	   that	   Kp,uu=CLin/CLout,	  describes	   the	   extent	   of	   drug	   concentration	   between	   the	   brain	   and	   blood	   under	  steady-­‐state	  conditions.	  The	  Kp,uu	  is	  equal	  to	  unity	  in	  the	  case	  of	  equal	  CLin	  and	  CLout	  values,	   for	   instance,	   for	   drugs	   that	  move	   across	  membranes	   via	   passive	   diffusion	  only	   (e.g.,	   by	   transcellular	   or	   paracellular	   pathways).	   Although	   passive	   diffusion	  may	  be	  determined	  by	  the	  physicochemical	  properties	  of	  drugs,	  the	  influx	  and	  efflux	  clearances	  may	  be	  effected	  by	   the	   influx/efflux	   transporters	   expressed	  at	   the	  CNS	  barriers	   and	  by	  drug	   elimination	   via	  metabolism	   in	  brain.	   In	  practice,	  Kp,uu	  can	  be	  calculated	   as	   the	   concentration	   ratio	   of	   unbound	   drug	   in	   brain	   ECF	   (or	   CSF)	   to	  unbound	   drug	   in	   plasma	   at	   steady-­‐state	   such	   that:	   Kp,uu	   =	   Cu,brain,ss/Cu,plasma,ss	   =	  CLin/CLout.	  	  In	   the	  present	   study,	   only	   total	   plasma	   concentrations	   (Cp)	   of	   cefadroxil	  were	  measured	  and	  not	  unbound	  concentrations	  in	  plasma	  (Cu,plasma).	  However,	  the	  Cp	  of	  cefadroxil	  is	  expected	  to	  be	  comparable	  to	  Cu,plasma	  since	  essentially	  all	  of	  the	  drug	  is	  unbound	  in	  plasma	  (i.e.,	  fu	  ≈	  1)	  [28].	  As	  a	  result,	  the	  Kp,uu	  of	  cefadroxil	  in	  brain	  ECF	  is	  also	  equal	  to	  0.050±0.006	  in	  wildtype	  mice	  which	  increased	  to	  0.121±0.016	  in	  Pept2	  null	  mice	  (Table	  4-­‐1).	  The	  fact	  that	  Kp,uu	  is	  much	  lower	  than	  unity	  for	  both	  genotypes	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suggests	   that,	   in	   addition	   to	   PEPT2,	   other	   efflux	   transporters	   are	   involved	   in	  removing	  cefadroxil	  from	  the	  brain.	  Cefadroxil	  is	  a	  substrate	  of	  several	  CNS	  barrier	  transporters	   including	   the	   organic	   anion	   transporters	   (OATs)	   [29],	   multidrug	  resistance-­‐associated	   proteins	   (MRPs)	   [30,	   31],	   and	   organic	   anion	   transporting	  polypeptides	   (OATPs)	   [32].	   Moreover,	   our	   previous	   study	   showed	   that	   co-­‐administration	  of	  probenecid	  (an	  inhibitor	  of	  OATs,	  MRPs,	  and	  OATPs)	  caused	  a	  2.5-­‐fold	   increase	   in	   the	   Kp,uu	  of	   cefadroxil	   in	   rat	   brain	   ECF	   during	  microdialysis	   [22].	  	  This	  finding	  supports	  our	  current	  study	  results,	  suggesting	  that	  cefadroxil	  is,	  indeed,	  effluxed	  from	  brain	  to	  plasma	  by	  PEPT2	  along	  with	  the	  OATs,	  MRPs	  and/or	  OATPs.	  	  Given	   the	   2.4-­‐fold	   increase	   in	   the	   Kp,uu	   of	   cefadroxil	   in	  Pept2	   null	  mice	   (i.e.,	   from	  0.050	  to	  0.121),	  we	  examined	  whether	  this	  change	  was	  due	  to	  an	  increase	  in	  the	  CLin	  of	   cefadroxil	   or	   a	  decrease	   in	   the	  drug’s	  CLout.	   In	   this	   regard,	  permeability-­‐surface	  area	   studies	   were	   performed	   and,	   as	   shown	   in	   Figure	   4-­‐5,	   no	   difference	   was	  observed	  between	  genotypes	  in	  the	  PS	  product.	  Thus,	  we	  concluded	  that	  PEPT2	  had	  no	   effect	   on	   the	   CLin	   of	   cefadroxil	   and	   that,	   by	   default,	   PEPT2	   reduced	   the	  penetration	  of	  drug	  into	  brain	  ECF	  (and	  CSF)	  by	  increasing	  CLout.	  	  	  Immunolocalization	   demonstrates	   that	   PEPT2	   is	   expressed	   on	   the	   apical	  membrane	   (CSF-­‐facing)	  of	   choroid	  plexus	   epithelia	   at	   the	  BCSFB	   [16].	   In	   contrast,	  there	   is	   no	   evidence	   that	   PEPT2	   is	   expressed	   at	   the	   BBB	   [16,	   33].	   	   Thus,	   a	   likely	  explanation	  is	  that	  PEPT2	  affects	  the	  CLout	  of	  cefadroxil	  by	  removing	  drug	  from	  the	  CSF,	   which	   then	   provides	   the	   “driving	   force”	   to	   reduce	   drug	   levels	   in	   brain	   ECF.	  There	  are	  no	  barriers	  (i.e.,	  tight	  junctions)	  at	  the	  brain	  ECF-­‐CSF	  interfaces,	  including	  the	   interior	  ependymal	  wall	  of	  ventricles	  and	  the	  exterior	  pial-­‐glial	  surfaces	  of	   the	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subarachnoid	  space	  [34].	  As	  a	  result,	  water	  and	  solutes	  are	  able	  to	  move	  (relatively)	  freely	   between	   the	   ECF	   and	   CSF	   via	   diffusion	   and	   bulk	   flow,	   depending	   upon	   the	  direction	  of	  the	  concentration	  gradient	  and	  hydrostatic	  pressure.	  Moreover,	  recent	  findings	  revealed	  perivascular	  pathways	  as	  another	  mechanism	  for	  the	  exchange	  of	  fluids	  between	  brain	  compartments	  [35].	  Thus,	  subarachnoid	  CSF	  moves	  into	  brain	  parenchyma	  along	  paravascular	  spaces	  surrounding	  the	  penetrating	  arteries	  while	  paravenous	   drainage	   pathways	   facilitate	   the	   drainage	   of	   interstitial	   fluid	   (or	   ECF)	  into	  CSF.	  The	  above	  mechanism	  makes	  for	  efficient	  fluid	  exchange	  even	  for	  species	  with	  large	  brain	  volumes	  (e.g.,	  humans).	  The	  BBB	  is	  widely	  believed	  to	  be	  the	  most	  important	  barrier	  in	  the	  CNS	  due	  to	  its	  proximity	  to	  brain	  cells	  [36,	  37].	  In	  contrast,	  the	  choroid	  plexus	  (i.e.,	  BCSFB)	  is	  viewed	  as	  a	  “kidney”	  for	  the	  brain	  because	  of	  its	  ability	   to	   remove	   metabolites	   and	   toxins	   from	   the	   CNS	   and	   maintain	   brain	  homeostasis	   [15,	   34].	   However,	   it	   is	   difficult	   to	   evaluate	   the	   impact	   of	   BCSFB	  transporters	  alone	  on	  substrate	  distribution	  in	  the	  brain	  parenchyma	  because	  many	  transporters	  are	  expressed	  only	  at	  the	  BBB	  or	  situated	  at	  both	  the	  BBB	  and	  BCSFB	  [38,	   39].	   PEPT2,	   as	   a	   transporter	   at	   the	   BCSFB	   and	   not	   BBB,	   provides	   a	   unique	  opportunity	   to	   evaluate	   the	   significance	   of	   choroid	   plexus	   transporters	   on	   the	  distribution	   of	   drugs	   in	   brain	   ECF.	   The	   current	   study	   demonstrated	   that	   PEPT2	  ablation	   resulted	   in	   the	  approximate	  2-­‐fold	   increase	  of	   cefadroxil	   in	  both	  CSF	  and	  brain	  ECF.	  	  This	  important	  finding	  confirms	  the	  sink	  function	  of	  the	  CSF	  circulation	  as	  well	  as	  the	  contribution	  of	  BCSFB-­‐located	  transporters	  on	  brain	  ECF	  levels.	  	  	  Whereas	  Kp,uu	  describes	  the	  extent	  of	  drug	  distribution	  between	  brain	  ECF	  and	  blood	   at	   steady-­‐state,	   Vu,brain	   describes	   drug	   distribution	   inside	   the	   brain	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parenchyma	  [26,	  40].	  For	  a	  drug	  that	  distributes	  evenly	  throughout	  the	  whole	  brain	  tissue,	   Vu,brain	   is	   expected	   to	   be	   around	   0.8	  mL/g	   brain	   [41],	   the	  water	   volume	   in	  brain	  parenchyma	  of	  which	  brain	  ECF	  accounts	  for	  ~	  0.18	  mL/g	  brain	  [25].	  Given	  its	  low	   lipophilicity,	   cefadroxil	   has	   negligible	   nonspecific	   binding	   to	   brain	   tissue	  components,	   which	   was	   confirmed	   using	   equilibrium	   dialysis	   in	   rat	   brain	  homogenate	   (data	   not	   shown).	   As	   a	   result,	   the	   decrease	   in	   the	   Vu,brain	  of	   all	   brain	  regions	  by	  PEPT2	  ablation	  is	  likely	  due	  to	  the	  absence	  of	  uptake	  function	  by	  PEPT2	  at	  the	  membrane	  of	  neural	  cells.	  	  It	  should	  be	  appreciated	  that,	  in	  this	  study,	  PEPT2	  ablation	  did	  not	  significantly	  change	  the	  plasma	  clearance	  of	  cefadroxil	  after	  intravenous	  infusion.	  This	  finding	  is	  probably	  due	  to	  the	  saturation	  of	  PEPT2	  in	  kidney	  proximal	  tubules	  with	  the	  dose	  administered,	   thereby,	   reducing	   the	   tubular	   reabsorption	   component	   of	   renal	  clearance	  which	  is	  the	  major	  route	  of	  cefadroxil	  elimination	  [42].	  Cefadroxil	  has	  a	  Km	  value	   of	   about	   10-­‐40	   µM	   for	   PEPT2,	   which	   is	   highly	   dependent	   upon	   the	  experimental	   study	   design	   [13,	   43-­‐45].	   During	   the	   4-­‐hr	   intravenous	   infusion	   of	  cefadroxil,	   steady-­‐state	   plasma	   concentrations	   of	   drug	  were	   about	   4.4	   µg/mL	   (or	  12.1	  µM),	   numbers	   that	  were	   close	   to	   the	   lower	   end	  of	  Km	   values	   reported	   in	   the	  literature.	  In	  fact,	  although	  dose-­‐dependent	  differences	  in	  clearance	  were	  observed	  for	  cefadroxil	  in	  both	  wildtype	  and	  Pept2	  null	  mice	  [12],	  the	  authors	  were	  not	  able	  to	   discern	   differences	   between	   the	   two	   genotypes	  when	   the	   highest	   dose	   level	   of	  drug	  was	  administered	  (i.e.,	  100	  nmol/g	  intravenous	  bolus	  injection).	  Moreover,	  the	  differential	   plasma	   concentration-­‐time	   profiles	   of	   cefadroxil	   were	   more	   apparent	  once	   the	   drug	   levels	   were	   about	   10	   µM	   or	   lower.	   In	   contrast,	   concentrations	   of	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cefadroxil	  in	  brain	  ECF	  and	  CSF	  were	  in	  the	  range	  of	  0.2-­‐0.5	  µg/mL	  (or	  0.5-­‐1.5	  µM),	  values	  that	  were	  much	  lower	  than	  the	  Km	  of	  cefadroxil	  for	  PEPT2.	  Thus,	  our	  ability	  to	  elucidate	  the	  significance	  of	  PEPT2	  function	  in	  brain	  was	  more	  favorable.	  	  Using	  intracerebral	  microdialysis,	  this	  study	  examined	  the	  role	  of	  PEPT2	  on	  the	  distribution	  of	  cefadroxil	  in	  various	  brain	  compartments.	  As	  shown	  in	  the	  schematic	  (Figure	  4-­‐6),	  PEPT2	  in	  wildtype	  mice	  functions	  as	  an	  efflux	  transporter	  at	  the	  blood-­‐CSF	   interface	   and	   as	   an	   uptake	   transporter	   at	   the	   ECF-­‐brain	   cell	   interface.	   In	   the	  absence	   of	   PEPT2	   function	   (i.e.,	   null	   mice),	   cefadroxil	   concentrations	   increased	  significantly	   in	   the	  CSF	  and	  brain	  ECF.	  However,	   the	  amount	  of	  drug	   in	  brain	  cells	  did	   not	   change	   significantly	   because,	   although	   brain	   ECF	   levels	   of	   cefadroxil	  increased,	  the	  drug	  had	  a	  reduced	  uptake	  into	  neurons	  during	  PEPT2	  ablation.	  Thus,	  the	  PEPT2	  transporter	  plays	  an	  important	  role	  in	  reducing	  cefadroxil	  concentrations	  in	  brain	  ECF	  and	  CSF,	  but	  not	  on	  drug	  levels	  in	  brain	  cells,	  due	  to	  its	  dual	  function	  in	  brain.	  	  Results	  from	  this	  study	  set	  a	  good	  example	  in	  demonstrating	  that	  total	  amounts	  of	   drug	   in	   brain	   do	   not	   necessarily	   reflect	   the	   distribution	   of	   drug	   in	  subcompartments	   (i.e.,	   locally),	   especially	   in	   brain	   ECF.	   Although	   CSF	  concentrations	   of	   cefadroxil	   in	   this	   study	   were	   comparable	   to	   that	   in	   brain	   ECF,	  other	   investigators	   have	   reported	   differences	   in	   drug	   distribution	   between	   these	  two	  brain	   fluids	   in	  general,	  suggesting	  that	  CSF	   is	  not	  always	  a	  good	  surrogate	   for	  drug	  levels	   in	  brain	  ECF	  [46].	  For	  drugs	  whose	  pharmacological	  response	  depends	  upon	  ECF	  concentrations,	   it	  may	  be	  better	   to	  determine	  their	  distribution	   in	  brain	  ECF	  and	  not	  depend	  upon	  sampling	  whole	  brain	  or	  CSF.	  Microdialysis	  serves	  as	  an	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exquisite,	   although	   complicated,	   tool	   to	   directly	  measure	   the	   regional	   distribution	  kinetics	  of	  drug,	  including	  ECF,	  in	  brain	  [47].	  	  Due	  to	  the	  presence	  of	  multiple	  barriers,	  such	  as	  endothelial	  tight	  junctions	  and	  efflux	   transporters,	   it	   is	   difficult	   to	   deliver	   β-­‐lactam	   antibiotics	   into	   brain	   for	   the	  treatment	  of	   the	  CNS	  diseases	   (e.g.,	  meningitis,	   cerebritis	   and	  glioma).	  At	  present,	  cephalosporin	   antibiotics	   (e.g.,	   ceftriaxone	   and	   cefotaxime)	   used	   to	   treat	   CNS	  infections	  [48]	  are	  not	  PEPT2	  substrates	  [49].	  Cefadroxil,	  as	  a	  substrate	  of	  multiple	  efflux	   transporters	   including	   PEPT2,	   has	   very	   low	   levels	   in	   CSF	   and	   brain	   ECF,	  thereby,	  excluding	  its	  use	  for	  CNS	  infections	  [22].	  Thus,	  it	  is	  reasonable	  to	  propose	  that	   drug	   candidates	   for	   CNS	   therapy	   be	   avoided	   during	   the	   drug	   development	  process,	   based	   on	   available	   knowledge	   about	   the	   general	   structural	   features	   of	  PEPT2	  substrates	  [3,	  50].	  	  A	  better	  understanding	  of	  PEPT2	  structure-­‐function	   is	  also	   important	  because	  of	   the	   presence	   of	   genetic	   variants	   of	   PEPT2.	   In	   this	   regard,	   a	   study	   of	   PEPT2	  polymorphisms	  in	  human	  showed	  that	  two	  main	  variants	  existed,	  namely	  hPEPT2*1	  and	  hPEPT2*2	   [51].	  Whereas	   allelic	   frequencies	   of	   the	   two	  main	  haplotypes	  were	  even	   among	   Caucasians	   and	   Africans,	   different	   variant	   frequencies	   were	   found	  among	   other	   ethnic	   groups	   [52].	   Moreover,	   when	   hPEPT2*1	   and	   hPEPT2*2	  were	  expressed	  in	  Chinese	  hamster	  ovary	  cells,	  a	  3-­‐fold	  difference	  in	  Km	  was	  observed	  for	  GlySar	  uptake	   [51].	   It	  has	  been	  reported	   that	   the	  hPEPT2*2	  haplotype,	  along	  with	  the	   5-­‐aminolevulinic	   acid	   dehydratase	   single	   nucleotide	   polymorphism	   2,	   can	  increase	  the	  levels	  of	  5-­‐aminolevulinic	  acid	  (5-­‐ALA)	  in	  brain	  and	  increase	  the	  risk	  of	  lead-­‐induced	   neurotoxicity	   [53-­‐55].	   Thus,	   in	   addition	   to	   affecting	   the	   neurological	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effects	   of	   endogenous	   peptides/mimetics	   such	   as	   5-­‐ALA,	   PEPT2	   polymorphisms	  may	  alter	  the	  pharmacological	  effects	  of	  drugs	  targeting	  CNS	  diseases,	  though	  more	  evidence	  is	  needed	  to	  confirm	  this	  premise.	  	  In	   conclusion,	   this	   is	   the	   first	   study	   to	   determine	   the	   in	   vivo	   significance	   of	  PEPT2	  on	  the	  distribution	  of	  cefadroxil	  (an	  important	  β-­‐lactam	  antibiotic)	   in	  brain	  parenchyma,	  brain	  ECF	  and	  CSF.	  By	  applying	  intracerebral	  microdialysis	  to	  wildtype	  and	   Pept2	   null	   mice,	   the	   ECF	   and	   CSF	   levels	   of	   cefadroxil	   were	   similar	   in	   each	  genotype,	  and	  increased	  about	  2-­‐	  to	  2.5-­‐fold	  during	  PEPT2	  ablation.	  These	  findings	  convincingly	  demonstrate	  the	   impact	  of	  PEPT2	  on	  brain	  ECF	  as	  well	  as	  the	  known	  role	   of	   PEPT2	   in	   removing	   peptide/mimetic	   drugs	   from	   the	   CSF	   to	   plasma.	  Moreover,	   this	   study	   establishes	   that	   PEPT2	   is	   involved	   in	   the	   uptake	   of	  peptide/mimetic	   drugs	   from	   brain	   ECF	   into	   the	   brain	   cells.	   Finally,	   our	   results	  suggest	   that	   PEPT2	   plays	   an	   important	   role	   in	   modulating	   the	   physiological,	  pharmacological	  and	  toxicological	  activities	  of	  CNS-­‐relevant	  endogenous	  substrates	  and	  drugs.	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Table 4-1 Distribution of cefadroxil in plasma and brain following a 4-hr intravenous 
infusion of drug at 0.15 mg/min/kg in wildtype (WT) and Pept2 null (KO) mice 
Parameters	   Unit	  
Wildtype	   	   Pept2	  null	  
KO/WT	  
t-­‐test	  
Mean	  ± 	  SEM	   n	   CV%	  
	  
Mean	  ± 	  SEM	   n	   CV%	  
p	  
value	  
CL	   mL/min/kg	   34.8	  ±	  1.2	   10	   11.0	   	   36.5	  ±	  3.4	   12	   32.6	   1.05	   0.6504	  †	  
Cp,240	   µg/mL	   4.35	  ±	  0.14	   10	   10.4	   	   4.45	  ±	  0.35	   12	   27.4	   1.02	   0.7953	  
†	  
Cu,ECF,220-­‐240	   µg/mL	   0.215	  ±	  0.019	   10	   28.0	   	   0.489	  ±	  0.059	   12	   41.7	   2.28	   0.0006	  
†	  
Ccsf	   µg/mL	   0.268	  ±	  0.033	   6	   30.4	   	   0.533	  ±	  0.090	   9	   50.6	   1.99	   0.0198	  
†	  
Cu,ECF,210/Cp,210	  
‡	   	   0.050	  ±	  0.006	   10	   36.0	   	   0.121	  ±	  0.016	   12	   45.9	   2.39	   0.0010	  
†	  
Abrain	   µg/g	  brain	   0.374	  ±	  0.065	   12	   60.1	   	   0.331	  ±	  0.058	   11	   58.1	   0.88	   0.6282	  
Acell	   µg/g	  brain	   0.339	  ±	  0.065	   12	   66.9	   	   0.244	  ±	  0.058	   11	   78.3	   0.72	   0.2961	  
Vu,brain	   mL/g	  brain	   2.17	  ±	  0.43	   12	   68.1	   	   0.83	  ±	  0.17	   11	   68.7	   0.38	   0.0109	  
†	  
CL is the plasma clearance; Cp,240 the plasma concentration at the end of infusion (i.e., 240 
min); Cu,ECF,220-240, the unbound concentration in brain ECF during the 220-240 min 
microdialysis period; Ccsf, the cefadroxil concentration in cerebrospinal fluid; Cu,ECF,210/Cp,210, 
the concentration ratio of unbound drug in brain ECF to total drug in plasma at 210 min after 
initiating the infusion; Abrain, the total amount of cefadroxil in brain parenchyma, corrected for 
vascular volume; Acell, the amount of cefadroxil in brain cells, corrected for ECF; and Vu,brain, 
the unbound volume of distribution in brain. 
† Welch’s t-test was performed to compare wildtype and Pept2 null mice in the case of unequal 
variance. For equal variance, a student’s t-test was performed.  
‡ Cu,ECF,210/Cp,210 is equivalent to Cu,ECF/Cu,plasma (i.e., Kp,uu) since the total plasma concentration 
of cefadroxil equals the unbound plasma concentration of drug (Cu,plasma), given that cefadroxil 
is essentially unbound in plasma (i.e., fu ≈ 1) [28].  	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  Figure	  4-­‐1	   Concentration-­‐time	  profiles	  of	  cefadroxil	  in	  the	  plasma	  (total	  drug,	  Cp)	  and	   brain	   extracellular	   fluid	   (unbound	   drug,	   Cu,ECF)	   during	   a	   4-­‐hr	  intravenous	   infusion	   of	   0.15	   mg/min/kg	   cefadroxil	   in	   wildtype	   and	  
Pept2	   null	   mice.	   Data	   are	   expressed	   as	   mean	   ±	   SEM	   (n=10-­‐12).	  ***p<0.001	  when	  comparing	  Cp	  or	  Cu,ECF	  between	  the	  two	  genotypes,	  as	  indicated	  by	  two-­‐way	  ANOVA	  with	  Bonferroni	  correction	  for	  multiple	  comparisons.	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  Figure	  4-­‐2	   Concentrations	   of	   cefadroxil	   in	   the	   plasma	   (total	   drug,	   Cp,240),	   brain	  extracellular	   fluid	   (unbound	   drug,	   Cu,ECF	   or	   Cu,ECF,220-­‐240)	   and	  cerebrospinal	  fluid	  (Ccsf),	  as	  well	  as	  amount	  of	  cefadroxil	  in	  the	  brain	  parenchyma	  (Abrain)	  and	  brain	  cells	   (Acell)	  of	  wildtype	  and	  Pept2	  null	  mice	  at	   the	  end	  of	   the	  4-­‐hr	   intravenous	   infusion	  of	  0.15	  mg/min/kg	  cefadroxil.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	  (n=6-­‐12).	  *p<0.05	  and	  **p<0.001	  when	   comparing	   a	   parameter	   between	   two	   genotypes,	   as	  indicated	  by	  Welch’s	  t-­‐test	  (for	  unequal	  variance)	  and	  by	  student’s	  t-­‐test	  (for	  equal	  variance).	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  Figure	  4-­‐3	   Ratio	   of	   unbound	   concentration	   in	   brain	   ECF	   to	   total	   plasma	  concentration	  (Cu,ECF/Cp)	  as	  a	  function	  of	  time	  during	  a	  4-­‐hr	  constant	  intravenous	   infusion	   of	   0.15	   mg/min/kg	   cefadroxil	   in	   wildtype	   and	  
Pept2	   null	   mice.	   Data	   are	   expressed	   as	   mean	   ±	   SEM	   (n=10-­‐12).	  *p<0.05	   and	   ***p<0.001	   when	   comparing	   a	   ratio	   between	   two	  genotypes,	   as	   indicated	   by	   two-­‐way	   ANOVA	   with	   Bonferroni	  correction	  for	  multiple	  comparisons.	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  Figure	  4-­‐4	   Unbound	   volume	   of	   distribution	   (Vu,brain)	   of	   cefadroxil	   in	   different	  brain	   regions	   (A)	   and	  whole	   brain	   (averaged	   from	   the	   five	   regions)	  (B)	  of	  wildtype	  and	  Pept2	  null	  mice	  at	   the	  end	  of	  a	  4-­‐hr	   intravenous	  infusion	  of	  0.15	  mg/min/kg	  cefadroxil.	  Data	  are	  expressed	  as	  mean	  ±	  SEM	   (n=11-­‐12).	   Two-­‐way	   ANOVA	   indicated	   that	   genotype	   and	   not	  brain	   region	   was	   an	   influencing	   factor	   for	   Vu,brain.	   Welch’s	   t-­‐test	  indicated	   a	   significant	   differences	   in	   Vu,brain	   between	   the	   two	  genotypes.	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  Figure	  4-­‐5	   Permeability-­‐surface	  area	  (PS)	  product	  of	  cefadroxil	  in	  different	  brain	  regions	   based	   on	   the	   study	   design	   using	   a	   10-­‐min	   intravenous	  infusion	   of	   0.15	   mg/min/kg	   cefadroxil	   in	   wildtype	   and	   Pept2	   null	  mice.	   Data	   are	   expressed	   as	   mean	   ±	   SEM	   (n=3).	   Two-­‐way	   ANOVA	  indicated	  that	  brain	  region	  but	  not	  genotype	  was	  an	  influencing	  factor	  for	  PS	  product	   (i.e.,	   specific	   to	   cerebellum	  as	   compared	   to	   the	   other	  brain	  regions).	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 Figure	  4-­‐6	   A	   schematic	   illustration	   showing	   the	   dual	   role	   of	   PEPT2	   in	   affecting	  the	   disposition	   of	   cefadroxil	   (CEF)	   in	   brain.	   Apical	   membrane	   (AP),	  basolateral	   membrane	   (BL),	   blood-­‐brain	   barrier	   (BBB),	   blood-­‐cerebrospinal	  fluid	  barrier	  (BCSFB),	  cerebrospinal	  fluid	  (CSF),	  choroid	  plexus	  (CP),	  ependyma	  (EP),	  extracellular	  fluid	  (ECF),	  wildtype	  (WT)	  and	  Pept2	  null	  (KO)	  mice.	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  CHAPTER 5
FUTURE DIRECTION 
The	   function	   of	   PEPT2	   in	   the	   renal	   active	   secretion	   of	   small	   peptides	   and	  peptide-­‐analogs	   has	   been	  well	   studied	   and	   confirmed	   in	   several	   studies.	   Previous	  studies	   have	   also	   suggested	   that	   PEPT2	  profoundly	   reduces	   the	   substrate	   level	   in	  cerebrospinal	   fluid	   (CSF)	   as	   an	   efflux	   transporter	   at	   the	   apical	   membrane	   of	  epithelial	   cells	   in	   choroid	   plexus	   (i.e.,	   the	   BCSFB).	   This	   dissertation	   (Chapter	   3)	  further	   demonstrates	   that	   the	   efflux	   function	   of	   PEPT2	   also	   reduces	   the	  concentration	   of	   cefadroxil	   (as	   a	   model	   drug	   for	   PEPT2	   substrates)	   in	   brain	  extracullular	   fluid	   (ECF),	   which	   is	   the	   target	   site	   of	   most	   compounds	   for	   their	  neurological	   effect.	   The	   impact	   of	   PEPT2	   on	   the	   substrate	   level	   in	   brain	   ECF	  provides	   us	   a	   better	   understanding	   on	   the	   mechnism	   of	   PEPT2	   in	   limiting	   the	  neurological	  effect	  of	  some	  substrates,	  e.g.	   the	  antinociceptive	  effect	  of	  kyotorphin	  and	  the	  neurological	  toxicity	  of	  5-­‐ALA.	  Due	  to	  the	  lack	  of	  barrier	  between	  brain	  ECF	  and	   CSF,	   molecules	   are	   able	   to	   move	   freely	   across	   the	   ependyma	   via	   diffusion	  and/or	  fluid	  flow	  between	  the	  two	  fluid	  compartments,	  which	  facilitates	  the	  efflux	  of	  substrate	  at	  the	  BCSFB	  via	  PEPT2	  and	  the	  distribution	  of	  substrate	  in	  brain	  ECF.	  The	  above	  mechanism	   is	  consistent	  with	   the	  observance	  of	  comparable	  concentrations	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in	   brain	   ECF	   and	   CSF	   for	   wildtype	   and	   Pept2	   null	   mice	   at	   steady-­‐state	   during	  cefadroxil	  i.v.	  infusion.	  At	  steady-­‐state,	  drug	  levels	  in	  different	  locations	  of	  brain	  (i.e.	  brain	   cells,	   ECF,	   and	   CSF)	   reflects	   the	   extent	   of	   distribution	  without	   confounding	  temporal	  effects	  (e.g.	  the	  Cu,ECF/Cu,blood	  changes	  prior	  to	  but	  not	  at	  steady-­‐state).	  The	  kinetic	  relationship	  between	  brain	  ECF	  and	  CSF	  is	  also	  valuable	  to	  explore	  in	  order	  to	  better	  understanding	  the	  role	  of	  PEPT2	  in	  brain	  in	  the	  clinical	  setting	  of	  bolus	  and	  repeated	   dosing.	   To	   obtain	   more	   kinetic	   information	   about	   the	   cefadroxil	  distribution	  in	  brain	  ECF	  and	  CSF,	  a	  future	  study	  could	  be	  performed	  to	  monitor	  the	  concentrations	  of	  drug	  in	  brain	  ECF	  and	  CSF	  using	  microdialysis	  and	  cisterna	  magna	  sampling,	   respectively,	   at	   steady-­‐state	   and	   during	   the	   elimination	   phase	   after	   the	  termination	  of	   cefadroxil	   i.v.	   infusion.	  A	  pharmacokinetic	  model	  based	  on	   the	  data	  from	  microdialysis	   study	  using	  nonlinear	  mixed	  effect	  modeling	   (NONMEM)	  could	  be	  developed	  to	  describe	  the	  complicated	  movements	  of	  substrates	  among	  multiple	  locations	   in	   the	   central	   nervous	   system	   (CNS).	   This	   pharmacokinetic	  model	   could	  better	  our	  understanding	  in	  the	  kinetics	  of	  regional	  brain	  distribution	  for	  cefadroxil	  in	  mice	  and	  the	  quantitative	  significance	  of	  PEPT2	  in	  cefadroxil	  disposition	  in	  brain,	  including	   the	   efflux	   function	   at	   BCSFB	   and	   uptake	   function	   at	   the	   brain	   cell	  membrane.	   Based	   on	   the	   developed	   pharmacokinetic	   model,	   simulation	   could	   be	  performed	  to	  predict	  the	  drug	  concentration	  –	  time	  profiles	  in	  brain	  cells,	  ECF,	  and	  CSF	  for	  the	  repeated	  bolus	  dosing,	  which	  is	  more	  relevant	  in	  clinical	  practice.	  	  In	   addition	   to	   PEPT2,	   cefadroxil	   has	   been	   reported	   to	   be	   a	   substrate	   of	   other	  membrane	   transporters	   including	   OATs,	   MRPs,	   and	   OATPs.	   This	   dissertation	  (Chapter	   2)	   demonstrated	   that	   the	   cefadroxil	   distribution	   in	   brain	   ECF	   (i.e.	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Cu,ECF/Cu,blood)	   was	   increased	   by	   co-­‐administration	   of	   probenecid,	   an	   inhibitor	   for	  OATs,	  MRPs,	  and	  OATPs	  that	  are	  expressed	  at	  both	  BCSFB	  and	  blood-­‐brain	  barrier	  (BBB).	   The	   low	   distribution	   of	   cefadroxil	   in	   brain	   ECF	   probably	   results	   from	   the	  combinational	   efflux	   functions	  of	  multiple	   transporters	   at	   the	  barriers	   in	   the	  CNS.	  On	   the	   other	   hand,	   PEPT2	   and	   the	   probenecid-­‐inhibitable	   transporters	   are	  suggested	   to	   have	   opposite	   transport	   direction	   at	   the	   membrane	   of	   brain	   cells	  according	   to	   the	   results	   from	   rat	   brain	   slice	   study.	   Since	   the	   above-­‐mentioned	  transporters	  also	  transport	  other	  cephlosporins,	  it	  would	  be	  worthwhile	  to	  further	  investigate	   and	   compare	   the	   contributions	   of	   the	   relevant	   transporters	   on	   the	  distribution	  of	   cefadroxil	   (as	  a	  model	  drug	   for	   cephalosporins)	   in	  brain	   cells,	  ECF,	  and	  CSF.	  A	  better	  understanding	  of	  the	  role	  of	  transporters	  in	  the	  brain	  distribution	  of	   cephalosporins	  may	  be	  useful	   for	   future	  drug	  design	  of	   cephalosporin	   for	  brain	  infections	  and	  for	  predicting	  drug-­‐drug	  interaction	  mediated	  by	  brain	  transporters.	  To	  further	  study	  the	  combinational	  effects	  of	  multiple	  transporters	  on	  the	  cefadroxil	  distribution	  in	  brain	  ECF	  and	  CSF,	  microdialysis	  study	  could	  be	  performed	  in	  future	  on	   wildtype	   and	   Pept2	   null	   mice	   with	   co-­‐administrations	   of	   probenecid	   and/or	  other	   more	   specific	   inhibitors	   for	   OATs,	   MRPs,	   or	   OATPs.	   And	   the	   impact	   of	  transporters	   on	   the	   cefadroxil	   transport	   across	   plasma	   membrane	   of	   brain	   cells	  could	   be	   assessed	   and	   compared	   by	   performing	   brain	   slice	   study	   using	   brains	  collected	  from	  wildtype	  and	  Pept2	  null	  mice.	  	  Although	  previous	   studies	   showed	   the	   function	  of	  PEPT2	   in	   reducing	   the	  CNS	  effects	  of	  endogenous	  substances	  (e.g.,	  the	  antinociceptive	  effect	  of	  kyotorphin,	  and	  the	  neurological	  toxicity	  of	  5-­‐ALA),	  little	  information	  is	  available	  on	  the	  role	  of	  brain	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PEPT2	  on	  the	  pharmacological	  effect	  of	  an	  exogenous	  substance.	  Therefore,	  it	  would	  be	  valuable	  to	  investigate	  the	  impact	  of	  brain	  PEPT2	  on	  the	  antibacterial	  activity	  of	  cefadroxil	   using	   wildtype	   and	   Pept2	   null	   mice	   during	   experimental	   meningitis.	  Specifically,	  a	  survival	  study	  could	  be	  performed	  to	  evaluate	  the	  therapeutic	  effects	  of	  cefadroxil	  in	  mice	  with	  meningitis	  induced	  by	  the	  penicillin-­‐susceptible	  strain	  of	  Streptococcus	   pneumoniae.	   It	   was	   also	   reported	   that	   the	   expression	   of	   peptide	  transporters	  may	   be	   influenced	   by	   inflammation	   (e.g.,	   LPS	   treatment	   upregulates	  PEPT2	   transcripts	   in	   choroid	   plexus).	   Thus,	   PEPT2	   expression	   in	   brain	   could	   be	  altered	   in	  mice	   induced	  with	  meningitis,	  which	   could	  be	  measured	  using	  Western	  blot	   analysis.	   Still,	   a	   microdialysis	   study	   could	   be	   performed	   to	   re-­‐evaluate	   the	  impact	   of	   PEPT2	   on	   the	   distribution	   of	   substrate	   in	   brain	   ECF	   and	   CSF	   during	  meningitis.	   The	   expression	   and	   function	   of	   PEPT2	   under	   disease-­‐state	   conditions	  may	  be	  more	  relevant	  to	  clinical	  practice	  and	  drug	  efficacy.	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APPENDIX	  A 	  
INDIVIDUAL DATA FROM CHAPTER 3 
Table	  A-­‐1	  	   The	   relative	   recoveries	   %	   (RR)	   measured	   for	   3-­‐mm	   CMA	   12	  microdialysis	  probe	  in	  brain	  ECF,	  1-­‐mm	  CMA	  12	  microdialysis	  probe	  in	  brain	  CSF,	  and	  10-­‐mm	  CMA	  20	  microdialysis	  probe	  in	  the	  blood	  for	  the	   rat	  microdialysis	   study	   of	   cefadroxil	   in	   the	   absence	   (Day	   1)	   and	  presence	  (Day	  2)	  of	  probenecid.	  
Animal	   RRECF,Day	  1	   RRECF,Day	  1	   	   RRCSF,Day	  1	   RRCSF,Day	  1	   	   RRblood,Day	  1	   RRblood,Day	  1	  
1	   -­‐a	   11.94	   	   13.09	   -­‐	   	   64.31	   62.52	  
2	   -­‐	   16.85	   	   11.84	   -­‐	   	   60.32	   59.57	  
3	   13.3	   19.22	   	   4.24	   4.57	   	   84.73	   80.48	  
4	   14.58	   19.59	   	   4.28	   9.67	   	   75.38	   76.5	  
6	   11.7	   11.25	   	   5.01	   5.85	   	   78.89	   65.71	  
8	   14.94	   10.6	   	   5.21	   2.97	   	   71.05	   72.8	  
Mean	   13.63	   14.91	   	   7.28	   5.77	   	   72.45	   69.60	  
SEM	   0.73	   1.68	   	   1.66	   1.43	   	   3.72	   3.38	  
Mean	   14	   	   6.7	   	   71	  
SEM	   1	   	   1.1	   	   2	  a	  Due	  to	  the	  instability	  of	  the	  LC-­‐MS	  signals	  for	  cefadroxil-­‐D4,	  the	  correct	  RR	  couldn’t	  be	  calculated.	  Thus	  the	  RR	  on	  the	  other	  day	  was	  used	  for	  calculation	  of	  unbound	  concentration	  in	  tissue.	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  Table	  A-­‐2	   The	  unbound	  concentration	  –	   time	  profiles	  of	   cefadroxil	   in	   rat	  brain	  ECF	  in	  the	  absence	  and	  presence	  of	  probenecid	  
The	  unbound	  concentration	  (ng/mL)of	  cefadroxil	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   14.0	   19.7	   28.2	   55.5	   4.4	   NA	   24.3	   7.9	  
30	   10.3	   50.3	   76.6	   NA	   41.9	   NA	   44.8	   11.2	  
50	   27.0	   63.2	   78.6	   111.2	   49.9	   NA	   66.0	   12.9	  
70	   86.8	   69.7	   75.1	   115.6	   76.8	   NA	   84.8	   7.5	  
90	   52.5	   82.7	   90.0	   NA	   88.1	   NA	   78.3	   7.2	  
110	   60.3	   92.7	   102.1	   129.6	   71.0	   NA	   91.1	   11.1	  
130	   51.7	   102.2	   112.2	   120.9	   NA	   NA	   96.8	   12.6	  
150	   63.5	   112.1	   NA	   140.4	   143.2	   212.7	   134.4	   22.2	  
170	   76.1	   110.9	   110.0	   154.7	   125.9	   NA	   115.5	   11.6	  
190	   62.4	   105.7	   91.1	   123.9	   115.1	   228.6	   121.1	   23.2	  
210	   47.3	   94.5	   79.8	   100.9	   90.0	   143.1	   92.6	   12.7	  
230	   37.5	   80.9	   58.8	   NA	   67.0	   135.4	   75.9	   15.0	  
250	   22.1	   73.3	   54.8	   NA	   64.0	   108.9	   64.6	   12.8	  
270	   27.5	   63.4	   47.8	   54.8	   51.6	   110.2	   59.2	   11.3	  
290	   24.6	   62.0	   NA	   50.2	   55.8	   88.6	   56.2	   9.4	  
310	   20.8	   58.4	   38.5	   45.0	   53.5	   74.9	   48.5	   7.5	  
330	   17.8	   51.7	   37.3	   43.4	   44.8	   68.3	   43.9	   6.8	  
350	   9.9	   48.4	   29.6	   44.2	   42.6	   63.9	   39.8	   7.5	  
370	   15.7	   45.0	   NA	   NA	   36.0	   58.6	   38.8	   7.3	  
390	   12.2	   43.7	   25.1	   37.6	   37.5	   57.8	   35.6	   6.4	  
410	   15.4	   40.5	   24.8	   35.7	   34.6	   57.9	   34.8	   5.9	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   90.4	   88.8	   34.4	   73.9	   88.8	   223.2	   99.9	   26.1	  
30	   213.6	   178.1	   66.9	   150.6	   NA	   540.1	   229.9	   74.2	  
50	   241.3	   230.1	   87.5	   179.6	   252.1	   809.9	   300.1	   104.9	  
70	   260.0	   264.2	   120.7	   213.5	   304.0	   904.4	   344.5	   114.9	  
90	   298.7	   292.8	   141.5	   247.4	   331.2	   1035.1	   391.1	   131.6	  
110	   336.7	   291.5	   192.4	   269.5	   350.4	   1030.7	   411.9	   125.9	  
130	   347.8	   392.1	   238.1	   286.2	   409.5	   1153.4	   471.2	   139.0	  
150	   394.9	   403.8	   257.2	   302.7	   415.0	   1125.3	   483.2	   131.0	  
170	   458.4	   418.4	   NA	   317.5	   467.1	   1222.2	   576.7	   149.3	  
190	   384.2	   429.5	   220.3	   307.7	   393.8	   1070.4	   467.6	   124.4	  
210	   340.0	   393.6	   217.2	   259.7	   359.6	   876.0	   407.7	   97.4	  
230	   257.6	   333.1	   160.2	   229.0	   336.3	   688.4	   334.1	   75.9	  
250	   218.8	   312.8	   140.7	   213.7	   328.3	   555.5	   295.0	   59.3	  
270	   179.2	   271.9	   NA	   176.8	   296.2	   479.7	   280.8	   50.4	  
290	   152.0	   237.9	   101.1	   162.0	   269.4	   398.4	   220.1	   43.5	  
310	   144.9	   209.2	   82.7	   155.0	   248.0	   335.4	   195.9	   36.3	  
330	   136.8	   227.4	   77.6	   146.9	   239.4	   303.1	   188.5	   33.6	  
350	   119.4	   208.7	   65.4	   126.9	   222.0	   240.1	   163.7	   28.4	  
370	   117.4	   214.7	   NA	   122.8	   221.3	   220.0	   179.3	   22.1	  
390	   113.6	   190.0	   56.8	   115.3	   219.9	   216.5	   152.0	   27.1	  
410	   114.8	   181.1	   41.7	   111.2	   NA	   184.5	   126.6	   24.1	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Table	  A-­‐3	   The	  unbound	  concentration	  –	   time	  profiles	  of	   cefadroxil	   in	   rat	  brain	  CSF	  in	  the	  absence	  and	  presence	  of	  probenecid	  
The	  unbound	  concentration	  (ng/mL)of	  cefadroxil	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   103.20	   90.65	   20.29	   NA	   25.98	   NA	   60.03	   17.54	  
30	   183.68	   179.23	   NA	   NA	   48.99	   NA	   137.30	   31.24	  
50	   228.01	   178.26	   NA	   35.64	   64.56	   89.02	   119.10	   33.04	  
70	   351.78	   223.56	   NA	   NA	   61.21	   NA	   212.19	   59.45	  
90	   322.23	   245.43	   67.11	   43.40	   59.39	   98.72	   139.38	   47.32	  
110	   297.24	   244.37	   74.10	   45.88	   56.52	   108.52	   137.77	   43.49	  
130	   283.37	   272.58	   NA	   51.04	   NA	   113.05	   180.01	   47.36	  
150	   311.98	   263.31	   83.04	   56.95	   61.00	   110.64	   147.82	   45.33	  
170	   338.35	   290.50	   89.43	   54.95	   68.22	   126.52	   161.33	   49.80	  
190	   276.86	   259.21	   NA	   58.31	   56.06	   103.31	   150.75	   44.46	  
210	   230.76	   204.45	   72.01	   NA	   45.04	   88.05	   128.06	   34.17	  
230	   188.17	   168.55	   NA	   40.08	   38.16	   90.54	   105.10	   28.76	  
250	   154.11	   157.45	   46.90	   29.82	   27.33	   NA	   83.12	   27.26	  
270	   133.74	   132.40	   39.42	   NA	   25.00	   73.95	   80.90	   20.75	  
290	   107.93	   130.65	   44.42	   NA	   22.68	   60.96	   73.33	   18.30	  
310	   105.94	   129.03	   NA	   27.27	   25.16	   61.70	   69.82	   19.02	  
330	   91.40	   108.90	   38.54	   NA	   17.27	   61.26	   63.47	   15.28	  
350	   71.28	   110.28	   NA	   NA	   16.95	   67.55	   66.51	   15.63	  
370	   80.75	   115.01	   31.51	   NA	   16.44	   NA	   60.93	   18.50	  
390	   72.12	   97.01	   27.81	   NA	   NA	   61.34	   64.57	   11.72	  
410	   82.63	   92.39	   32.24	   NA	   NA	   60.38	   66.91	   10.91	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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The	  unbound	  concentration	  (ng/mL)of	  cefadroxil	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   24.11	   67.03	   31.58	   9.20	   43.71	   NA	   35.13	   8.89	  
30	   47.57	   155.77	   66.66	   22.51	   136.32	   284.77	   118.93	   39.28	  
50	   57.55	   201.63	   77.02	   28.97	   202.36	   436.50	   167.34	   61.70	  
70	   65.17	   241.24	   NA	   36.82	   252.02	   493.75	   217.80	   74.70	  
90	   83.72	   282.94	   NA	   40.05	   291.11	   579.18	   255.40	   87.25	  
110	   77.84	   257.84	   118.89	   40.97	   265.35	   600.00	   226.82	   83.69	  
130	   82.17	   322.12	   119.27	   51.70	   324.85	   612.60	   252.12	   86.96	  
150	   95.57	   329.21	   NA	   57.94	   324.52	   654.53	   292.35	   97.30	  
170	   98.09	   373.41	   128.77	   56.75	   348.56	   721.55	   287.86	   102.28	  
190	   85.59	   367.52	   NA	   62.43	   330.87	   764.12	   322.11	   115.63	  
210	   76.59	   279.99	   112.09	   54.92	   259.21	   583.91	   227.79	   80.97	  
230	   66.54	   246.20	   94.69	   44.86	   NA	   565.35	   203.53	   88.63	  
250	   51.39	   215.53	   NA	   40.11	   194.15	   508.34	   201.90	   77.18	  
270	   45.64	   189.26	   NA	   39.08	   176.11	   482.53	   186.52	   73.41	  
290	   39.45	   188.42	   77.16	   36.22	   148.83	   NA	   98.01	   27.72	  
310	   37.64	   165.49	   NA	   36.07	   126.88	   469.05	   167.03	   72.66	  
330	   33.09	   154.51	   80.96	   33.55	   NA	   NA	   75.53	   23.37	  
350	   35.25	   145.85	   NA	   27.75	   108.07	   411.90	   145.76	   64.03	  
370	   30.08	   126.23	   67.19	   31.61	   104.56	   412.25	   128.65	   58.86	  
390	   27.05	   117.11	   NA	   29.78	   103.69	   382.49	   132.02	   59.59	  
410	   26.91	   107.67	   NA	   28.18	   82.91	   NA	   61.42	   16.49	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Table	  A-­‐4	   The	  unbound	  concentration	  –	   time	  profiles	  of	  cefadroxil	   in	  rat	  blood	  in	  the	  absence	  and	  presence	  of	  probenecid	  
The	  unbound	  concentration	  (ng/mL)of	  cefadroxil	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   4266	   3109	   1167	   3856	   3245	   3384	   3171	   437	  
30	   NA	   9768	   6424	   8125	   8664	   10427	   8681	   634	  
50	   9277	   9745	   NA	   7262	   8750	   10252	   9057	   468	  
70	   8315	   7928	   6338	   7992	   8527	   10169	   8212	   503	  
90	   8760	   8426	   6774	   8048	   7292	   9753	   8175	   434	  
110	   8641	   9409	   8128	   NA	   7274	   9313	   8553	   361	  
130	   8910	   9480	   7123	   7435	   8266	   9352	   8428	   405	  
150	   9565	   8626	   7137	   7251	   8620	   9366	   8428	   420	  
170	   9010	   9176	   NA	   7850	   8424	   9964	   8885	   326	  
190	   7817	   7223	   5732	   NA	   6824	   7230	   6965	   316	  
210	   3921	   4023	   3697	   2423	   3279	   3799	   3524	   244	  
230	   2732	   2450	   1871	   1283	   1776	   2348	   2077	   216	  
250	   1460	   1351	   1033	   862	   1250	   1388	   1224	   94	  
270	   1378	   1094	   716	   553	   745	   1014	   917	   123	  
290	   891	   749	   511	   405	   633	   829	   670	   77	  
310	   741	   634	   403	   378	   495	   NA	   530	   63	  
330	   672	   545	   345	   348	   458	   635	   501	   57	  
350	   513	   466	   NA	   283	   390	   479	   427	   37	  
370	   540	   415	   286	   226	   348	   427	   374	   46	  
390	   507	   398	   269	   NA	   332	   464	   394	   39	  
410	   399	   396	   228	   193	   327	   426	   328	   40	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	  	  	   	  
	  	   133	  
The	  unbound	  concentration	  (ng/mL)of	  cefadroxil	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   2906	   2969	   3136	   2661	   3611	   6071	   3559	   519	  
30	   10842	   12437	   10916	   9933	   11948	   15797	   11979	   844	  
50	   11016	   12200	   9128	   9302	   13527	   14279	   11575	   875	  
70	   11218	   13017	   10581	   10449	   14992	   14265	   12420	   798	  
90	   11811	   13337	   9144	   11478	   14600	   15232	   12600	   918	  
110	   12296	   13830	   10223	   13558	   14961	   15258	   13354	   762	  
130	   12145	   17674	   10920	   13404	   15016	   16196	   14226	   1038	  
150	   11478	   16071	   10540	   13081	   14246	   15012	   13405	   865	  
170	   12035	   16011	   10181	   13541	   14683	   15210	   13610	   889	  
190	   10187	   14094	   8199	   12363	   11982	   12758	   11597	   854	  
210	   6830	   8200	   4959	   7494	   7227	   6583	   6882	   448	  
230	   3576	   4887	   2496	   5003	   4540	   4956	   4243	   412	  
250	   2966	   3231	   1899	   3730	   2972	   3141	   2990	   246	  
270	   1598	   2584	   1251	   2278	   2525	   2229	   2077	   219	  
290	   1348	   2026	   937	   1854	   1654	   1659	   1580	   158	  
310	   1150	   1866	   808	   1396	   1157	   1417	   1299	   145	  
330	   793	   1450	   630	   1072	   1011	   1026	   997	   114	  
350	   711	   1209	   591	   1024	   755	   841	   855	   92	  
370	   594	   1087	   471	   828	   653	   766	   733	   88	  
390	   621	   926	   416	   865	   570	   460	   643	   86	  
410	   680	   967	   416	   682	   503	   468	   619	   83	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Table	  A-­‐5	   The	  plasma	  concentration	  –	  time	  profiles	  of	  cefadroxil	  in	  the	  absence	  and	  presence	  of	  probenecid	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
5	   5532	   5816	   930	   4565	   3735	   1999	   3763	   798	  
18	   10719	   11888	   8060	   10106	   11729	   12658	   10860	   670	  
90	   9764	   9185	   7490	   6820	   8178	   11077	   8753	   640	  
150	   8635	   9756	   6500	   7925	   8071	   12104	   8832	   784	  
185	   8388	   7179	   6850	   6142	   6897	   8706	   7360	   402	  
190	   6456	   5933	   4994	   4685	   5140	   6812	   5670	   351	  
210	   3348	   3032	   2505	   2039	   2907	   2878	   2785	   186	  
240	   1560	   1479	   1114	   865	   1235	   1828	   1347	   141	  
300	   756	   813	   328	   452	   553	   820	   621	   84	  
420	   425	   439	   237	   364	   346	   538	   391	   42	  	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
5	   135	   171	   102	   98	   161	   231	   149	   20	  
18	   5305	   6776	   6598	   4083	   4205	   1371	   4723	   816	  
90	   13155	   15742	   15145	   13085	   14154	   13241	   14087	   464	  
150	   12261	   15100	   12919	   16010	   13841	   17913	   14674	   857	  
185	   14225	   15056	   13560	   14791	   15840	   16856	   15055	   478	  
190	   11174	   14212	   10447	   13178	   14548	   13705	   12877	   687	  
210	   10022	   11361	   8718	   11451	   11701	   12487	   10957	   553	  
240	   4770	   7575	   4140	   7336	   7636	   7611	   6511	   657	  
300	   2722	   4176	   2461	   4184	   4160	   4389	   3682	   348	  
420	   1083	   1837	   997	   1777	   1563	   1682	   1490	   148	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Table	  A-­‐6	   The	   ratio	   of	   unbound	   cefadroxil	   in	   rat	   brain	   ECF	   to	   that	   in	   blood	  versus	  time	  in	  the	  absence	  and	  presence	  of	  probenecid	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   0.0033	   0.0063	   0.0241	   0.0144	   0.0013	   NA	   0.0099	   0.0038	  
30	   NA	   0.0051	   0.0119	   NA	   0.0048	   NA	   0.0073	   0.0016	  
50	   0.0029	   0.0065	   NA	   0.0153	   0.0057	   NA	   0.0076	   0.0022	  
70	   0.0104	   0.0088	   0.0118	   0.0145	   0.0090	   NA	   0.0109	   0.0010	  
90	   0.0060	   0.0098	   0.0133	   NA	   0.0121	   NA	   0.0103	   0.0013	  
110	   0.0070	   0.0099	   0.0126	   NA	   0.0098	   NA	   0.0098	   0.0009	  
130	   0.0058	   0.0108	   0.0158	   0.0163	   NA	   NA	   0.0122	   0.0020	  
150	   0.0066	   0.0130	   NA	   0.0194	   0.0166	   0.0227	   0.0157	   0.0025	  
170	   0.0084	   0.0121	   NA	   0.0197	   0.0149	   NA	   0.0138	   0.0019	  
190	   0.0080	   0.0146	   0.0159	   NA	   0.0169	   0.0316	   0.0174	   0.0035	  
210	   0.0121	   0.0235	   0.0216	   0.0416	   0.0274	   0.0377	   0.0273	   0.0044	  
230	   0.0137	   0.0330	   0.0314	   NA	   0.0377	   0.0577	   0.0347	   0.0064	  
250	   0.0152	   0.0543	   0.0531	   NA	   0.0512	   0.0785	   0.0504	   0.0093	  
270	   0.0200	   0.0580	   0.0668	   0.0992	   0.0693	   0.1086	   0.0703	   0.0129	  
290	   0.0276	   0.0828	   NA	   0.1240	   0.0881	   0.1069	   0.0859	   0.0149	  
310	   0.0281	   0.0922	   0.0956	   0.1188	   0.1082	   NA	   0.0886	   0.0145	  
330	   0.0264	   0.0948	   0.1082	   0.1248	   0.0977	   0.1076	   0.0933	   0.0140	  
350	   0.0193	   0.1037	   NA	   0.1562	   0.1091	   0.1333	   0.1043	   0.0212	  
370	   0.0291	   0.1085	   NA	   NA	   0.1032	   0.1372	   0.0945	   0.0188	  
390	   0.0240	   0.1098	   0.0933	   NA	   0.1128	   0.1246	   0.0929	   0.0164	  
410	   0.0386	   0.1024	   0.1084	   0.1845	   0.1059	   0.1360	   0.1126	   0.0195	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   0.0311	   0.0299	   0.0110	   0.0278	   0.0246	   0.0368	   0.0268	   0.0036	  
30	   0.0197	   0.0143	   0.0061	   0.0152	   NA	   0.0342	   0.0179	   0.0042	  
50	   0.0219	   0.0189	   0.0096	   0.0193	   0.0186	   0.0567	   0.0242	   0.0067	  
70	   0.0232	   0.0203	   0.0114	   0.0204	   0.0203	   0.0634	   0.0265	   0.0076	  
90	   0.0253	   0.0220	   0.0155	   0.0216	   0.0227	   0.0680	   0.0292	   0.0079	  
110	   0.0274	   0.0211	   0.0188	   0.0199	   0.0234	   0.0675	   0.0297	   0.0077	  
130	   0.0286	   0.0222	   0.0218	   0.0214	   0.0273	   0.0712	   0.0321	   0.0079	  
150	   0.0344	   0.0251	   0.0244	   0.0231	   0.0291	   0.0750	   0.0352	   0.0081	  
170	   0.0381	   0.0261	   NA	   0.0234	   0.0318	   0.0804	   0.0400	   0.0095	  
190	   0.0377	   0.0305	   0.0269	   0.0249	   0.0329	   0.0839	   0.0395	   0.0091	  
210	   0.0498	   0.0480	   0.0438	   0.0347	   0.0498	   0.1331	   0.0598	   0.0148	  
230	   0.0720	   0.0682	   0.0642	   0.0458	   0.0741	   0.1389	   0.0772	   0.0130	  
250	   0.0738	   0.0968	   0.0741	   0.0573	   0.1105	   0.1769	   0.0982	   0.0175	  
270	   0.1122	   0.1052	   NA	   0.0776	   0.1173	   0.2152	   0.1255	   0.0214	  
290	   0.1128	   0.1174	   0.1079	   0.0874	   0.1629	   0.2401	   0.1381	   0.0228	  
310	   0.1260	   0.1121	   0.1024	   0.1110	   0.2143	   0.2367	   0.1504	   0.0241	  
330	   0.1724	   0.1568	   0.1231	   0.1371	   0.2368	   0.2954	   0.1869	   0.0270	  
350	   0.1680	   0.1727	   0.1107	   0.1239	   0.2939	   0.2854	   0.1924	   0.0323	  
370	   0.1975	   0.1975	   NA	   0.1483	   0.3389	   0.2872	   0.2339	   0.0315	  
390	   0.1829	   0.2052	   0.1365	   0.1333	   0.3859	   0.4704	   0.2524	   0.0577	  
410	   0.1687	   0.1872	   0.1003	   0.1631	   NA	   0.3937	   0.2026	   0.0456	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Table	  A-­‐7	   The	   ratio	   of	   unbound	   cefadroxil	   in	   rat	   brain	   CSF	   to	   that	   in	   blood	  versus	  time	  in	  the	  absence	  and	  presence	  of	  probenecid	  




Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   0.0242	   0.0292	   0.0174	   NA	   0.0080	   NA	   0.0197	   0.0037	  
30	   NA	   0.0183	   NA	   NA	   0.0057	   NA	   0.0120	   0.0037	  
50	   0.0246	   0.0183	   NA	   NA	   0.0074	   0.0087	   0.0147	   0.0033	  
70	   0.0423	   0.0282	   NA	   NA	   0.0072	   NA	   0.0259	   0.0072	  
90	   0.0368	   0.0291	   0.0099	   0.0054	   0.0081	   0.0101	   0.0166	   0.0053	  
110	   0.0344	   0.0260	   0.0091	   NA	   0.0078	   0.0117	   0.0178	   0.0048	  
130	   0.0318	   0.0288	   NA	   0.0069	   NA	   0.0121	   0.0199	   0.0050	  
150	   0.0326	   0.0305	   0.0116	   0.0079	   0.0071	   0.0118	   0.0169	   0.0047	  
170	   0.0376	   0.0317	   NA	   0.0070	   0.0081	   0.0127	   0.0194	   0.0058	  
190	   0.0354	   0.0359	   NA	   NA	   0.0082	   0.0143	   0.0235	   0.0058	  
210	   0.0589	   0.0508	   0.0195	   NA	   0.0137	   0.0232	   0.0332	   0.0083	  
230	   0.0689	   0.0688	   NA	   0.0312	   0.0215	   0.0386	   0.0458	   0.0089	  
250	   0.1055	   0.1165	   0.0454	   0.0346	   0.0219	   NA	   0.0648	   0.0176	  
270	   0.0971	   0.1211	   0.0551	   NA	   0.0335	   0.0729	   0.0759	   0.0140	  
290	   0.1211	   0.1746	   0.0870	   NA	   0.0358	   0.0736	   0.0984	   0.0214	  
310	   0.1430	   0.2036	   NA	   0.0721	   0.0508	   NA	   0.1174	   0.0285	  
330	   0.1360	   0.1997	   0.1118	   NA	   0.0377	   0.0964	   0.1163	   0.0241	  
350	   0.1389	   0.2364	   NA	   NA	   0.0434	   0.1409	   0.1399	   0.0322	  
370	   0.1495	   0.2772	   0.1102	   NA	   0.0472	   NA	   0.1460	   0.0396	  
390	   0.1422	   0.2436	   0.1035	   NA	   NA	   0.1322	   0.1554	   0.0249	  
410	   0.2071	   0.2336	   0.1412	   NA	   NA	   0.1418	   0.1809	   0.0191	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Mean	   SEM	  
1	   2	   3	   4	   5	   6	  
10	   0.0083	   0.0226	   0.0101	   0.0035	   0.0121	   NA	   0.0113	   0.0029	  
30	   0.0044	   0.0125	   0.0061	   0.0023	   0.0114	   0.0180	   0.0091	   0.0024	  
50	   0.0052	   0.0165	   0.0084	   0.0031	   0.0150	   0.0306	   0.0131	   0.0041	  
70	   0.0058	   0.0185	   NA	   0.0035	   0.0168	   0.0346	   0.0159	   0.0051	  
90	   0.0071	   0.0212	   NA	   0.0035	   0.0199	   0.0380	   0.0180	   0.0056	  
110	   0.0063	   0.0186	   0.0116	   0.0030	   0.0177	   0.0393	   0.0161	   0.0053	  
130	   0.0068	   0.0182	   0.0109	   0.0039	   0.0216	   0.0378	   0.0165	   0.0051	  
150	   0.0083	   0.0205	   NA	   0.0044	   0.0228	   0.0436	   0.0199	   0.0063	  
170	   0.0082	   0.0233	   0.0126	   0.0042	   0.0237	   0.0474	   0.0199	   0.0064	  
190	   0.0084	   0.0261	   NA	   0.0050	   0.0276	   0.0599	   0.0254	   0.0089	  
210	   0.0112	   0.0341	   0.0226	   0.0073	   0.0359	   0.0887	   0.0333	   0.0120	  
230	   0.0186	   0.0504	   0.0379	   0.0090	   NA	   0.1141	   0.0460	   0.0169	  
250	   0.0173	   0.0667	   NA	   0.0108	   0.0653	   0.1619	   0.0644	   0.0247	  
270	   0.0286	   0.0732	   NA	   0.0172	   0.0698	   0.2165	   0.0810	   0.0325	  
290	   0.0293	   0.0930	   0.0823	   0.0195	   0.0900	   NA	   0.0628	   0.0145	  
310	   0.0327	   0.0887	   NA	   0.0258	   0.1097	   0.3311	   0.1176	   0.0509	  
330	   0.0417	   0.1065	   0.1284	   0.0313	   NA	   NA	   0.0770	   0.0195	  
350	   0.0496	   0.1207	   NA	   0.0271	   0.1431	   0.4896	   0.1660	   0.0764	  
370	   0.0506	   0.1161	   0.1427	   0.0382	   0.1601	   0.5381	   0.1743	   0.0754	  
390	   0.0435	   0.1265	   NA	   0.0344	   0.1820	   0.8309	   0.2435	   0.1364	  
410	   0.0396	   0.1113	   NA	   0.0414	   0.1648	   NA	   0.0893	   0.0247	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Table	  A-­‐8	   Pharmacokinetic	   parameters	   of	   unbound	   cefdroxil	   in	   rat	   blood	   and	  brain	  in	  the	  absence	  and	  presence	  of	  probenecid	  
The	  PK	  parameters	  of	  unbound	  cefadroxil	  in	  rats	  on	  Day	  1	  (no	  probenecid)	  
Parameters	  
	   Animal	  No.	  
Mean	   SEM	  
Unit	   1	   2	   3	   4	   5	   6	  
Blood	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   1876	   1889	   1418	   1587	   1699	   2014	   1747	   90	  
AUCu	  (0-­‐inf)	   μg*min/mL	   1942	   1949	   1456	   1616	   1759	   2089	   1802	   97	  
Cu,ss,blood	   μg/mL	   9.16	   9.09	   7.13	   7.51	   8.44	   9.56	   8.48	   0.40	  
MRTiv	   min	   79.6	   72.5	   73.1	   54.1	   72.8	   73.6	   70.9	   3.5	  
t1/2	   min	   55.1	   50.3	   50.6	   37.5	   50.4	   51.0	   49.2	   2.5	  
CL	   mL/min/kg	   15.4	   15.4	   20.6	   18.6	   17.1	   14.4	   16.9	   1.0	  
Vss	   L/kg	   1.23	   1.12	   1.51	   1.00	   1.24	   1.06	   1.19	   0.07	  
Brain	  ECF	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   14.9	   28.9	   26.5	   34.7	   28.7	   52.3	   31.0	   5.0	  
AUCu	  (0-­‐inf)	   μg*min/mL	   17.3	   40.3	   31.5	   47.2	   36.6	   66.1	   39.8	   6.7	  
Kp,uu,ECF	  (0–420)	   	   0.0079	   0.0153	   0.0187	   0.0219	   0.0169	   0.0260	   0.0178	   0.0025	  
Kp,uu,ECF	  (0-­‐inf)	   	   0.0089	   0.0207	   0.0216	   0.0292	   0.0208	   0.0316	   0.0222	   0.0033	  
Brain	  CSF	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   79.0	   72.5	   21.4	   12.0	   15.6	   33.9	   39.1	   12.0	  
AUCu	  (0-­‐inf)	   μg*min/mL	   95.3	   105.8	   28.4	   30.3	   19.3	   65.0	   57.3	   15.1	  
Kp,uu,CSF	  (0–420)	   	   0.0421	   0.0384	   0.0151	   0.0076	   0.0092	   0.0169	   0.0215	   0.0061	  
Kp,uu,CSF	  (0-­‐inf)	   	   0.0491	   0.0543	   0.0195	   0.0187	   0.0110	   0.0311	   0.0306	   0.0072	  	  
The	  PK	  parameters	  of	  unbound	  cefadroxil	  in	  rats	  on	  Day	  2	  (with	  probenecid)	  
Parameters	  
	   Animal	  No.	  
Mean	   SEM	  
Unit	   1	   2	   3	   4	   5	   6	  
Blood	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   2515	   3177	   2137	   2700	   3040	   3237	   2801	   175	  
AUCu	  (0-­‐inf)	   μg*min/mL	   2595	   3295	   2188	   2790	   3092	   3276	   2873	   177	  
Cu,ss,blood	   μg/mL	   11.89	   16.59	   10.55	   13.34	   14.65	   15.47	   13.75	   0.93	  
MRTiv	   min	   78.7	   87.4	   70.4	   88.7	   71.5	   66.0	   77.1	   3.8	  
t1/2	   min	   54.6	   60.6	   48.8	   61.5	   49.6	   45.7	   53.5	   2.7	  
CL	   mL/min/kg	   11.6	   9.1	   13.7	   10.8	   9.7	   9.2	   10.7	   0.7	  
Vss	   L/kg	   0.91	   0.80	   0.97	   0.95	   0.69	   0.60	   0.82	   0.06	  
Brain	  ECF	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   96.8	   113.1	   53.9	   81.9	   115.8	   269.3	   121.8	   30.9	  
AUCu	  (0-­‐inf)	   μg*min/mL	   140.2	   208.1	   60.2	   114.6	   223.3	   298.7	   174.2	   35.0	  
Kp,uu,ECF	  (0–420)	   	   0.0385	   0.0356	   0.0252	   0.0303	   0.0381	   0.0832	   0.0418	   0.0085	  
Kp,uu,ECF	  (0-­‐inf)	   	   0.0540	   0.0631	   0.0275	   0.0411	   0.0722	   0.0912	   0.0582	   0.0092	  
Brain	  CSF	   	   	   	   	   	   	   	   	   	  
AUCu	  (0–420)	   μg*min/mL	   23.4	   89.3	   34.0	   15.9	   82.3	   195.2	   73.3	   27.4	  
AUCu	  (0-­‐inf)	   μg*min/mL	   31.3	   112.7	   72.8	   27.9	   102.4	   354.0	   116.9	   49.6	  
Kp,uu,CSF	  (0–420)	   	   0.0093	   0.0281	   0.0159	   0.0059	   0.0271	   0.0603	   0.0244	   0.0081	  
Kp,uu,CSF	  (0-­‐inf)	   	   0.0121	   0.0342	   0.0333	   0.0100	   0.0331	   0.1081	   0.0385	   0.0146	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Table	  A-­‐9	   The	   relative	   recoveries	   %	   (RR)	   measured	   for	   3-­‐mm	   CMA	   12	  microdialysis	  probe	  in	  brain	  ECF,	  1-­‐mm	  BASi	  IBR	  microdialysis	  probe	  in	  brain	  CSF,	  and	  10-­‐mm	  CMA	  20	  microdialysis	  probe	  in	  the	  blood	  for	  the	  rat	  microdialysis	  study	  of	  cefadroxil	   in	  the	  absence	  and	  presence	  of	  Ala-­‐Ala.	  
Animal	   RRECF,Day	  1	   	   RRCSF,Day	  1	   	   RRblood,Day	  1	  
1	   13.0	   	   11.8	   	   70.9	  
2	   14.5	   	   12.9	   	   68.6	  
3	   15.1	   	   17.9	   	   NA	  
4	   18.3	   	   13.0	   	   NA	  
5	   22.1	   	   8.4	   	   74.6	  
6	   20.1	   	   NA	   	   70.0	  
7	   10.3	   	   10.1	   	   73.4	  
Mean	   16.2	   	   12.3	   	   71.5	  
SEM	   1.6	   	   1.3	   	   1.1	  NA:	  samples	  are	  not	  available	  due	  to	  the	  defects	  of	  microdialysis	  probes.	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Mean	   SEM	  
1	   2	   3	   4	   5	   6	   7	  
10	   56.2	   143.2	   35.5	   167.7	   38.5	   128.2	   127.1	   99.5	   20.6	  
30	   115.8	   267.6	   124.4	   248.4	   108.6	   315.9	   344.3	   217.9	   37.8	  
50	   131.7	   276.2	   139.4	   265.7	   105.7	   313.9	   408.8	   234.5	   42.4	  
70	   147.9	   298.4	   148.0	   266.9	   142.1	   326.9	   442.0	   253.2	   43.0	  
90	   157.3	   307.3	   170.9	   291.2	   128.3	   323.6	   490.0	   266.9	   47.7	  
110	   162.2	   351.2	   169.4	   297.8	   118.7	   315.1	   449.4	   266.3	   45.3	  
130	   178.3	   392.2	   184.7	   315.5	   133.6	   294.4	   471.2	   281.4	   46.7	  
150	   186.5	   398.1	   172.6	   323.1	   137.9	   294.2	   531.4	   292.0	   53.2	  
170	   194.1	   367.9	   190.6	   346.0	   151.4	   309.6	   553.7	   301.9	   52.7	  
190	   199.9	   437.0	   173.7	   336.0	   150.0	   331.4	   578.3	   315.2	   58.8	  
210	   194.1	   506.3	   188.6	   332.2	   146.1	   307.7	   603.3	   325.5	   65.2	  
230	   211.5	   452.5	   196.5	   346.2	   150.4	   299.6	   635.8	   327.5	   64.3	  
250	   239.7	   413.5	   215.9	   398.0	   151.1	   298.4	   583.5	   328.6	   55.6	  
270	   258.7	   359.1	   195.6	   367.9	   198.7	   318.8	   664.3	   337.6	   60.6	  
290	   254.5	   348.5	   181.5	   392.3	   174.5	   294.1	   668.2	   330.5	   64.0	  
310	   270.0	   363.6	   192.7	   421.2	   171.5	   290.1	   717.5	   346.7	   70.2	  
330	   257.1	   376.3	   195.5	   411.1	   164.0	   309.8	   758.3	   353.2	   75.6	  
350	   269.7	   374.8	   229.0	   413.2	   173.5	   285.4	   812.6	   365.5	   80.7	  
370	   286.7	   404.1	   219.2	   463.5	   176.7	   297.9	   847.1	   385.0	   85.7	  
390	   287.8	   401.5	   212.7	   429.4	   165.1	   292.4	   915.6	   386.4	   95.1	  
410	   286.9	   403.1	   218.8	   473.9	   171.5	   293.5	   947.0	   399.3	   99.3	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Mean	   SEM	  
1	   2	   3	   4	   5	   7	  
10	   95.0	   39.3	   16.0	   399.3	   NA	   22.0	   114.3	   66.3	  
30	   208.8	   77.4	   7.4	   562.1	   609.7	   62.9	   254.7	   108.3	  
50	   178.0	   95.5	   7.3	   516.0	   657.3	   77.9	   255.3	   108.6	  
70	   170.8	   101.5	   8.6	   516.0	   402.0	   91.6	   215.1	   81.3	  
90	   170.0	   126.8	   NA	   547.6	   639.0	   101.0	   316.9	   104.3	  
110	   207.0	   134.2	   7.7	   571.2	   669.0	   113.4	   283.7	   110.2	  
130	   160.9	   131.4	   9.9	   590.5	   768.7	   140.2	   300.3	   124.0	  
150	   162.0	   138.1	   10.6	   627.4	   881.4	   145.1	   327.4	   140.7	  
170	   169.4	   142.6	   12.6	   646.4	   924.9	   153.0	   341.5	   146.8	  
190	   190.1	   158.8	   12.2	   655.2	   994.8	   160.4	   361.9	   155.0	  
210	   160.8	   297.2	   15.4	   659.0	   974.6	   161.2	   378.0	   149.1	  
230	   370.0	   238.2	   29.9	   664.2	   935.6	   190.5	   404.7	   137.2	  
250	   341.6	   236.9	   29.6	   802.2	   890.2	   240.9	   423.6	   140.4	  
270	   253.7	   173.2	   22.3	   833.1	   883.7	   236.9	   400.5	   148.7	  
290	   247.5	   168.1	   19.3	   830.4	   715.6	   247.2	   371.3	   132.3	  
310	   257.0	   176.0	   21.2	   940.7	   755.5	   238.5	   398.1	   148.2	  
330	   234.6	   175.8	   20.1	   951.4	   707.1	   246.9	   389.3	   146.4	  
350	   232.3	   179.2	   18.0	   905.2	   758.9	   NA	   418.7	   158.8	  
370	   222.2	   178.2	   24.6	   916.2	   799.7	   244.8	   397.6	   149.7	  
390	   231.4	   166.0	   26.9	   913.8	   790.2	   252.5	   396.8	   148.4	  
410	   243.6	   171.5	   24.2	   999.8	   789.0	   278.2	   417.7	   157.3	  NA:	  samples	  are	  not	  available	  due	  to	  the	  technical	  problem	  during	  the	  microdialysis	  study.	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Mean	   SEM	  
1	   2	   5	   6	   7	  
10	   2195	   1360	   451	   2066	   4224	   2059	   624	  
30	   10969	   10796	   7480	   8918	   11708	   9974	   775	  
50	   10917	   9560	   7189	   8062	   11491	   9444	   817	  
70	   9938	   8326	   7527	   7888	   11236	   8983	   698	  
90	   9850	   7319	   7884	   7088	   10480	   8524	   689	  
110	   10066	   8429	   7924	   7657	   10046	   8824	   518	  
130	   9077	   8478	   7537	   8363	   11598	   9011	   692	  
150	   9005	   8785	   8193	   9038	   11123	   9229	   497	  
170	   8828	   8552	   8577	   9017	   10945	   9184	   449	  
190	   9203	   8287	   8330	   8259	   11233	   9063	   571	  
210	   9939	   8763	   7983	   8807	   10206	   9139	   410	  
230	   9108	   9516	   8538	   8563	   9833	   9112	   256	  
250	   10596	   8151	   7825	   9232	   11515	   9464	   705	  
270	   10002	   7533	   8352	   9140	   10982	   9202	   605	  
290	   8880	   7415	   7751	   9553	   10438	   8807	   560	  
310	   9336	   7950	   8035	   9461	   10520	   9061	   482	  
330	   9990	   7766	   8108	   9739	   9799	   9080	   472	  
350	   9358	   8231	   7048	   9431	   9229	   8659	   458	  
370	   8563	   7701	   10495	   9452	   11458	   9534	   668	  
390	   9262	   8033	   9184	   11187	   10251	   9583	   533	  
410	   10101	   7327	   8403	   10387	   10649	   9373	   645	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Mean	   SEM	  
1	   2	   3	   4	   5	   6	   7	  
5	   5634	   5465	   63	   6806	   5504	   6821	   5822	   5159	   877	  
18	   13185	   12265	   8046	   12559	   12057	   13550	   12428	   12013	   690	  
120	   9347	   8202	   6080	   9183	   8854	   9329	   9807	   8686	   473	  
180	   8844	   8862	   6742	   9746	   8200	   10566	   9244	   8886	   457	  
235	   9143	   7723	   7376	   9854	   8413	   10519	   7739	   8681	   451	  
300	   9365	   7437	   7208	   9647	   9622	   10472	   8906	   8951	   456	  
360	   7930	   8642	   7001	   9054	   9525	   11014	   11300	   9209	   589	  
420	   9988	   8261	   7571	   10378	   9817	   10816	   10786	   9660	   477	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Table	  A-­‐14	   The	   cefadroxil	   amount	   in	   brain	   slice	   (Abrain),	   the	   cefadroxil	  concentration	   in	   buffer	   (Cbuffer),	   and	   the	   unbound	   volume	   of	  distribution	  of	   cefadroxil	   (Vu,brain)	   in	   rat	  brain	  slice	  study	   for	  Control	  group	  (cefadroxil	  only)	  
Slice	  
Animal	  No.	  1	   	   Animal	  No.2	  
Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	  
ng/g	  brain	   ng/mL	   mL/g	  brain	   	   ng/g	  brain	   ng/mL	   mL/g	  brain	  
1	   1193	  
286.7	  
4.49	   	   965	  
298.3	  
3.47	  
2	   1021	   3.83	   	   1039	   3.74	  
3	   1113	   4.18	   	   1006	   3.62	  
4	   921	   3.44	   	   1051	   3.79	  
5	   1130	   4.25	   	   759	   2.71	  
	   	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	  
Slice	  
Animal	  No.	  3	   	   Animal	  No.4	  
Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	  
ng/g	  brain	   ng/mL	   mL/g	  brain	   	   ng/g	  brain	   ng/mL	   mL/g	  brain	  
1	   884	  
304.5	  
3.10	   	   1091	  
286.1	  
4.11	  
2	   854	   2.99	   	   1053	   3.96	  
3	   862	   3.02	   	   1068	   4.02	  
4	   952	   3.35	   	   1118	   4.21	  
5	   878	   3.08	   	   1053	   3.96	  	  
Average	  of	  Vu,brain	  (mL/g	  brain)	  for	  the	  control	  group	  (Cefadroxil	  only)	  
Animal	   1	   2	   3	   4	   Mean	   SEM	  
Vu,brain	   4.04	   3.46	   3.11	   4.05	   3.67	   0.23	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Table	  A-­‐15	   The	   cefadroxil	   amount	   in	   brain	   slice	   (Abrain),	   the	   cefadroxil	  concentration	   in	   buffer	   (Cbuffer),	   and	   the	   unbound	   volume	   of	  distribution	  of	   cefadroxil	   (Vu,brain)	   in	   rat	  brain	   slice	   study	   for	  Ala-­‐Ala	  inhibition	  group	  
Slice	  
Animal	  No.	  1	   	   Animal	  No.2	   	   Animal	  No.3	  
Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	   	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
	   ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
1	   190	  
302.6	  
0.59	   	   162	  
329.4	  
0.44	   	   556	  
291.7	  
2.00	  
2	   186	   0.58	   	   157	   0.42	   	   515	   1.85	  
3	   189	   0.59	   	   153	   0.41	   	   478	   1.71	  
4	   185	   0.57	   	   151	   0.40	   	   535	   1.92	  
5	   185	   0.57	   	   167	   0.45	   	   489	   1.75	  	  
Average	  of	  Vu,brain	  (mL/g	  brain)	  with	  5	  mM	  Ala-­‐Ala	  	  
Animal	   1	   2	   3	   Mean	   SEM	  
Vu,brain	   0.58	   0.43	   1.84	   0.95	   0.45	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Table	  A-­‐16	   The	   cefadroxil	   amount	   in	   brain	   slice	   (Abrain),	   the	   cefadroxil	  concentration	   in	   buffer	   (Cbuffer),	   and	   the	   unbound	   volume	   of	  distribution	   of	   cefadroxil	   (Vu,brain)	   in	   rat	   brain	   slice	   study	   for	   GlySar	  inhibition	  group	  
Slice	  
Animal	  No.	  1	   	   Animal	  No.2	   	   Animal	  No.3	  
Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	   	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
	   ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
1	   301	  
302.1	  
0.99	   	   339	  
312.4	  
1.09	   	   341	  
303.3	  
1.14	  
2	   300	   0.99	   	   341	   1.10	   	   328	   1.09	  
3	   302	   1.00	   	   320	   1.03	   	   345	   1.15	  
4	   311	   1.03	   	   384	   1.25	   	   367	   1.23	  
5	   307	   1.02	   	   363	   1.18	   	   364	   1.22	  	  
Average	  of	  Vu,brain	  (mL/g	  brain)	  with	  5	  mM	  GlySar	  	  
Animal	   1	   2	   3	   Mean	   SEM	  
Vu,brain	   1.01	   1.13	   1.17	   1.10	   0.05	  	  	   	  
	  	   148	  
Table	  A-­‐17	  	   The	   cefadroxil	   amount	   in	   brain	   slice	   (Abrain),	   the	   cefadroxil	  concentration	   in	   buffer	   (Cbuffer),	   and	   the	   unbound	   volume	   of	  distribution	   of	   cefadroxil	   (Vu,brain)	   in	   rat	   brain	   slice	   study	   for	  probenecid	  inhibition	  group	  
Slice	  
Animal	  No.	  1	   	   Animal	  No.2	   	   Animal	  No.3	  
Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	   	   Abrain	   Cbuffer	   Vu,brain	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	   	  
ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
	   ng/g	  
brain	   ng/mL	  
mL/g	  
brain	  
1	   1563	  
286.8	  
5.91	   	   1469	  
275.2	  
5.79	   	   1594	  
288.2	  
6.29	  
2	   1524	   5.76	   	   1560	   6.15	   	   1700	   6.71	  
3	   1504	   5.69	   	   1558	   6.15	   	   1634	   6.45	  
4	   1629	   6.17	   	   1511	   5.96	   	   1466	   5.77	  
5	   1530	   5.78	   	   1468	   5.78	   	   1648	   6.50	  	  
Average	  of	  Vu,brain	  (mL/g	  brain)	  with	  1	  mM	  Probenecid	  	  
Animal	   1	   2	   3	   Mean	   SEM	  
Vu,brain	   5.86	   5.97	   6.35	   6.06	   0.15	  	  	   	  
	  	   149	  
APPENDIX	  B 	  
INDIVIDUAL DATA FROM CHAPTER 4 
Table	  B-­‐1	   The	  relative	  recovery	  (RR)	  calculated	  from	  the	  in	  vivo	  retrodialysis	  of	  [3H]cefadroxil	  on	  three	  wild-­‐type	  mice	  
	   Animal	  No.	  
Mean	   SEM	  
	   1	   2	   3	  
RR	   0.0459	   0.0449	   0.0488	   0.0465	   0.0011	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Table	  B-­‐2	   The	  unbound	  concentration	  –	  time	  profiles	  of	  cefadroxil	  in	  brain	  ECF	  in	  of	  wild-­‐type	  and	  Pept2	  null	  mice	  in	  the	  microdialysis	  study	  




10	   30	   50	   70	   90	   110	   130	   150	   170	   190	   210	   230	  
6	   60	   101	   84	   129	   154	   147	   144	   133	   130	   143	   155	   166	  
7	   117	   144	   157	   191	   254	   254	   290	   277	   351	   318	   342	   286	  
8	   24	   57	   74	   83	   84	   94	   96	   133	   118	   119	   132	   146	  
10	   46	   80	   100	   108	   124	   131	   130	   140	   158	   177	   173	   192	  
12	   14	   52	   70	   84	   128	   109	   81	   101	   105	   136	   144	   150	  
13	   61	   108	   171	   228	   234	   228	   258	   280	   265	   260	   258	   312	  
14	   64	   139	   188	   184	   198	   254	   277	   247	   237	   262	   252	   219	  
15	   31	   71	   110	   133	   212	   164	   159	   211	   234	   167	   156	   177	  
16	   60	   158	   169	   173	   199	   224	   205	   205	   228	   232	   222	   214	  
17	   38	   99	   139	   145	   179	   170	   166	   177	   188	   224	   247	   284	  
Mean	   52	   101	   126	   146	   177	   177	   181	   190	   201	   204	   208	   215	  
SEM	   9	   12	   14	   15	   17	   19	   23	   20	   24	   21	   21	   19	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10	   30	   50	   70	   90	   110	   130	   150	   170	   190	   210	   230	  
2	   14	   94	   213	   338	   340	   389	   353	   484	   437	   469	   585	   568	  
5	   44	   90	   121	   169	   186	   178	   212	   215	   237	   239	   230	   239	  
6	   58	   151	   192	   234	   314	   413	   449	   394	   404	   415	   413	   374	  
7	   41	   106	   152	   189	   243	   284	   381	   609	   619	   708	   708	   806	  
8	   72	   138	   175	   200	   208	   222	   262	   299	   282	   262	   265	   232	  
9	   189	   165	   177	   146	   213	   185	   193	   186	   NA	   224	   190	   197	  
10	   100	   273	   374	   456	   486	   533	   695	   776	   740	   654	   692	   727	  
11	   144	   260	   331	   351	   361	   372	   378	   396	   460	   419	   387	   378	  
13	   62	   323	   361	   439	   432	   458	   667	   508	   570	   503	   553	   484	  
14	   112	   357	   387	   475	   482	   705	   680	   665	   682	   652	   624	   649	  
15	   40	   135	   207	   214	   196	   400	   531	   566	   615	   626	   529	   576	  
16	   55	   187	   260	   361	   514	   542	   583	   632	   606	   604	   667	   641	  
Mean	   84	   196	   248	   300	   327	   374	   427	   453	   492	   454	   465	   489	  
SEM	   17	   31	   32	   40	   36	   53	   61	   61	   58	   56	   61	   59	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Table	  B-­‐3	  	   The	   plasma	   concentration	   –	   time	   profiles	   of	   cefadroxil	   in	   wild-­‐type	  and	  Pept2	  null	  mice	  in	  the	  microdialysis	  study	  




5	   10	   20	   40	   60	   80	   100	   120	   180	   240	  
6	   1420	   2310	   3110	   3370	   3670	   2970	   3850	   3710	   3870	   4310	  
7	   2590	   3140	   3680	   5310	   3760	   5040	   4880	   3640	   4360	   4250	  
8	   1020	   2240	   2760	   4310	   4110	   3690	   3370	   4660	   4180	   4980	  
10	   1330	   3040	   3210	   3320	   4000	   4150	   3610	   4800	   4110	   4310	  
12	   806	   2160	   3330	   4090	   3900	   5170	   4490	   2970	   5390	   4100	  
13	   1010	   2340	   2450	   3320	   5320	   3060	   3800	   4560	   4680	   5020	  
14	   1500	   2150	   2510	   3250	   2900	   4770	   4220	   3830	   4550	   4570	  
15	   NA	   1500	   2860	   4760	   3660	   3620	   3230	   4190	   3450	   4310	  
16	   937	   1640	   2700	   2900	   2430	   2010	   3020	   3470	   3500	   4200	  
17	   883	   1750	   2340	   3440	   3213	   2800	   3260	   2660	   2820	   3440	  
Mean	   1277	   2227	   2895	   3807	   3696	   3728	   3773	   3849	   4091	   4349	  
SEM	   184	   171	   136	   246	   245	   332	   190	   226	   230	   142	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5	   10	   20	   40	   60	   80	   100	   120	   180	   240	  
2	   636	   869	   1820	   2670	   2310	   3000	   3330	   2990	   4950	   3820	  
5	   1020	   1850	   2330	   3630	   3500	   4410	   2813	   4160	   4840	   6290	  
6	   1660	   1900	   2260	   3410	   3670	   4240	   3227	   4587	   4060	   3140	  
7	   1700	   2200	   4010	   4930	   4440	   4240	   5050	   5100	   5600	   5040	  
8	   1370	   2390	   2540	   2660	   3070	   3740	   3910	   4740	   4580	   5560	  
9	   891	   NA	   5600	   3040	   4910	   3710	   3780	   3720	   3310	   3890	  
10	   953	   1890	   2740	   3670	   6490	   4700	   4720	   4540	   4660	   6240	  
11	   1160	   2173	   2240	   4450	   3240	   3050	   3150	   2940	   3220	   4740	  
13	   74	   1600	   5100	   1890	   2520	   2820	   3420	   3067	   2413	   2253	  
14	   117	   2080	   2620	   3120	   3690	   3720	   3840	   3340	   3150	   4070	  
15	   942	   1150	   1990	   3450	   3340	   2590	   2920	   3270	   4430	   3640	  
16	   1000	   1690	   2300	   2470	   3840	   4330	   3770	   3810	   4270	   4710	  
Mean	   960	   1799	   2963	   3283	   3752	   3713	   3661	   3855	   4124	   4449	  
SEM	   147	   138	   360	   244	   324	   202	   196	   218	   266	   352	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Table	  B-­‐4	  	   The	  brain	  ECF-­‐to-­‐plasma	  concentration	  ratio	  of	  cefadroxil	  in	  wild-­‐type	  and	  Pept2	  null	  mice	  in	  the	  microdialysis	  study	  




30	   50	   70	   90	   110	   150	   210	  
6	   0.031	   0.024	   0.039	   0.045	   0.039	   0.035	   0.038	  
7	   0.032	   0.035	   0.044	   0.051	   0.060	   0.070	   0.079	  
8	   0.016	   0.018	   0.021	   0.024	   0.024	   0.030	   0.029	  
10	   0.025	   0.027	   0.027	   0.032	   0.031	   0.032	   0.041	  
12	   0.014	   0.018	   0.019	   0.026	   0.030	   0.025	   0.030	  
13	   0.038	   0.040	   0.056	   0.069	   0.055	   0.061	   0.053	  
14	   0.049	   0.061	   0.049	   0.044	   0.063	   0.059	   0.055	  
15	   0.019	   0.026	   0.036	   0.062	   0.045	   0.055	   0.040	  
16	   0.057	   0.064	   0.078	   0.080	   0.069	   0.059	   0.058	  
17	   0.035	   0.042	   0.048	   0.059	   0.058	   0.064	   0.079	  
Mean	   0.031	   0.035	   0.042	   0.049	   0.047	   0.049	   0.050	  
SEM	   0.004	   0.005	   0.006	   0.006	   0.005	   0.005	   0.006	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30	   50	   70	   90	   110	   150	   210	  
2	   0.043	   0.086	   0.128	   0.107	   0.123	   0.124	   0.134	  
5	   0.031	   0.034	   0.043	   0.052	   0.052	   0.048	   0.042	  
6	   0.054	   0.054	   0.059	   0.085	   0.107	   0.091	   0.115	  
7	   0.024	   0.033	   0.044	   0.052	   0.056	   0.114	   0.133	  
8	   0.053	   0.061	   0.059	   0.054	   0.051	   0.064	   0.052	  
9	   0.039	   0.045	   0.034	   0.057	   0.049	   0.053	   0.053	  
10	   0.086	   0.076	   0.082	   0.103	   0.115	   0.169	   0.128	  
11	   0.081	   0.087	   0.111	   0.117	   0.122	   0.129	   0.098	  
13	   0.100	   0.165	   0.164	   0.139	   0.141	   0.186	   0.237	  
14	   0.125	   0.114	   0.128	   0.127	   0.197	   0.205	   0.174	  
15	   0.051	   0.061	   0.073	   0.071	   0.129	   0.148	   0.132	  
16	   0.078	   0.084	   0.089	   0.127	   0.143	   0.157	   0.149	  
Mean	   0.064	   0.075	   0.085	   0.091	   0.107	   0.124	   0.121	  
SEM	   0.009	   0.011	   0.012	   0.010	   0.013	   0.015	   0.016	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6	   34.8	   	   2	   39.3	  
7	   35.3	   	   5	   23.8	  
8	   30.1	   	   6	   47.8	  
10	   34.8	   	   7	   29.8	  
12	   36.6	   	   8	   27.0	  
13	   29.9	   	   9	   38.6	  
14	   32.8	   	   10	   24.0	  
15	   34.8	   	   11	   31.6	  
16	   35.7	   	   13	   66.6	  
17	   43.6	   	   14	   36.9	  
Mean	   34.84	   	   15	   41.2	  
SEM	   1.21	   	   16	   31.8	  
CV%	   11.0	   	   Mean	   36.5	  
	   	   	   SEM	   3.4	  
	   	   	   CV%	   32.6	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6	   279	   	   5	   630	  
7	   244	   	   6	   1110	  
10	   246	   	   7	   359	  
12	   424	   	   8	   350	  
13	   214	   	   9	   666	  
16	   200	   	   10	   703	  
Mean	   268	   	   11	   319	  
SEM	   33	   	   13	   326	  
CV%	   30.4	   	   15	   333	  
	   	   	   Mean	   533	  
	   	   	   SEM	   90	  
	   	   	   CV%	   50.6	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Table	  B-­‐7	  	   The	   vascular	   volume-­‐corrected	   amount	   of	   cefadroxil	   (Abrain)	   in	  wild-­‐type	  and	  Pept2	  null	  mice	  in	  the	  microdialysis	  study	  
Abrain	  (ng/g	  brain)	  of	  different	  brain	  regions	  in	  wild-­‐type	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
3	   NA	   297	   	   282	   190	   329	  
4	   NA	   409	   	   337	   313	   332	  
6	   296	   191	   	   205	   173	   230	  
7	   535	   296	   	   285	   250	   190	  
8	   993	   713	   	   327	   440	   635	  
10	   617	   334	   	   305	   301	   312	  
12	   193	   149	   	   270	   189	   256	  
13	   111	   131	   	   210	   172	   160	  
14	   193	   246	   	   252	   322	   391	  
15	   589	   875	   	   941	   965	   1283	  
16	   181	   163	   	   276	   187	   207	  
17	   382	   517	   	   529	   653	   717	  	  	  
Abrain	  (ng/g	  brain)	  of	  different	  brain	  regions	  in	  Pept2	  null	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
5	   351	   223	   	   242	   199	   279	  
6	   1333	   606	   	   473	   421	   660	  
7	   233	   189	   	   221	   271	   292	  
8	   467	   187	   	   266	   210	   209	  
9	   349	   334	   	   234	   266	   469	  
10	   511	   611	   	   519	   495	   641	  
11	   80	   106	   	   103	   100	   141	  
13	   139	   172	   	   166	   207	   251	  
14	   517	   504	   	   448	   438	   975	  
15	   221	   244	   	   240	   297	   318	  
16	   119	   113	   	   173	   159	   219	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The	  average	  Abrain	  from	  five	  brain	  regions	  









3	   275	   	   5	   259	  
4	   347	   	   6	   698	  
6	   219	   	   7	   241	  
7	   311	   	   8	   268	  
8	   622	   	   9	   330	  
10	   374	   	   10	   556	  
12	   211	   	   11	   106	  
13	   157	   	   13	   187	  
14	   281	   	   14	   577	  
15	   931	   	   15	   264	  
16	   203	   	   16	   157	  
17	   560	   	   Mean	   331	  
Mean	   374	   	   SEM	   58	  
SEM	   65	   	   CV%	   58.1	  
CV%	   60.1	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3	   261	   	   5	   216	  
4	   320	   	   6	   631	  
6	   189	   	   7	   96	  
7	   260	   	   8	   226	  
8	   595	   	   9	   295	  
10	   339	   	   10	   425	  
12	   184	   	   11	   38	  
13	   101	   	   13	   100	  
14	   241	   	   14	   460	  
15	   899	   	   15	   160	  
16	   164	   	   16	   41	  
17	   509	   	   Mean	   244	  
Mean	   339	   	   SEM	   58	  
SEM	   65	   	   CV%	   78.3	  
CV%	   66.9	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Table	  B-­‐9	  	   The	  unbound	  volume	  of	  distribution	  of	  cefadroxil	  in	  brain	  (Vu,brain)	  of	  wild-­‐type	  and	  Pept2	  null	  mice	  measured	  in	  the	  microdialysis	  study	  
Vu,brain	  (mL/g	  brain)	  of	  different	  brain	  regions	  in	  wild-­‐type	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
3	   NA	   4.05	   	   3.85	   2.59	   4.49	  
4	   NA	   2.72	   	   2.25	   2.08	   2.21	  
6	   1.79	   1.15	   	   1.24	   1.04	   1.39	  
7	   1.87	   1.04	   	   1.00	   0.87	   0.67	  
8	   6.80	   4.88	   	   2.24	   3.01	   4.35	  
10	   3.22	   1.74	   	   1.59	   1.57	   1.63	  
12	   1.28	   0.99	   	   1.80	   1.26	   1.70	  
13	   0.35	   0.42	   	   0.67	   0.55	   0.51	  
14	   0.88	   1.12	   	   1.15	   1.47	   1.78	  
15	   3.33	   4.94	   	   5.32	   5.45	   7.25	  
16	   0.85	   0.76	   	   1.29	   0.88	   0.97	  
17	   1.35	   1.82	   	   1.86	   2.30	   2.53	  	  	  
Vu,brain	  (mL/g	  brain)	  of	  different	  brain	  regions	  in	  Pept2	  null	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
5	   1.47	   0.93	   	   1.01	   0.83	   1.17	  
6	   3.56	   1.62	   	   1.26	   1.13	   1.76	  
7	   0.29	   0.23	   	   0.27	   0.34	   0.36	  
8	   2.01	   0.81	   	   1.15	   0.90	   0.90	  
9	   1.77	   1.69	   	   1.19	   1.35	   2.37	  
10	   0.70	   0.84	   	   0.71	   0.68	   0.88	  
11	   0.21	   0.28	   	   0.27	   0.27	   0.37	  
13	   0.29	   0.36	   	   0.34	   0.43	   0.52	  
14	   0.80	   0.78	   	   0.69	   0.67	   1.50	  
15	   0.38	   0.42	   	   0.42	   0.51	   0.55	  
16	   0.19	   0.18	   	   0.27	   0.25	   0.34	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The	  average	  Vu,brain	  from	  five	  brain	  regions	  









3	   3.74	   	   5	   1.08	  
4	   2.31	   	   6	   1.87	  
6	   1.32	   	   7	   0.30	  
7	   1.09	   	   8	   1.15	  
8	   4.26	   	   9	   1.67	  
10	   1.95	   	   10	   0.76	  
12	   1.41	   	   11	   0.28	  
13	   0.50	   	   13	   0.39	  
14	   1.28	   	   14	   0.89	  
15	   5.26	   	   15	   0.46	  
16	   0.95	   	   16	   0.24	  
17	   1.97	   	   Mean	   0.83	  
Mean	   2.17	   	   SEM	   0.17	  
SEM	   0.43	   	   CV%	   68.7	  
CV%	   68.1	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Table	  B-­‐10	  	   The	   plasma	   concentration	   –	   time	   profiles	   of	   cefadroxil	   in	  permeability-­‐surface	  area	  product	  study	  
The	  plasma	  concentration	  of	  cefadroxil	  (ng/mL)	  in	  wild-­‐type	  mice	  
Animal	  No.	  
Time	  (min)	  
1	   2.5	   5	   7.5	   10	  
1	   1130	   1840	   3400	   3950	   4250	  
2	   1990	   2660	   3880	   4510	   4188	  
3	   1570	   2480	   3400	   4610	   4920	  
Mean	   1563	   2327	   3560	   4357	   4453	  
SEM	   203	   203	   131	   168	   191	  
	   	   	   	   	   	  
The	  plasma	  concentration	  of	  cefadroxil	  (ng/mL)	  in	  Pept2	  null	  mice	  
Animal	  No.	  
Time	  (min)	  
1	   2.5	   5	   7.5	   10	  
1	   1450	   2400	   3250	   3910	   4410	  
2	   1730	   2710	   3960	   4650	   5160	  
3	   1680	   2200	   3690	   4450	   4630	  
Mean	   1620	   2437	   3633	   4337	   4733	  
SEM	   70	   121	   169	   180	   182	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Table	  B-­‐11	  	   The	  vascular	  volume-­‐corrected	  amount	   in	  brain	   (Abrain)	   of	   cefadroxil	  in	  the	  study	  measuring	  permeability-­‐surface	  area	  product	  
Abrain	  (ng/g	  brain)	  of	  cefadroxil	  in	  different	  brain	  regions	  in	  wild-­‐type	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   9.12	   14.73	   	   6.80	   10.89	   32.56	  
2	   16.56	   15.18	   	   15.54	   16.44	   31.39	  
3	   9.55	   4.10	   	   6.89	   8.82	   25.60	  
Mean	   11.74	   11.34	   	   9.74	   12.05	   29.85	  
SEM	   1.97	   2.96	   	   2.37	   1.86	   1.76	  
	   	   	   	   	   	   	  
Abrain	  (ng/g	  brain)	  of	  cefadroxil	  in	  different	  brain	  regions	  in	  Pept2	  null	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   11.24	   12.14	   	   12.81	   10.09	   25.48	  
2	   9.43	   8.17	   	   11.47	   14.27	   34.53	  
3	   7.24	   3.82	   	   11.40	   8.15	   14.29	  
Mean	   9.30	   8.04	   	   11.89	   10.83	   24.77	  
SEM	   0.95	   1.96	   	   0.38	   1.47	   4.78	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Table	  B-­‐12	  	   The	  permeability-­‐surface	  area	   (PS)	  product	  of	   cefadroxil	   in	  different	  brain	  regions	  based	  on	  the	  study	  using	  a	  10-­‐min	  intravenous	  infusion	  of	  0.15	  mg/min/kg	  cefadroxil	  
PS	  (µL/min/g	  brain)	  of	  cefadroxil	  in	  wild-­‐type	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   0.317	   0.512	   	   0.236	   0.378	   1.131	  
2	   0.487	   0.446	   	   0.457	   0.483	   0.923	  
3	   0.288	   0.124	   	   0.208	   0.266	   0.773	  
Mean	   0.364	   0.361	   	   0.300	   0.376	   0.942	  
SEM	   0.051	   0.098	   	   0.064	   0.051	   0.085	  
	   	   	   	   	   	   	  
PS	  (µL/min/g	  brain)	  of	  cefadroxil	  in	  Pept2	  null	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   0.374	   0.404	   0.427	   0.336	   0.849	   0.374	  
2	   0.265	   0.230	   0.322	   0.401	   0.971	   0.265	  
3	   0.222	   0.117	   0.349	   0.250	   0.438	   0.222	  
Mean	   0.287	   0.250	   0.366	   0.329	   0.753	   0.287	  
SEM	   0.037	   0.068	   0.026	   0.036	   0.132	   0.037	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Table	  B-­‐13	  	   The	  vascular	  space	  in	  brain	  (Vbl)	  measured	  using	  [14C]dextran	  in	  wild-­‐type	  and	  Pept2	  null	  mice	  
The	  Vbl	  (µL/g	  brain)	  in	  wild-­‐type	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   9.61	   10.05	   	   7.63	   9.07	   12.14	  
2	   7.86	   7.82	   	   7.04	   8.77	   11.66	  
3	   7.66	   7.95	   	   8.03	   7.13	   13.14	  
4	   8.80	   8.68	   	   9.38	   9.64	   13.85	  
5	   7.82	   9.19	   	   8.30	   7.87	   13.82	  
Mean	   8.35	   8.74	   	   8.07	   8.50	   12.92	  
SEM	   0.37	   0.41	   	   0.39	   0.45	   0.44	  
	   	   	   	   	   	   	  
The	  Vbl	  (µL/g	  brain)	  in	  Pept2	  null	  mice	  
Animal	  
No.	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
1	   8.05	   8.08	   	   8.09	   8.33	   13.20	  
2	   10.23	   9.55	   	   10.35	   9.55	   14.21	  
3	   8.73	   8.35	   	   8.96	   8.87	   12.62	  
4	   7.81	   9.03	   	   8.46	   9.76	   13.88	  
5	   8.20	   7.54	   	   9.38	   8.08	   14.60	  
Mean	   8.61	   8.51	   	   9.05	   8.92	   13.70	  
SEM	   0.43	   0.35	   	   0.39	   0.33	   0.35	  	  
The	  average	  of	  Vbl	  (µL/g	  brain)	  in	  all	  mice	  including	  two	  genotypes	  
	  
Left	   	   Right	  
Cerebellum	  
Cortex	   Basal	  ganglia	   	   Cortex	   Basal	  ganglia	  
Mean	   8.48	   8.62	   	   8.56	   8.71	   13.31	  
SEM	   0.26	   0.25	   	   0.29	   0.26	   0.28	  
CV%	   9.66	   9.00	   	   10.75	   9.31	   6.69	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1	   0.69	   0.67	  
2	   0.62	   0.64	  
3	   0.60	   0.65	  
4	   0.69	   0.67	  
5	   0.62	   0.62	  
Mean	   0.64	   0.65	  
SEM	   0.02	   0.01	  
Mean	   0.65	  
SEM	   0.01	  
CV%	   4.7	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APPENDIX	  C 	  
REVISITING ATENOLOL AS A LOW PASSIVE 
PERMEABILITY MARKER 
ABSTRACT	  Atenolol,	  a	  hydrophilic	  beta	  blocker,	  has	  been	  widely	  used	  as	  a	  model	  drug	  for	  low	  passive	  permeability	   in	   the	   research	  of	   biological	  membrane	  barriers	   such	   as	  blood-­‐brain	  barrier	  (BBB)	  and	   intestinal	  epithelium.	  To	  assess	  whether	  S-­‐atenolol,	  the	   enantiomer	   responsible	   for	   the	   pharmacological	   effects,	   presents	   the	  characteristics	   of	   BBB	   transport	   of	   a	   low	  passive	   permeable	   drug,	   a	  microdialysis	  study	  was	  performed	  to	  monitor	  the	  concentrations	  of	  unbound	  S-­‐atenolol	  in	  brain	  extracellular	  fluid	  (ECF)	  and	  venous	  blood	  of	  rats	  during	  and	  after	  intravenous	  drug	  infusion.	  The	  ratio	  of	  unbound	  drug	  concentrations	  in	  brain	  ECF	  to	  that	  in	  blood	  at	  the	   steady	   sate,	   i.e.	   the	   unbound	   partition	   coefficient	   (Kp,uu),	  was	   3.55%	  ±	   0.40%,	  much	   less	   than	   unity.	   The	   unbound	   volume	   of	   distribution	   in	   brain	   (Vu,brain)	   of	   S-­‐atenolol	   was	   also	   measured,	   which	   was	   0.686	   ±	   0.104	   mL/g	   brain,	   indicating	   S-­‐atenolol	  being	  evenly	  distributed	  within	  brain	  parenchyma.	  In	  addition,	  equilibrium	  dialysis	  showed	  limited	  nonspecific	  binding	  of	  S-­‐atenolol	  in	  brain	  homogenate	  with	  unbound	   fraction	   (fu,brain)	   of	   0.90	   ±	   0.052.	   It	   is	   concluded	   that	   Kp,uu	   being	   much	  
	  	   169	  
smaller	   than	   unity	   indicates	   active	   efflux	   transport	   of	   S-­‐atenolol	   at	   the	   BBB,	   thus	  casting	   doubt	   upon	   the	   use	   of	   atenolol	   as	   a	   model	   drug	   of	   passive	   diffusion	   in	  studies	  of	  BBB	  transport	  or	  intestinal	  absorption.	  	  
INTRODUCTION	  Beta	  blockers	  are	  a	   class	  of	  drugs	  particularly	  used	   for	  cardiovascular	  disease	  including	   angina,	   myocardial	   infarction,	   heart	   failure,	   and	   hypertension.	   Their	  pharmacological	   mechanism	   is	   based	   on	   the	   ability	   of	   blocking	   beta-­‐adrenergic	  receptors	   to	   slow	   heartbeats	   and	   decrease	   oxygen	   demand	   [1].	   The	   first	   beta	  blocker	   developed	   was	   propranolol,	   a	   highly	   lipophilic	   chemical	   with	   log	  octanol/water	   partition	   coefficient	   (log	   P)	   of	   3.65	   and	   with	   approximately	   90%	  plasma	   protein	   binding	   [2].	   Also	   belonging	   to	   the	   beta	   blocker	   family,	   atenolol	  oppositely	  has	  very	  high	  hydrophilicity	  with	   log	  P	  of	  0.23	  and	   low	  plasma	  protein	  binding	   of	   approximately	   5%	   [3].	   It	   is	  widely	   believed	   that	   high	   hydrophilicity	   of	  atenolol	   leads	   to	   its	   low	   penetration	   into	   brain,	   thus	   having	   significantly	   lower	  incidence	  rate	  of	  side	  effects	  related	  to	  central	  nervous	  system	  (CNS),	  such	  as	  sleep	  disturbance	   and	   hallucination	   [4,	   5].	   As	   one	   of	   the	   widest	   used	   beta	   blocker	   for	  angina	  and	  hypertension,	  the	  racemic	  mixture	  of	  atenolol	  is	  used	  in	  the	  clinic,	  while	  its	  pharmacological	  activity	  resides	  mainly	  in	  the	  enantiomer,	  S-­‐atenolol	  [6].	  	  Like	   intestinal	   epithelium,	   the	  BBB	   is	   characterized	   by	   tight	   junctions	   formed	  between	   adjacent	   cerebral	   capillary	   endothelial	   cells,	   which	   decrease	   the	   BBB	  permeability	   of	   ions	   and	   other	   small	   hydrophilic	   molecules	   by	   restricting	   the	  paracellular	  pathways	  [7].	  Atenolol	  has	  for	  a	  long	  time	  been	  considered	  as	  a	  typical	  representative	   of	   a	   hydrophilic	   small	  molecule	  with	   low	  passive	  permeability	   and	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low	   paracellular	   diffusion	   across	   intestinal	   membrane	   and	   blood-­‐brain	   barrier	  (BBB).	  Thus,	  it	  has	  been	  widely	  used	  as	  a	  model	  drug	  in	  developing	  and	  evaluating	  
in	  vitro	  or	   in	  situ	  models	   for	   intestinal	  absorption	  and	  CNS	  penetration	  along	  with	  another	   two	   beta	   blockers,	   the	   highly	   lipophilic	   propranolol	   and	   intermediate	  lipophilic	  metoprolol	  (log	  P	  of	  2.15)	  [8-­‐10].	  The	   passive	   diffusion	   rate	   of	   a	   drug	   is	   a	   factor	   affecting	   its	   rate	   of	   transport	  across	  the	  BBB	  in	  both	  directions,	  which	  can	  be	  described	  by	   influx	  clearance	   into	  brain	  (CLin)	  and	  efflux	  clearance	  from	  brain	  (CLout).	  Included	  in	  these	  measures	  are	  factors	   influencing	  drug	   rate	   of	   transport	   at	  BBB	   such	   as	   transporters	   (influx	   and	  efflux),	  as	  well	  as	  brain	  metabolism	  and	  bulk	  flow	  influence	  on	  CLout	  [11].	  The	  ratio	  of	  CLin	  to	  CLout	  is	  equal	  to	  the	  unbound	  partition	  coefficient,	  Kp,uu,	  which	  is	  defined	  as	  the	  ratio	  of	  unbound	  drug	  concentration	  in	  brain	  extracellular	  fluid	  (ECF)	  to	  that	  in	  blood	  at	   the	   steady	   state.	  Although	  Kp,uu	   is	   related	   to	   the	   ratio	  of	  CLin	   to	  CLout,	   the	  Kp,uu	  value	  reflects	  the	  extent	  of	  unbound	  drug	  concentration	  equilibration	  between	  brain	  and	  blood,	  but	  not	  the	  rate	  with	  which	  a	  drug	  cross	  the	  BBB.	  A	  compound	  with	  low	  lipophilicity	  tends	  to	  have	  a	  low	  permeability	  across	  the	  endothelial	  cells	  of	  the	  BBB.	  The	  measure	  of	  a	  drug	  having	  only	  passive	  transport	  across	  the	  BBB	  is	  that	  the	  transport	  in	  both	  directions	  are	  equal	  (CLin	  =	  CLout),	  making	  Kp,uu	  be	  equal	  to	  unity,	  i.e.	  that	  the	  free	  drug	  concentration	  in	  brain	  ECF	  is	  equal	  to	  that	  in	  blood	  at	  steady	  state.	   Low	   permeable	   drugs	   should	   take	   longer	   to	   achieve	   equilibrium	   status	   in	  brain	  and	  also	  show	  longer	  time	  to	  diffuse	  out	  of	  the	  brain	  compartment	  during	  the	  elimination	  phase.	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If	  atenolol	  is	  a	  typical	  drug	  with	  low	  passive	  permeability	  and	  not	  a	  substrate	  of	  any	  transporter,	  its	  Kp,uu	  is	  expected	  to	  be	  unity	  and	  possibly	  the	  half-­‐life	  of	  atenolol	  in	   brain	   ECF	   to	   be	   slower	   than	   that	   in	   blood.	   However,	   a	   previous	   microdialysis	  study	  of	  atenolol	  in	  rats	  showed	  a	  ratio	  of	  area	  under	  curve	  (AUC)	  of	  unbound	  drug	  concentration-­‐time	  profiles	  in	  brain	  ECF	  to	  AUC	  in	  plasma	  of	  only	  3.8	  ±	  0.6%	  after	  an	  intravenous	  10	  mg	  bolus	  dose	  [12].	  This	  is	  not	  consistent	  with	  the	  expectation	  of	  equal	   unbound	   concentrations	   in	   both	   sides	   of	   the	  BBB,	   given	   the	   limited	  protein	  binding	  of	  atenolol	  in	  plasma.	  	  To	   in-­‐depth	   investigate	   the	   in	   vivo	   net	   flux	   of	   S-­‐atenolol	   BBB	   transport,	   a	  microdialysis	  study	  was	  carried	  out	  to	  evaluate	  Kp,uu	  at	  steady	  state,	  and	  to	  study	  the	  intra-­‐brain	   distribution	   of	   S-­‐atenolol	   by	   assessing	   the	   unbound	   drug	   volume	   of	  distribution	   in	  brain	  (Vu,brain)	  and	  the	  unbound	  drug	   fraction	   in	  brain	  homogenate.	  Modeling	  and	   simulation	  were	  used	   to	  map	   the	  properties	  of	   atenolol	   from	  a	   rate	  and	  extent	  perspective.	  
MATERIALS	  AND	  METHODS	  
Chemicals	  S-­‐atenolol	  and	  atenolol-­‐D7	  were	  purchased	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA).	   Isoflurane	  was	   obtained	   from	   Baxter	  Medical	   AB	   (Kista,	   Sweden).	   All	   other	  chemicals	   were	   of	   analytical	   grade.	   Ringer’s	   solution	   was	   prepared	   to	   perfuse	  microdialysis	   probes	   and	   comprised	   145mM	  NaCl,	   0.6mM	  KCl,	   1.0	  mM	  MgCl2,	   1.2	  mM	  CaCl2,	   and	   0.2	  mM	   ascorbic	   acid	   in	   2	  mM	  phosphate	   buffer	   (pH	   7.4).	   Normal	  saline	  was	   obtained	   from	  Braun	  Medical	  AB	   (Stockholm,	   Sweden),	   and	  water	  was	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purified	   using	   a	  Milli-­‐Q	   system	   (Millipore,	   Bedford,	  MA,	  USA).	   Ammonium	   acetate	  and	  acetonitrile	  were	  purchased	  from	  Merck	  (Darmstadt,	  Germany).	  
Animals	  Male	   Sprague-­‐Dawley	   rats	   (250-­‐310	   g)	   were	   obtained	   from	   Taconic	   (Lille	  Skensved,	   Denmark).	   The	   animals	   were	   acclimated	   for	   one	   week	   before	   the	  experiment	  with	  12-­‐hour	  day-­‐night	  cycle.	  The	  microdialysis	  study	  was	  approved	  by	  the	  Animal	  Ethics	  Committee	  of	  Uppsala	  University,	  Sweden	  (C328/10).	  
Microdialysis	  For	   the	   microdialysis	   study,	   vessel	   catheters	   and	   microdialysis	   probes	   were	  implanted	  in	  rats	  as	  previously	  described.	  Briefly,	  the	  rats	  were	  anesthetized	  using	  2.5%	   isoflurane	   and	   their	   body	   temperature	   were	   maintained	   at	   37°C	   using	  CMA/150	   temperature	   controller	   (CMA,	   Stockholm,	   Sweden)	   throughout	   the	  surgery.	   Firstly,	   a	   catheter	   made	   from	   PE-­‐50	   fused	   with	   silicon	   tubing	   was	  implanted	  into	  the	  femoral	  vein	  for	  S-­‐atenolol	  infusion,	  followed	  by	  the	  insertion	  of	  a	   PE-­‐50	   catheter	   fused	   with	   PE-­‐10	   into	   the	   femoral	   artery	   for	   blood	   sampling.	  Secondly,	  an	  incision	  was	  made	  to	  insert	  a	  CMA/20	  microdialysis	  probe	  with	  10	  mm	  flexible	   polyarylethersulphone	   (PAES)	   membrane	   into	   the	   right	   jugular	   vein	   for	  sampling	   unbound	   S-­‐atenolol	   in	   blood.	   Then,	   the	   head	   of	   the	   rat	   was	   fixed	   on	   a	  stereotaxic	   frame	   and	   a	   guide	   cannula	   was	   implanted	   into	   striatum	   with	   the	  coordinates	  0.8	  mm	  anterior,	  2.7	  mm	  lateral	  to	  the	  bregma,	  and	  3.8	  mm	  ventral	  to	  the	  surface	  of	   the	  skull.	  Dental	   cement	  was	  used	   to	   fix	   the	  guide	  cannula	  onto	   the	  skull	   with	   an	   anchor	   screw.	   The	   tubings	   of	   the	   two	   blood	   catheters	   and	  microdialysis	  probe	  were	  tunneled	  subcutaneously	  and	  fixed	  at	  the	  back	  of	  the	  neck.	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At	   the	  end	  of	   the	   surgery,	   the	  dummy	   inside	   the	  guide	  cannula	  was	   replaced	  by	  a	  CMA/12	  microdialysis	  probe	  with	  a	  3	  mm	  polycarbonate	  membrane	  (20	  kDa	  cutoff)	  for	   sampling	   S-­‐atenolol	   in	   brain.	   The	   rats	   were	   allowed	   to	   recover	   for	   one	   day	  before	   the	  microdialysis	   study	  and	   to	  move	   freely	   in	   a	  CMA	  120	   system	  with	   free	  access	  to	  food	  and	  water.	  As	   shown	   in	   Figure	   C-­‐1,	   the	   rats	  were	   divided	   into	   two	   groups	  with	   different	  dosing	  regimens.	  The	  infusion	  solution	  had	  a	  drug	  concentration	  of	  5	  mg/mL.	  Group	  1	  (n=9)	  received	  S-­‐atenolol	  starting	  with	  a	  fast	  infusion	  at	  0.4	  mg/min/kg	  for	  15	  min	  followed	  by	   a	   slow	   infusion	   of	   0.182	  mg/min/kg	   for	   165	  min	  using	   a	  Harvard	  22	  pump	   (Harvard	   Apparatus	   Inc.,	   Holliston,	   MA,	   U.S.A),	   in	   order	   to	   rapidly	   achieve	  steady	  state	  concentrations	  in	  plasma.	  Samples	  were	  collected	  for	  another	  3	  hr	  after	  the	  end	  of	  drug	   infusion	   in	   four	  rats	   (Group	  1a).	  The	  rats	   in	  Group	  1b	  (n=5)	  were	  decapitated	  at	  the	  end	  of	  the	  infusion	  to	  harvest	  the	  brains	  in	  order	  to	  measure	  the	  total	  S-­‐atenolol	  amount	  in	  brain	  tissue.	  In	  Group	  2	  (n=4),	  S-­‐atenolol	  was	  given	  as	  a	  single	   constant	   infusion	   for	   3	   hr	   at	   a	   rate	   of	   0.167	   mg/min/kg,	   and	   continuing	  sampling	   for	  3	  hr	   thereafter.	   In	  all	   rats,	   the	  microdialysis	  perfusion	  was	  started	  at	  the	  beginning	  of	  the	  stabilization	  period,	  90	  min	  before	  S-­‐atenolol	  dosing.	  Atenolol-­‐D7	   was	   used	   to	   measure	   the	   relative	   recovery	   across	   the	   microdialysis	   probes	  throughout	   the	   study,	   using	   retrodialysis	   by	   drug.	   Atenolol-­‐D7	   was	   added	   to	   the	  Ringer’s	   solution	  at	  50	  ng/mL	   for	  brain	  probe	  and	  at	  200	  ng/mL	   for	  blood	  probe,	  which	   were	   perfused	   through	   the	   microdialysis	   probes	   using	   a	   CMA	   400	   pump	  (CMA,	   Solna,	   Sweden)	   at	   a	   flow	   rate	   of	   1	   µL/min.	   The	   dialysates	   were	   collected	  every	   15	   min	   by	   a	   fraction	   collector	   (CMA	   142,	   Solna,	   Sweden)	   until	   the	   end	   of	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experiment.	  For	  the	  animals	  with	  their	  drug	  elimination	  phase	  monitored,	  100	  µL	  of	  blood	  was	  drawn	  from	  the	  femoral	  artery	  pre-­‐dose	  and	  at	  5,	  10,	  90,	  150,	  185,	  200,	  240,	  and	  360	  min	  after	   the	  start	  of	  S-­‐atenolol	   infusion.	  For	   the	  rats	  decapitated	  at	  the	  end	  of	  drug	  infusion,	  the	  blood	  was	  collected	  pre-­‐dose	  and	  at	  5,	  10,	  30,	  60,	  90,	  120,	  150,	  and	  175	  min.	  All	  blood	  samples	  were	  centrifuged	  at	  7200	  g	   for	  5	  min	  to	  obtain	  plasma,	  which	  together	  with	  brain	  and	  microdialysis	  samples	  were	  frozen	  at	  -­‐20°C	  until	  analysis.	  
Equilibrium	  Dialysis	  The	   unbound	   fraction	   of	   S-­‐atenolol	   in	   brain	   (fu,brain)	   at	   three	   different	   drug	  concentrations	   was	   measured	   in	   vitro	   using	   equilibrium	   dialysis	   of	   brain	  homogenate.	   Briefly,	   Sprague-­‐Dawley	   rats	   were	   decapitated	   under	   isoflurane	  anesthesia	   and	   the	   brains	   were	   collected	   and	   homogenized	   following	   addition	   of	  four	  volumes	  of	  180	  mM	  phosphate	  buffer	  (PBS).	  After	  being	  spiked	  with	  132.5,	  265,	  and	  1325	  ng/mL	  S-­‐atenolol	  (corresponding	  to	  0.5,	  1,	  5	  µM),	  respectively,	  150	  µL	  of	  the	  blank	  homogenate	  was	  dialyzed	  against	  PBS	  pH	  7.4	  for	  6	  h	  using	  a	  Pierce	  Rapid	  Equilibrium	   Dialysis	   Device	   (RED)	   (Thermo	   Scientific,	   Rockford,	   IL,	   USA)	   (n=5	   of	  each	   concentration).	   Equilibrium	  dialysis	  was	   immediately	   started	  with	   a	   shaking	  speed	  of	  200	  rpm	  at	  37°C	  (MaxQ4450,	  Thermo	  Fisher	  Scientific,	  Nino	  Lab,	  Sweden).	  Samples	  were	   collected	   from	  both	   buffer	   and	   homogenate	   sides	   at	   the	   end	   of	   the	  incubation	   period	   of	   6	   h.	   The	   stability	   of	   S-­‐atenolol	   in	   brain	   homogenate	   was	  evaluated	   by	   incubating	   homogenate	   containing	   the	   drug	   at	   the	   three	  concentrations	  and	  collecting	  samples	  before	  and	  after	   the	   incubation.	   In	  order	   to	  obtain	   the	   same	  matrix	   for	   all	   samples	   in	   the	   chemical	   assay,	   the	   same	  volume	  of	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buffer	  was	   added	   to	   brain	   homogenate	   samples	   and	   vice	   versa.	   All	   samples	  were	  stored	   at	   -­‐20°C	   until	   assay.	   The	   unbound	   fraction	   of	   S-­‐atenolol	   in	   diluted	   brain	  homogenate	  (fu,hD)	  was	  calculated	  from	  the	  buffer/homogenate	  concentration	  ratio	  as:	   𝑓!,!! = !!"##$%!!!"!#$%&'$     Eq(1) The	   unbound	   fraction	   of	   S-­‐atenolol	   in	   brain	  was	   calculated	   according	   to	   Eq	   2	  after	   correction	   for	   the	   dilution	   factor	  D	   associated	  with	   the	   preparation	   of	   brain	  homogenate	  (D=5	  in	  this	  study):	  𝑓!,!"#$% = !!!! !!!,!!!!      Eq(2) 
Chemical	  Analysis	  Liquid	   chromatography	   coupled	  with	   tandem	  mass	   spectrometry	   (LC-­‐MS/MS)	  was	   used	   to	   determine	   the	   concentrations	   of	   S-­‐atenolol	   and	   atenolol-­‐D7	   in	   the	  microdialysis	   samples.	   Five	   µL	   of	   the	   brain	   microdialysis	   samples	   were	   directly	  injected.	  The	  blood	  dialysate	  samples	  (15	  µL)	  having	  high	  drug	  concentrations	  were	  diluted	  by	  adding	  150	  µL	  Ringer’s	   solution	  before	  analysis.	  After	   thawing	   to	   room	  temperature,	  the	  plasma	  samples	  were	  precipitated	  at	  a	  ratio	  of	  1:3	  with	  acetonitrile	  containing	   500	   ng/mL	   atenolol-­‐D7	   as	   internal	   standard.	   Following	   vortexing	   and	  centrifugation	  for	  3	  min	  at	  7200	  g,	  25	  µL	  of	  the	  supernatant	  was	  further	  diluted	  by	  mixing	  it	  with	  1	  mL	  of	  5	  mM	  ammonium	  acetate	  solution	  and	  then	  injecting	  10	  µL	  of	  the	  mixture	  into	  the	  LC-­‐MS/MS.	  The	  brain	  samples	  were	  homogenized	  with	  a	  tissue-­‐saline	   ratio	   of	   1:4	   (w/v),	   prepared	   as	   described	   above.	   Then	   150	   µL	   of	   the	  homogenate	  was	  mixed	  with	  150	  µL	  of	  50	  ng/mL	  atenolol-­‐D7	  aqueous	  solution,	  and	  further	  precipitated	  with	  150	  µL	  acetonitrile.	  After	  3-­‐min	  centrifugation	  at	  7200	  g,	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the	  supernatant	  was	  diluted	  10-­‐fold	  with	  5	  mM	  ammonium	  acetate,	  injecting	  50	  µL.	  The	  homogenate	   samples	   from	  equilibrium	  dialysis	  were	  prepared	  with	   the	   same	  procedures	  as	  above.	  Standard	  curves	  and	  quality	  control	  samples	  with	  the	  different	  matrices	  were	  prepared	  and	  measured	   together	  with	   the	   samples	   to	  quantify	   and	  validate	  drug	  concentrations.	  The	   LC-­‐MS/MS	   system	   consisted	   of	   two	   Shimadzu	   LC-­‐10ADvp	   pumps	  (Shimadzu,	   Kyoto,	   Japan),	   a	   SIL-­‐HTc	   autosampler	   (Shimadzu,	   Kyoto,	   Japan),	   and	   a	  Quattro	   Ultima	   mass	   spectrometer	   (Waters,	   Milford,	   MA,	   USA).	   A	   HyPurity	   C18	  column	   (50*4.6	   mm,	   3	   µm	   particle	   size),	   equipped	   with	   a	   HyPurity	   C18	   guard	  column	   (10*4.0	  mm,	   3	   µm	   particle	   size,	   Thermo	   Scientific	   Hypersil-­‐Keystone,	   PA,	  USA),	  was	   used	   for	   chromatographic	   separation	  with	   a	   gradient	   elution	   involving	  mobile	  phase	  A	  (5	  mM	  ammonium	  acetate	  in	  water)	  and	  mobile	  phase	  B	  (90:10	  v/v	  acetonitrile:water).	   The	   flow	   rate	   was	   set	   to	   0.8	   mL/min,	   which	   was	   split	   to	   0.3	  mL/min	   before	   entering	   the	   mass	   spectrometer,	   where	   positive	   electrospray	  ionization	   (ESI+)	   was	   applied.	   The	   transition	   mode	   was	   m/z	   266.9→145	   for	   S-­‐atenolol	   and	  m/z	   273.8→145	   for	   atenolol-­‐D7.	   All	   chromatographs	   were	   acquired	  and	  analyzed	  using	  Masslynx	  4.0	  (Waters,	  Milford,	  MA,	  USA).	  	  
Calculations	  and	  Pharmacokinetic	  Data	  Analysis	  The	  relative	  recovery	  of	  S-­‐atenolol	  for	  each	  microdialysis	  probe	  was	  evaluated	  using	  retrodialysis	  with	  atenolol-­‐D7	  as	  a	  calibrator	  according	  to	  𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = !!",!"#!!!!"#,!"#!!!",!"#!     Eq(3) where	   Cin,ATD7	  and	   Cout,ATD7	  are	   the	   concentrations	   of	   atenolol-­‐D7	   in	   perfusate	   and	  dialysate,	   respectively.	   The	   relative	   recovery	   simultaneously	   determined	   by	   the	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retrodialysis	  of	  atenolol-­‐D7	  was	  6.94	  ±	  0.67%	  for	  the	  microdialysis	  probes	  in	  brain	  and	  50.1	  ±	  1.9%	  for	  the	  probes	  in	  blood.	  The	  unbound	  concentration	  of	  S-­‐atenolol	  in	  brain	   ECF	   was	   calculated	   by	   dividing	   the	   measured	   S-­‐atenolol	   concentration	   in	  dialysate	  by	  the	  relative	  recovery.	  The	   unbound	   partition	   coefficient,	   Kp,uu,	   was	   calculated	   to	   characterize	   the	  extent	  of	  S-­‐atenolol	  equilibration	  across	  the	  BBB	  as:	  𝐾!,!! = !!,!!,!"#$%&'(!!,!!,!"##$     Eq(4) where	   Cu,ss,brainECF	  and	   Cu,ss,blood	  are	   the	   unbound	   drug	   concentrations	   in	   brain	   ECF	  and	  blood	  at	  steady	  state,	  respectively.	  The	   half-­‐lives	   in	   brain	   ECF	   and	   blood,	   t1/2,brainECF	  and	   t1/2,blood,	   were	   calculated	  based	   on	   microdialysis	   data	   from	   the	   elimination	   phase	   and	   the	   corresponding	  middle	  time	  points	  of	  microdialysis	  collection	  intervals:	  𝑡!/! = !.!"#!!       Eq(5) where	   λz	   is	   the	   terminal	   rate	   constant	   obtained	   from	   the	   last	   seven	   observations.	  The	  half-­‐lives	  of	  unbound	  S-­‐atenolol	   in	  brain	  ECF	  and	  blood	  were	  compared	  using	  paired	  t-­‐test.	  A	  pharmacokinetic	  model	  was	  developed	  using	  nonlinear	  mixed	  effect	  modeling	  (NONMEM,	   version	   7.3.0,	   ICON	   Development	   Solutions,	   Ellicott	   City,	   MD,	   US)	   to	  describe	  the	  rate	  of	  S-­‐atenolol	  transport	  across	  the	  BBB,	  via	  the	  influx	  clearance	  into	  the	  brain	  (CLin)	  and	  the	  efflux	  clearance	  from	  the	  brain	  (CLout).	  The	  method	  of	  first	  order	  conditional	  estimation	  with	  interaction	  (FOCEI)	  was	  used	  for	  modeling	  fitting.	  The	  interindividual	  variability	  was	  investigated	  for	  all	  pharmacokinetic	  parameters	  during	  the	  model	  development	  using	  an	  exponential	  model:	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𝑃! = 𝑃!"!𝑒!!     Eq(6) where	  Pi	  is	  the	  value	  of	  the	  parameter	  for	  the	  i-­‐th	  individual,	  while	  Ppop	  is	  the	  typical	  value	   of	   the	   parameter	   in	   the	   population.	   The	   interindividual	   variability	   was	  described	  by	  η,	  which	  was	  assumed	  to	  follow	  a	  normal	  distribution	  with	  a	  mean	  at	  0	  and	   standard	   deviation	   ω.	   In	   addition,	   different	   error	   models	   (proportional,	  additive,	  and	  slope-­‐intercept	  error	  models)	  were	  explored	  to	  evaluate	  the	  residual	  variability,	   i.e.	   the	   difference	   between	   predicted	   and	   observed	   concentrations,	   for	  each	  type	  of	  observations.	  	  The	  model	   selection	  was	   based	   on	   the	   objective	   function	   value	   (OFV),	  model	  parameter	   precision	   and	   graphical	   analysis.	   The	   likelihood	   ratio	   test	  was	   used	   to	  compare	   between	   nested	  models.	   Specifically,	   the	   difference	   in	   OFV	   between	   two	  nested	  models	   asymptotically	   follows	   χ2	   distribution,	   and	   a	   drop	   in	  OFV	  of	   ≥3.84	  indicates	   the	   superiority	   of	   the	   model	   for	   one-­‐parameter	   difference	   with	   p≤0.05.	  The	   parameter	   precision	   was	   described	   by	   relative	   standard	   error,	   RSE%,	   which	  was	  calculated	  as	  the	  standard	  error	  (S.E.)	  divided	  by	  the	  parameter	  estimate.	  The	  graphical	  analyses	  were	  performed	  using	  PsN	  (version	  4.4.0)	  and	  Xpose	  4	  (version	  4.5.3)	  together	  with	  R	  (version	  3.3.1).	  The	   previously	   developed	   integrated	   blood-­‐brain	   pharmacokinetic	   model	   for	  oxymorphone,	   oxycodone,	   and	   DAMGO	  was	   used	   in	   this	   study,	   with	  modification	  based	  on	  the	  data	   from	  the	  microdialysis	  study	  of	  S-­‐atenolol	   [13-­‐15].	  All	  observed	  data	  of	  S-­‐atenolol	  were	  included	  in	  the	  model	  comprising	  total	  plasma	  concentration	  in	   arterial	   blood,	   unbound	   concentration	   in	   venous	   blood	   from	   microdialysis	  sampling	   in	   jugular	   vein,	   and	   unbound	   concentration	   in	   brain	   ECF	   from	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microdialysis	   sampling	   in	   right	   striatum	   (Figure	   C-­‐2).	   The	   model	   also	   took	   into	  account	   the	   relative	   recovery	   by	   including	   the	   concentrations	   of	   the	   calibrator	  atenolol-­‐D7	  in	  dialysate	  from	  both	  probes.	  	  The	  model	  development	  started	  from	  building	  a	  plasma	  PK	  model,	  followed	  by	  additions	  of	  the	  other	  compartments	  in	  steps.	  The	  final	  model	  was	  determined	  with	  all	   data	   fitted	   simultaneously.	   In	   the	  model,	   the	   central	   compartment	  was	  divided	  into	   two	   compartments,	   an	   arterial	   compartment	   for	   plasma	   concentration	   and	   a	  venous	   compartment	   for	   microdialysis	   sampling.	   The	   two	   compartments	   were	  assumed	   to	   have	   equal	   unbound	   volume	   of	   distribution,	   that	   is,	   VA=VV.	   The	  transport	  of	  S-­‐atenolol	  across	   the	  BBB	  was	  parameterized	  by	  CLin	  and	  Kp,uu,	  which	  were	  assessed	  according	  to:	   𝐶𝐿!" = 𝑘!" ∙ 𝑉𝐴     Eq(7) 𝐾!,!! = !"!"!"!"#     Eq(8) 𝐶𝐿!"# = 𝑘!"# ∙ 𝑉!,!"#$%     Eq(9) where	  kin	  and	  kout	  denote	  the	  rate	  constants	  between	  the	  arterial	  compartment	  and	  the	  brain	  compartment.	  Vu,brain	  is	  the	  unbound	  volume	  of	  distribution	  in	  brain	  (mL/g	  brain),	   reflecting	   the	  drug	  distribution	  within	  brain	  parenchyma	  since	   it	  describes	  the	   relationship	   between	   the	   total	   drug	   amount	   in	   brain	   and	   the	   unbound	   drug	  concentration	  in	  brain	  ECF:	   𝑉!,!"#$! = !!"#$%!!!×!!"×!!"!!!!,!"#     Eq(10) where	   Abrain	   is	   the	   measured	   drug	   amount	   in	   brain	   and	   and	   Cp	   is	   the	   plasma	  concentration	  at	  the	  end	  of	  infusion.	  The	  volume	  of	  vascular	  space	  in	  rat	  brain	  (Vbl)	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is	  0.014	  mL/g	  brain	  [16].	  The	  blood-­‐to-­‐plasma	  concentration	  ratio	  of	  atenolol	  (Rbl-­‐p)	  is	  reported	  as	  1.07	  [17].	  All	  data	  are	  expressed	  as	  mean	  ±	  SEM	  in	  this	  report.	  All	  the	  plots	  were	  prepared	  using	   GraphPad	   Prism	   v5.04	   (GraphPad	   Software	   Inc.,	   San	   Diego,	   CA),	  which	  was	  also	  used	  for	  all	  statistical	  analysis.	  
RESULTS	  
Microdialysis	  study	  The	   unbound	   S-­‐atenolol	   concentrations	   in	   blood	   quickly	   increased	   during	   the	  15-­‐min	   fast	   infusion	   and	   was	   maintained	   at	   steady	   state	   (Cu,ss,blood)	   during	   the	  following	  165-­‐min	  slow	  infusion	  (Figure	  C-­‐3A).	  The	  concentrations	  in	  plasma	  were	  comparable	   to	   the	   unbound	   S-­‐atenolol	   concentration	   in	   blood,	   indicating	   a	   high	  unbound	  fraction	  in	  plasma	  (fu,p).	  Similarly,	  the	  steady-­‐state	  unbound	  concentration	  of	  S-­‐atenolol	   in	  brain	  ECF	  were	  quickly	  achieved	  after	   the	   the	   fast	   infusion	  and	   its	  concentration-­‐time	   profile	   during	   elimination	   phase	   exhibited	   a	   similar	   decrease	  shape	  to	  that	  in	  blood.	  However,	  the	  S-­‐atenolol	  in	  brain	  ECF	  exhibited	  a	  much	  lower	  level	   than	   that	   in	   blood	   throughout	   the	   whole	   experiment.	   Specifically,	   the	   S-­‐atenolol	  steady-­‐state	  concentration	  in	  blood	  calculated	  from	  90-­‐180	  min	  was	  4429	  ±	  94	  ng/mL,	  nearly	  30	  folds	  of	  that	  in	  brain	  ECF	  (158	  ±	  20	  ng/mL).	  The	  ratio	  of	  Cu,brain	  to	  Cu,blood	  was	  plotted	  versus	  time	  in	  Figure	  C-­‐4.	  It	  is	  seen	  that	  the	  Cu,brain/Cu,blood	  was	  relatively	   steady	   along	   the	   time	   during	   not	   only	   the	   infusion	   period	   but	   also	   the	  elimination	   phase.	   The	   unbound	   partition	   coefficient	   (Kp,uu)	   was	   determined	   as	  3.55%	  ±	   0.40%	  based	   on	   Cu,ss,brainECF	   and	   Cu,ss,blood	  from	   the	   steady	   state	   at	   90-­‐180	  min.	  It	  is	  also	  found	  that	  the	  Cu,brainECF/Cu,blood	  at	  the	  first	  time	  point	  was	  abnormally	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high,	  which	  was	  probably	  resulted	  from	  the	  difference	  in	  the	  dead	  volumes	  between	  brain	   probe	   and	   blood	   probe,	   i.e.	   the	   dialysate	   from	   the	   brain	   probe	   flowed	   out	  earlier	  than	  the	  blood	  probe.	  This	  discrepancy	  was	  likely	  to	  affect	  the	  observations	  notably	  only	  when	  the	  tissue	  concentration	  changes	  quickly	  within	  a	  short	  time,	  e.g.	  right	  after	  the	  start	  of	  the	  infusion.	  The	  Vu,brain	  of	  S-­‐atenolol	  was	  0.686	  ±	  0.104	  mL/g	  brain,	  which	  was	  not	  significantly	  different	  from	  the	  brain	  water	  volume	  (0.8	  mL/g	  brain)	   (p=0.137),	   suggesting	   even	   distribution	   in	   brain	   tissue,	   i.e.	   similar	   drug	  concentration	   in	   brain	   ECF	   and	   intracellular	   fluid	   (ICF).	   Figure	   C-­‐3B	   shows	   the	  concentration-­‐time	  profile	  of	  atenolol	  in	  Group	  2	  without	  the	  initial	  fast	  infusion	  but	  only	   with	   3-­‐hour	   constant	   i.v.	   infusion	   at	   0.167	   mg/min/kg.	   It	   is	   seen	   that	   the	  atenolol	   level	   gradually	   increased	   during	   the	   infusion	   in	   blood	   and	   brain	   ECF	   to	  4127	  ±	  103	  ng/mL	  and	  256	  ±	  41	  ng/mL	  at	   the	   last	   time	  point	  before	   the	   infusion	  termination	   (microdialysis	   samples	   from	  165	  –	  180	  min),	   respectively.	  During	   the	  elimination	   phase,	   for	   both	   groups,	   the	   S-­‐atenolol	   concentration	   in	   brain	   ECF	  decreased	  in	  a	  similar	  extent	  to	  the	  decrease	  of	  drug	  concentration	  in	  blood,	  which	  was	   further	   confirmed	   by	   the	   insignificant	   difference	   between	   the	   terminal	   half-­‐lives	  in	  the	  brain	  ECF	  and	  blood	  (82	  ±	  7	  min	  vs	  85	  ±	  10	  min	  ,	  p=0.325	  from	  paired	  t-­‐test).	  
Equilibrium	  dialysis	  From	  the	  equilibrium	  dialysis	  of	  brain	  homogenates,	  it	  was	  found	  that	  the	  fu,brain	  of	   S-­‐atenolol	  was	  0.74	  ±	  0.04,	   0.80	  ±	  0.04,	   and	  1.09	  ±0.15	   at	   0.5,	   1.0,	   and	  5.0	  µM,	  respectively.	  There	  was	  no	  significant	  difference	  among	  the	  three	  S-­‐atenolol	   levels	  with	  p=0.0833	  from	  one-­‐way	  ANOVA	  analysis.	  The	  average	  fu,brain	  from	  all	  the	  three	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groups	   was	   0.88	   ±	   0.07,	   comparable	   with	   a	   previously	   reported	   value	   of	   0.90	   ±	  0.052	   [18],	   indicating	   very	   limited	   binding	   in	   brain	   homogenate,	   in	   line	   with	   the	  Vu,brain	  estimates	  presented	  above.	  S-­‐atenolol	  was	  very	  stable	   in	  brain	  homogenate	  with	  zero	  degradation	  during	  the	  6	  hr	  incubation	  at	  37°C	  .	  
PK	  modeling	  To	   be	   able	   to	   calculate	   the	   permeability	   clearance	   values,	   and	   to	   better	  understand	   the	  kinetics	  of	  S-­‐atenolol	   transport	  at	   the	  BBB,	  a	  pharmacokinetic	  and	  brain	   distribution	   model	   was	   developed	   based	   on	   the	   microdialysis	   data.	   The	  individual	   plots	   in	   Figure	   C-­‐5	   show	   observations,	   individual	   predictions	   and	  population	  predictions	  of	  S-­‐atenolol	  in	  plasma,	  blood	  dialysate,	  and	  brain	  dialysate.	  It	  can	  be	  observed	  that	  there	  was	  a	  noticeable	  discrepancy	  between	  population	  and	  individual	   profiles	   for	   some	   individuals	   (e.g.	   ID	   11	   in	   brain	   dialysate),	  which	  may	  explain	  the	  large	  inter-­‐individual	  variation	  for	  some	  parameters	  (Table	  1).	  However,	  the	  model	   is	   appropriate	   in	   describing	   S-­‐atenolol	   distribution	   in	   blood	   and	   brain,	  given	   the	   close	  median	   lines	   of	   real	   data	   and	  model-­‐based	   simulation	   data	   in	   the	  visual	   predictive	   check	   based	   on	   200	   simulations	   (Figure	   C-­‐6).	   The	   relative	  recoveries	   estimated	   from	   the	   model	   are	   comparable	   to	   the	   values	   calculated	  directly	   from	  Eq	  1,	  and	  the	  model-­‐estimated	  Kp,uu	  of	  0.04	  is	  also	  comparable	  to	  the	  value	   of	   0.0355	   from	   Eq	   4.	   CLin	   is	   estimated	   as	   17.0	   µL/min/g	   brain,	   and	   the	  resultant	  CLout	  is	  approximately	  425	  µL/min/g	  brain	  based	  on	  the	  definition	  of	  Kp,uu,	  as	  the	  ratio	  of	  CLin	  to	  CLout.	  	  	  
	  	   183	  
DISCUSSION	  The	   permeability	   of	   compounds	   across	   biological	   barriers	   (e.g.	   intestinal	  epithelial	   cells	   and	   the	   endothelial	   cells	   at	   the	  BBB)	  has	  been	   studied	   for	  decades	  because	  of	  its	  close	  relationship	  with	  substance	  absorption	  and	  distribution,	  which	  is	   important	   to	   understand	   and	   predict	   their	   therapeutic	   effects	   and	   toxicity.	   The	  physicochemical	   properties,	   specifically	   lipophilicity	   and	   molecular	   weight,	   are	  important	   factors	  determining	   the	  pathways	  and	  rate	   for	  compounds	   to	  pass	  over	  biological	   barrier	   [19,	   20].	   Generally,	   small	   lipophilic	   drug	   tends	   to	   have	   high	  permeability	   across	   biological	   membranes,	   while	   hydrophilic	   compounds	   have	  lower	   rate	   to	   diffuse	   across	   lipid	   membrane,	   thus	   more	   likely	   to	   take	   the	  paracellular	  aqueous	  pathway	  to	  cross	  the	  barrier.	  However,	  tight	  junctions	  formed	  between	  adjacent	  cells	  at	  some	  barriers,	   represented	  by	   the	  BBB,	  severely	  restrict	  the	   passive	   diffusion	   of	   hydrophilic	   molecules	   via	   the	   paracelluar	   route,	   thus	  resulting	  in	  very	  low	  permeabilities	  [21].	  For	  years,	  a	  series	  of	  substances	  have	  been	  used	  to	  study	  the	  relationship	  between	  drug	  lipophilicity	  and	  permeability.	  Among	  these,	   beta	   blockers	   have	   received	   special	   attention	   due	   to	   their	   highly	   variable	  lipophilicity	  and	  accordingly	  diverse	  pharmacokinetic	  properties	  with	  a	  large	  range	  of	  pharmacokinetic	  parameters	  (10%	  to	  90%	  bioavailability;	  1	  hr	  up	  to	  24	  hr	  half-­‐lives;	  and	  5%	  to	  90%	  protein	  binding	   in	  plasma)	  [22].	  With	  LogP	  of	  3.65	  and	  0.23	  [2],	  propranolol	  and	  atenolol	  are	  the	  lipophilic	  and	  hydrophilic	  extremes	  of	  the	  beta	  blocker	  class,	  respectively,	  thus	  having	  been	  widely	  used	  in	  the	  studies	  of	  intestinal	  absorption	   and	   BBB	   penetration	   [10,	   23].	   In	   order	   to	   study	   and	   predict	   the	   drug	  permeability	   across	   biological	   barriers,	   substantial	   efforts	   have	   been	   made	   to	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develop	   a	   variety	   of	   models,	   e.g	   the	   in	   vitro	   Caco-­‐2	   cell	   model	   for	   intestinal	  absorption	   and	   brain	   capillary	   endothelial	   cell	   model	   for	   the	   BBB	   transport.	   To	  evaluate	   and	   characterize	   these	   models,	   propranolol	   and	   atenolol	   are	   commonly	  used	  as	  model	  drugs	  for	  lipophilic	  and	  hydrophilic	  passive	  diffusion,	  respectively	  [9,	  24,	  25].	  	  In	  addition	  to	  passive	  diffusion,	  carrier-­‐mediated	  transport	  also	  plays	  a	  critical	  role	  in	  drug	  transport	  across	  biological	  barriers.	  Some	  carriers,	  or	  transporters,	  are	  called	   active	   tranporters	   that	   are	   able	   to	   transport	   compounds	   against	  concentration	  gradient	  unidirectionally	  depending	  on	  the	   locations	  of	   transporters	  (luminal	  or	  abluminal	  membrane	  of	  the	  barriers)	  and	  their	  transport	  directions	  (out	  of	   or	   into	   barrier	   cells,	   i.e.	   epithelial	   and	   endothelial	   cells)	   [19,	   26,	   27].	   Some	  transporters	  play	  an	  important	  role	  in	  increasing	  uptake	  efficiency	  of	  nutrients	  like	  Peptide	  Transporter	  1	  (PEPT1)	  uptake	  function	  in	  small	   intestines	  [28]	  and	  L-­‐type	  amino	  acid	   transporter	  1	   (LAT1)	   in	  brain	   [7].	  While	   some	   transporters	   serve	  as	   a	  protection	   mechanism	   by	   removing	   xenobiotics	   and	   wastes	   from	   the	   body	   and	  important	   organs,	   like	   the	   well-­‐known	   P-­‐glycoprotein	   (P-­‐gp)	   [29].	   Due	   to	   the	  importance	  of	  transporters,	  the	  function	  of	  transporters	  is	  usually	  evaluated	  in	  the	  study	  of	  drug	  permeability	  across	  biological	  membrane	  in	  various	  in	  vivo,	  in	  situ,	  and	  
in	   vitro	   models.	   However,	   atenolol	   is	   still	   used	   as	   a	   model	   drug	   for	   low	  passive/paracellular	   diffusion	   in	   the	   permeability-­‐related	   studies	   without	   further	  systematic	  assessment	  of	  the	  possibility	  of	  being	  a	  transporter	  substrate.	  	  Substantial	   amount	   of	   transporters	   with	   different	   distribution	   and	   function	  have	   been	   discovered	   and	   characterized,	   resulting	   in	   a	   considerable	  work	   load	   to	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assess	   atenolol	   as	   a	   substrate	   for	   those	   transporters	   without	   mentioning	  transporters	  yet	  undiscovered.	  Alternately,	  the	  current	  study	  evaluated	  the	  kinetics	  of	   atenolol	   penetration	   into	   the	   brain	   to	   estimate	   whether	   there	   was	   any	  transporter	   participating	   in	   the	   atenolol	   transport	   across	   the	   BBB.	   The	   rate	   and	  extent	  of	  drug	  transport	  across	  the	  BBB	  are	  two	  important	  aspects	  related	  to	  brain	  penetration	   that	   should	   be	   clearly	   distinguished	   [11].	   To	   better	   illustrate	   the	  difference	   between	   rate	   and	   extent	   concepts,	   a	   series	   of	   simulations	   were	  performed	  for	  drug	  transport	  in	  the	  brain	  as	  shown	  as	  in	  Figure	  C-­‐7.	  Drug	  transport	  rate	   can	   be	   described	   by	   permeability	   clearance	   including	   influx	   and	   efflux	  clearance,	   i.e.	   CLin	   and	   CLout.	   The	   extent	   of	   drug	   distribution	   in	   brain	   ECF	   is	  represented	  by	  unbound	  partition	  coefficient,	  i.e.	  Kp,uu.	  For	  drugs	  with	  only	  passive	  diffusion	   that	   is	   driven	   by	   the	   concentration	   gradient	   at	   the	   BBB,	   CLin	   is	   equal	   to	  CLout	   no	   matter	   of	   low	   or	   high	   permeability,	   leading	   to	   the	   same	   unbound	  concentrations	  in	  the	  two	  sides	  of	  the	  BBB	  at	  the	  steady-­‐state	  (i.e.	  Kp,uu=1,	  Figure	  C-­‐7B,	   7C).	  With	   an	   involvement	   of	   transporters,	   CLin	   and	  CLout	   have	  different	   values	  due	   to	   the	   unidirectional	   property	   of	   active	   carrier-­‐mediated	   transport	   (not	  considering	   the	   scenario	   of	   equivalent	   counteractive	   function	   levels	   of	   influx	   and	  efflux	  transporters).	  Accordingly,	  unbound	  drug	  concentration	  is	  higher	  in	  the	  brain	  ECF	   than	   in	  blood	   (i.e.	  Kp,uu	  >1)	   for	   existence	  of	   influx	   transporters	   (CLin>CLout)	   as	  shown	   in	  Figure	  C-­‐7F	  and	  7G,	   and	  vice	  versa	   for	   efflux	   transporters	   (Figure	  C-­‐7D,	  7E).	  In	  all	  the	  situations,	  the	  absolute	  values	  of	  CLin	  and	  CLout	  affects	  the	  time	  of	  drug	  concentration	  in	  brain	  ECF	  reaching	  steady	  state	  during	  infusion	  as	  well	  as	  dropping	  to	   zero	   during	   elimination	   phase	   (i.e.	   non	   steady-­‐state	   phase).	   While	   the	   steady-­‐
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state	  drug	  concentration	  in	  brain	  ECF	  only	  depends	  on	  Kp,uu,	  which	  is	  determined	  by	  the	  ratio	  of	  CLin	  to	  CLout.	  It	   is	  also	  noted	  that	  the	  pharmacokinetic	  profiles	  in	  blood	  show	   two-­‐compartermental	   pharmacokinetic	   profiles	   for	   low	   CLin	   and	   CLout	  situations	  with	   the	   terminal	   elimination	   rate	   limited	   by	   the	   transport	   across	   bthe	  BBB	  (Figure	  C-­‐7B,	  7D,	  and	  7F).	  While	  the	  eliminate	  rates	  in	  brain	  ECF	  is	  the	  same	  as	  in	  blood	  for	  throughout	  elimination	  phases	  for	  high	  CLin	  and	  CLout	  (Figure	  C-­‐7C,	  7E,	  and	  7G).	  If	  atenolol	  is	  a	  hydrophilic	  drug	  without	  any	  involvement	  of	  transporters,	  it	  is	   supposed	   to	  have	   the	  profiles	  of	   low-­‐permeability	  passive	  diffusion	   in	  Figure	  C-­‐7B.	  However,	   the	  present	  microdialysis	   study	   showed	  an	  obvious	  different	  profile	  with	  the	  atenolol	  Kp,uu	  much	  lower	  than	  unity	  (3.55	  ±	  0.40	  %)	  measured	  from	  steady	  state,	   comparable	   with	   3.8	   ±	   0.6%	   of	   the	   AUC	   ratio	   of	   brain	   ECF	   to	   blood	   from	  previous	  microdialysis	   study	  with	   intravenous	  bolus	  dose	   [12].	   In	  addition,	  unlike	  the	   concentration-­‐time	   profiles	   of	   low-­‐permeability	   compound,	   the	   atenolol	  concentration	   in	   brain	   ECF	   during	   the	   elimination	   phase	   decreased	   at	   the	  comparable	  rate	  (t1/2:	  82	  ±	  7	  min	  for	  brain	  ECF	  and	  85	  ±	  10	  min	  for	  blood),	  so	  that	  the	   brain-­‐blood	   concentration	   ratio	   kept	   relatively	   constant	   during	   the	   whole	  experiment	   (Figure	   C-­‐7E).	   The	   above	   divergences	   suggest	   that	   efflux	   transporters	  are	  involved	  in	  the	  atenolol	  transport	  at	  the	  BBB,	  leading	  to	  a	  higher	  CLout	  than	  CLin.	  From	  the	  modeling	  approach,	  the	  CLin	  value	  of	  atenolol	  on	  rats	  was	  17.0	  µL/min/g	  brain,	  much	  lower	  than	  CLout	  of	  425	  µL/min/g	  brain.	  Although	  atenolol	  is	  the	  least	  lipophilic	  drug	  among	  beta	  blocker	  family	  with	  LogP	  of	  0.23,	  there	  are	  other	  drugs	  with	   lower	   and	   negative	   logP,	   e.g.	   M3G	   (LogP	   -­‐1.1),	   M6G	   (LogP	   -­‐0.76),	   acyclovir	  (LogP	  -­‐1.80),	  and	  amoxicillin	  (LogP	  -­‐1.71)	  [30].	  That	  may	  explain	  to	  some	  extent	  the	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influx	  clearance	  of	  atenolol	  is	  higher	  than	  M6G	  and	  M3G	  (1.66	  µL/min/g	  brain	  and	  0.11	  µL/min/g	  brain,	   respectively)	   [31,	  32].	  Considering	   the	  values	  obtained	   from	  the	  model	  and	  the	  comparison	  of	  atenolol	   to	  some	  other	  drugs	   in	   lipophilicity	  and	  CLin,	  it	  is	  concluded	  that	  efflux	  transporters	  are	  the	  only	  explanation	  to	  contribute	  to	  the	   high	   CLout	  of	   S-­‐atenolol,	   though	   it	   is	   hard	   to	   conclude	   on	   the	   effects	   of	   efflux	  transporter	  on	  CLin.	  	  Brain	   ECF	   bulk	   flow	   and	   metabolism	   may	   also	   contribute	   to	   discrepancies	  between	  CLin	  and	  CLout.	  Atenolol	  was	  found	  to	  be	  very	  stable	  in	  brain	  homogenates,	  thereby	   concluding	   that	  metabolism	   is	   not	   of	   importance.	   The	   relatively	   low	  bulk	  flow	  reported	  in	  rats	  of	  0.1-­‐0.3	  µL/min/g	  brain	  [33,	  34]	  is	  also	  of	  minor	  importance	  considering	  the	  estimation	  of	  CLin	  to	  17	  µL/min/g	  brain.	  	  In	   addition	   to	   Kp,uu	   that	   is	   related	   to	   drug	   transport	   at	   the	   BBB,	   Vu,brain	   is	   an	  important	  measure	  to	  understand	  drug	  distribution	  within	  the	  brain,	  describing	  the	  intra-­‐brain	   distribution	   [11].	   If	   drug	   is	   evenly	   distributed	   within	   the	   brain	  parenchymal	   fluid,	   Vu,brain	  is	   close	   to	   the	  water	   volume	   of	   brain	   (0.8	  mL/g	   brain),	  which	  was	  the	  case	  for	  S-­‐atenolol	  in	  this	  study.	  If	  drug	  is	  mainly	  is	  distributed	  inside	  brain	  cells	  or	  bound	  to	  brain	   tissues,	  Vu,brain	  tend	  to	  be	   larger	   than	  0.8	  mL/g	  brain.	  Vu,brain	   and	   fu,brain	   are	   two	   ways	   of	   describing	   distribution	   and	   binding	   within	   the	  brain,	  where	   fu,brain	  only	   describes	   binding	  while	  Vu,brain	  also	  describes	   intracellular	  distribution	  due	  to	  other	  reasons	  (e.g.	  brain	  cell	  membrane	  transporter).	  Similar	  to	  the	   nonspecific	   protein	   binding	   in	   plasma,	   hydrophilic	   drug	   generally	   have	   low	  binding	  in	  brain	  homogenate.	  From	  the	  equilibrium	  dialysis	  of	  brain	  homogenates,	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atenolol	   had	   an	   fu,brain	   of	   0.90	   ±	   0.052.	   In	   contrast,	   propranolol	   has	   extensive	  nonspecific	  binding	  in	  brain	  homogenate	  with	  fu,brain	  of	  0.029	  [18].	  	  It	  should	  be	  noted	  that	  it	  is	  the	  unbound	  free	  drug	  rather	  than	  the	  bound	  drug	  that	   directly	   interacts	   with	   pharmacological	   targets.	   As	   a	   result,	   unbound	   drug	  concentration	   is	   more	   relevant	   to	   drug	   therapeutic	   effect	   instead	   of	   total	   drug	  amount	   in	   brain.	   In	   addition	   to	   nonspecific	   protein	   binding,	   transporters	   at	   brain	  cells	  may	  also	  have	  an	  impact	  on	  intrabrain	  distribution.	  Similar	  to	  the	  mechanism	  of	  transporters	  regulating	  drug	  partitition	  coefficient	  at	  the	  BBB,	  if	  drug	  is	  actively	  uptake	  into	  brain	  cells	  via	  transporters,	  unbound	  drug	  concentration	  is	  higher	  than	  that	   in	  brain	  ECF,	   thus	   increasing	  Vu,brain.	   In	   the	   case	  of	   transporter	  pumping	  drug	  out	  of	   cells,	   less	  drug	   is	  distributed	   in	   the	  brain	  cells,	   leading	   to	   lower	  Vu,brain.	  The	  Vu,brain	  of	   S-­‐atenolol	   estimated	   from	  microdialysis	   and	  whole	   brain	  measurements	  was	  0.686	  ±	  0.104	  mL/g	  brain,	  indicating	  no	  effects	  of	  transporters	  at	  the	  brain	  cells	  on	   the	   drug	   intra-­‐brain	   distribution	   or	   there	   are	   transporters	   with	   counteractive	  functions	   transporting	   the	   drug	   in	   both	   the	   inward	   and	   outward	   directions.	   In	  summary,	  Kp,uu	  calculated	  from	  the	  steady	  state	  is	  an	  important	  parameter	  to	  assess	  drug	   active	   transport	   at	   the	   BBB	  without	   the	   confounding	   effect	   of	   the	   transport	  rate.	  In	  this	  study,	  S-­‐atenolol	  showed	  a	  Kp,uu	  of	  3.55	  ±	  0.40	  %	  that	  is	  much	  lower	  than	  unity,	  indicating	  that	  the	  efflux	  clearance	  is	  approximately	  28-­‐fold	  greater	  than	  the	  influx	  clearance,	  suggesting	  one	  or	  more	  efflux	  transporters	  are	  involved	  in	  the	  drug	  transport	  at	  the	  BBB.	  The	  Vu,brain	  of	  0.686	  ±	  0.104	  mL/g	  brain	  suggests	  that	  atenolol	  is	  evenly	  distributed	  in	  the	  brain	  tissue	  fluid	  after	  entering	  the	  brain.	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The	  next	  question	  is	  which	  transporters	  can	  actively	  remove	  atenolol	  from	  the	  brain.	   It	   has	   been	   reported	   that	   fruit	   juices	   reduced	   the	   intestinal	   absorption	   of	  atenolol.	   The	   Cmax	   and	   AUC	   were	   decreased	   by	   49%	   and	   40%,	   respectively,	   by	  orange	   juice	   and	   68%	   and	   81%,	   respectively,	   by	   apple	   juice	   based	   on	  pharmacokinetics	  studies	  on	  human	  subjects	  [35,	  36].	  There	  are	  controversy	  about	  the	   transporters	   responsible	   for	   the	   interaction	   between	   atenolol	   and	   fruit	   juices.	  The	   organic	   anion	   transporting	   polypeptide	   1A2	   (OATP1A2)	   is	   suggested	   to	   be	  responsible	  of	  the	  atenolol	  uptake	  in	  the	  OATP1A2-­‐expressed	  X.	  laevis	  oocytes	  [37].	  However,	  another	  study	  by	  Mimura	  et.al.	  suggested	  that	  organic	  cation	  transporter	  1	   (OCT1)	   rather	   than	   OATP	   probably	   contributes	   to	   the	   interaction	   between	  atenolol	  and	   flavonoids	   in	   fruit	   juices	   [38].	   It	  was	  also	  reported	   that	  hOCT2	  at	   the	  basolateral	  membrane	   of	   kidney	   tubules	   lead	   to	   renal	   active	   secretion	   of	   atenolol	  [39].	  Furthermore,	  the	  study	  performed	  by	  Yin	  et.al	  suggested	  that	  atenolol	  is	  also	  a	  substrate	   of	  multidrug	   and	   toxic	   compound	   extrusion	   (hMATE-­‐1	   and	   hMATE2-­‐K)	  located	  at	  the	  apical	  membrane	  of	  renal	  tubule,	  thus	  contributing	  to	  the	  elimination	  of	  atenolol	  from	  blood	  to	  urine	  together	  with	  OCT2	  [40].	  Among	  the	  above	  possible	  transporters	   for	   atenolol,	   only	   OATP	   has	   been	   found	   expressed	   at	   the	   BBB	   with	  bidirectional	  transport	  [41,	  42].	  The	  expression	  of	  OCT2	  was	  also	  found	  in	  the	  apical	  membrane	   of	   choroid	   plexus	   where	   blood-­‐CSF	   barrier	   is	   located,	   which	   may	   be	  relevant	  for	  efflux	  transport	  of	  substrates	  from	  cerebrospinal	  fluid	  to	  blood	  [43].	  	  In	   addition	   to	   solute	   carrier	   family	   (SLC),	   several	  members	  belonging	   to	  ATP-­‐binding	  cassette	  (ABC)	  transporter	  family	  are	  well	  known	  efflux	  transporters	  at	  the	  BBB	   with	   a	   wide	   range	   of	   substances,	   including	   P-­‐glycoprotein	   (Pgp),	   multidrug	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resistance	  protein	  (MRP),	  and	  breast	  cancer	  resistance	  protein	  (BCRP)	  [26].	  There	  have	  been	   few	   studies	   evaluating	   the	  potentials	   of	   atenolol	   as	   a	   substrate	   of	  MRP	  and	  BCRP,	  while	  controversial	  results	  were	  reported	  for	  function	  of	  Pgp	  on	  atenolol.	  Kallem	   et.al.	   reported	   that	   coadministration	   of	   elacridar,	   a	   Pgp	   inhibitor,	   did	   not	  significantly	   change	   the	   brain	   to	   plasma	   concentration	   ratio	   (Kp,brain)	   or	   brain-­‐to-­‐plasma	  AUC	  ratio	  of	  atenolol	  in	  rats	  and	  mice	  [44].	  In	  situ	  intestinal	  perfusion	  study	  showed	   Pgp	   inhibitor	   such	   as	   verapamil	   did	   not	   change	   absorption	   or	   intestinal	  permeability	   of	   atenolol	   [45,	   46].	   Similar	   conclusion	   that	   atenolol	   is	   not	   a	   Pgp	  substrate	  were	  drawn	  from	  in	  vitro	  studies	  using	  Caco-­‐2	  or	  Pgp	  transfected	  cell	  lines	  [47,	  48].	  On	  contrary,	  Pgp	   inhibitors	  (cyclosporin	  and	   itraconazole)	  were	  reported	  to	   slightly	   increase	   the	   absorption	   rate	   and	   bioavailability	   of	   atenolol	   [49,	   50].	   In	  addition,	  polarized	  transport	  of	  atenolol	  was	  found	  in	  a	  Pgp-­‐transfected	  IPEC-­‐J2	  cell	  lines	   and	   Caco-­‐2	   cell	   with	   the	   efflux	   ratio	   of	   3.5	   and	   2.3,	   respectively,	   and	   the	  polarized	   transport	  was	   levelled	  up	  by	  Pgp	   inhibitors	   (zosuquidar	  and	  verapamil)	  [51,	   52].	   In	   a	   collaborative	   study	   comparing	   Caco-­‐2	   cells	   from	   10	   laboratories,	  atenolol	  showed	  highly	  variable	  permeability	  and	  its	  efflux	  ratios	  ranged	  from	  0.18	  to	  3.76	  indicating	  possibility	  of	  involvement	  of	  transporter-­‐mediated	  transport	  [53].	  In	   summary,	   it	   is	   not	   clear	   which	   transporter(s)	   is	   responsible	   for	   the	   efflux	   of	  atenolol	  from	  brain	  even	  though	  atenolol	  may	  be	  a	  substrate	  of	  several	  transporters.	  In	  summary,	  the	  present	  study	  systematically	  evaluated	  the	  extent	  of	  S-­‐atenolol	  distribution	   in	   brain	   using	   microdialysis	   and	   suggests	   an	   involvement	   of	   some	  unidirectional	  carrier-­‐mediated	  transport	  of	  S-­‐atenolol	  across	  the	  BBB	  in	  addition	  to	  passive	   diffusion.	   Although	   it	   is	   currently	   unclear	   about	   which	   transporter	   is	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responsible	  for	  atenolol	  efflux	  transport	  at	  the	  BBB,	  it	  may	  be	  not	  appropriate	  to	  use	  atenolol	  as	  a	  mode	  drug	  for	  paracellular	  or	  low	  passive	  diffusion.	  	   	  
	  	   192	  
	  Figure	  C-­‐1	   Study	   design	   for	   the	   microdialysis	   study	   of	   S-­‐atenolol	   showing	   the	  schedules	  of	  S-­‐atenolol	  i.v.	  infusion	  (red	  and	  pink	  bars),	  microdialysis	  sampling	  (blue	  bars),	  plasma	  sampling	  (black	  arrow),	  and	  brain	  tissue	  samplings	  (red	  arrow).	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  Figure	  C-­‐2	   The	   schematic	   illustration	   describing	   the	   systematic	  pharmacokinetics	   and	   brain	   distribution	   of	   S-­‐atenolol	   and	   also	  transforming	   the	   microdialysis	   data	   by	   evaluating	   the	   probe	  recoveries.	   Solid	   arrows	   show	   the	   mass	   transport	   between	  compartments	   (squares).	   Dashed	   arrows	   represent	   the	  transformations	   and	   corrections	   from	   observed	   data	   (ovals)	   to	   the	  unbound	  drug	  concentration	  in	  brain	  and	  blood.	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  Figure	  C-­‐3	   The	   concentration-­‐time	   profiles	   of	   unbound	   S-­‐atenolol	   in	   blood	  (triangle	  points,	  solid	  line)	  and	  brain	  (circle	  points,	  solid	  lines)	  as	  well	  as	  bound	  S-­‐atenolol	  in	  plasma	  (triangle,	  dash	  lines)	  for	  Group	  1	  (n=9)	  with	   15-­‐min	   fast	   i.v.	   infusion	   followed	  by	   165-­‐min	   slow	   i.v.	   infusion	  (A)	  and	  Group	  2	  (n=4)	  with	  constant	  slow	  i.v.	  infusion	  for	  180	  min	  (B).	  The	  correct	  Cu,brain	  data	  were	  unavailable	  after	  240	  min	  for	  two	  rats	  due	  to	  the	  problem	  of	  LC-­‐MS/MS	  during	  the	  assay. 	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  Figure	  C-­‐4	   The	   ratio	   of	   unbound	   S-­‐atenolol	   in	   rat	   brain	   ECF	   to	   that	   in	   blood	  versus	  time	  for	  Group	  1	  (solid	  circles	  and	  lines)	  with	  15-­‐min	  fast	   i.v.	  infusion	  followed	  by	  165-­‐min	  slow	  i.v.	  infusion	  (n=9)	  and	  for	  Group	  2	  (empty	  circles	  and	  dash	  lines)	  with	  180-­‐min	  constant	  i.v.	  infusion.	  The	  unbound	   partition	   coefficient	   (Kp,uu)	  was	   calculated	   from	   the	   steady	  state	  during	  90-­‐180	  min.	  The	  correct	  Kp,uu	  data	  were	  unavailable	  after	  240	  min	  for	  two	  rats	  due	  to	  the	  problem	  of	  LC-­‐MS/MS	  during	  the	  assay. 	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  Table	  C-­‐1	  	   Estimates	  of	  the	  PK	  parameters	  of	  S-­‐atenolol	  in	  Rats	  
Parameter	   unit	   Estimate	   RSE(%)	   IIV	  (%)	   RSE	  IIV	  (%)	  
REC
blood
	   %	   49.9	   3.5	   12.2	   24.8	  
REC
brain
	   %	   6.73	   9.5	   27.9	   17.2	  
CL	   mL/min	   10.2	   2.4	   7.5	   16.9	  
V1	   mL	   215	   10.8	   30.3	   28.4	  
Q	   mL/min	   5.56	   8.9	   	   	  
V2	   mL	   402	   4.8	   	   	  
Fu	   	   1	   Fixed	   	   	  
QAV	   mL/min	   15.4	   9.2	   	   	  
CLin	   µL/min/gbrain	   17.0	   48.8	   134.2	   27.5	  
Kp,uu	   	   0.04	   11.3	   35.5	   18.0	  
Vu,brain	   mL/g	  brain	   0.686	   Fixed	   	   	  
σ
proportional,RECbrain
	   	   0.028	   9.4	   	   	  
σ
additive,RECblood
	   ng/mL	   7.83	   5.1	   	   	  
σ
proportional,plasma
	   	   0.184	   20.3	   	   	  
σ
proportional,blood
	   	   0.112	   8.8	   	   	  
σ
proportional,brain
	   	   0.0741	   12.3	   	   	  
σ
additive,brain
	   ng/mL	   0.22	   20.2	   	   	  Inter-­‐individual	  variation	  (IIV)	  is	  expressed	  as	  coefficient	  of	  variation.	  Relative	  ecoveries	  (REC)	  were	  estimated	  from	  the	  model	  for	  blood	  and	  brain	  microdialysis	  probes.	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